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Severe fatigue in breast cancer survivors
Worldwide, breast cancer is the most frequently diagnosed type of cancer among 
women (1). As the general population is growing and aging, the number of women 
diagnosed with breast cancer continues to increase. In the Netherlands, there were 
approximately 14,600 new breast cancer diagnoses in 2016 (2). At the same time, 
survival rates have been improved due to early detection of breast cancer in screening 
programs and advances in the treatment of breast cancer (3). Nowadays about 77% of 
Dutch breast cancer patients survive cancer up to ten years after diagnosis (2). 
  In the literature, the term “cancer survivor” has been defined in various ways (4). 
In this thesis, the definition from the practice guidelines for fatigue in cancer survivors 
will be followed: “individuals diagnosed at age of at least 18 years who have completed 
primary cancer treatment with curative intent, are in clinical remission and off 
therapy, as well as patients who are disease free and have transitioned to maintenance 
or adjuvant therapy (5).”
  Given the increasing number of breast cancer survivors, awareness of cancer- or 
treatment-related side-effects that persist after cancer treatment is important. Studies 
have shown that most breast cancer survivors report a good overall quality of life (QOL). 
However, a substantial subgroup suffers from debilitating symptoms after completion 
of curative cancer treatment (6). Fatigue, pain, arm lymphedema, postmenopausal 
symptoms, anxiety and depressive symptoms are frequently reported (7). 
Fatigue is reported as one of the most troublesome symptoms after cancer treatment 
(8). The definition used in the guidelines for fatigue in cancer survivors is “a distressing, 
persistent, subjective sense of physical, emotional and/or cognitive tiredness, related 
to cancer or cancer treatment, that is not proportional to recent activity and interferes 
with usual functioning (5).” 
 Cancer-related fatigue can persist for many years after cancer treatment and usually 
differs from fatigue that everyone experiences from time to time: it is continuously 
present, unpredictable, and not relieved by rest (9, 10). Cancer-related fatigue often 
limits the resumption of work and other activities, and has substantial negative impact 
on patients’ quality of life (5).
Need for further progress
In the past decades, substantial progress has been made in the field of cancer-related 
fatigue. A large number of studies has been conducted and provided more insight in 
the symptom. In 2015, a group of leading American researchers in the field released a 
joint guideline for cancer-related fatigue (5). This provides evidence-based recommen-
dations for the definition, screening, assessment, and management of the symptom. 
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Moreover, multiple interventions have been developed to treat cancer-related fatigue 
effectively, including educational, physical, and psychosocial interventions (5). 
 Despite of this progress achieved, we are not there yet. The current thesis was aimed 
at advancing the knowledge (part I) and treatment (part II) of severe fatigue in breast 
cancer survivors and DCIS, with a focus on cognitive behavioral therapy. 
PART I: ADVANCING KNOWLEDGE OF SEVERE FATIGUE IN BREAST CANCER 
SURVIVORS
This section will address four important, unresolved issues in the current literature 
on severe fatigue in breast cancer survivors. 
Prevalence and course 
Fatigue after breast cancer treatment is common, but prevalence rates vary 
substantially between studies. In a systematic review of Minton et al, it was concluded 
that fatigue is a problem for a significant percentage of breast cancer survivors, 
ascending to 50% in some studies (11). In a narrative review of Ganz et al., it was 
estimated that about one in three patients are fatigued after breast cancer treatment 
(12). More detailed conclusions on the prevalence rate and the course of severe fatigue 
after completion of breast cancer treatment could not be drawn. Thus, although a large 
body of research has focused on cancer-related fatigue, prevalence and course of this 
symptom in breast cancer survivors are still unclear.
Fatigue-related factors
Servaes et al. and Prue et al. (13, 14) provided an overview of fatigue-related factors 
in a systematic review on survivors of various cancer diagnosis. Both reported mixed 
findings regarding demographic factors, like age, marital status and education. No 
relationship was found between fatigue and disease- and treatment-related factors, 
but fatigue was found to be related to multiple psychological and behavioral factors 
(13, 14).  
 However, these reviews did not specifically focus on breast cancer survivors and 
are outdated as the literature searches were conducted at least 10 years ago. The levels 
of evidence for the relationship between fatigue and relevant factors are still unclear. 
Besides, some relevant fatigue-related factors could be missed, because sample sizes 
of included individual studies were too small and there possibly was a lack of power 
to detect these relationships. A meta-analysis has not been conducted yet, but could 
provide insight in two clinically relevant types of fatigue-related factors: (i) risk 
factors to identify patients at increased risk for developing severe fatigue after cancer 
C
h
ap
te
r 
1
12
treatment, and (ii) fatigue-perpetuating factors (involved in the maintenance of fatigue 
over time) to identify potential target factors for fatigue-oriented interventions.  
Fatigue in patients treated for DCIS 
In the nineties, breast cancer screening programs were introduced. These screening 
programs  have improved the early detection of breast cancer, but also led to a large 
increase in the number of detected benign breast conditions. The most commonly 
diagnosed benign condition is ductal carcinoma in situ (DCIS), a non-invasive condition 
confined to the ducts of the breasts (15, 16).
The incidence of detected DCIS in the Netherlands has increased from 338 new cases 
in 1990 to 2057 new cases in 2016 (2).  It is estimated that if left untreated, DCIS  would 
develop into invasive breast cancer in about 20 to 30% of cases (17). DCIS is generally 
treated with surgery and/or radiotherapy to prevent this potential progression (18). 
 Being treated with anti-cancer interventions can be confusing for patients with 
DCIS. Although DCIS is non-invasive, patients often wonder whether they have cancer 
or not (18). Besides, patients may suffer from debilitating symptoms after completion 
of treatment, just like cancer survivors. Fatigue could be one of the symptoms induced 
by cancer treatment. 
 Given the rising number of DCIS patients, it needs to be explored if fatigue is a 
problem in this specific patient group. Prevalence and related factors of fatigue have 
not specifically been examined in DCIS patients yet.  
Detecting severe fatigue in oncology practice
The NCCN guideline for cancer-related fatigue (9) recommends that  “patients should 
be screened for the presence and severity of fatigue at their initial clinical visit, at 
appropriate intervals during and after cancer treatment, and as clinically indicated.” 
Health care professional are advised to assess the presence and severity of fatigue 
using a (semi)quantitative measure. 
 Despite of the recommendations in the guideline, patients are often not screened 
in routine clinical practice. Time limitations are an important barrier. Patients do also 
not always communicate with their clinicians about fatigue and clinicians may not 
recognize it as a problem (19). To prevent severe, clinically relevant levels of fatigue 
from being overlooked in routine clinical practice, a quick screening tool would be 
helpful. In the Netherlands, a standard screening tool to detect severe fatigue is not 
implemented in routine clinical care yet. However, the Distress Thermometer has been 
recommended as screening tool for psychological distress and was implemented in 
several hospitals (20). This screening tool also includes a problem list with a fatigue 
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item. So far, the usability of the fatigue item of this screening tool to detect severe 
fatigue has not been explored.
PART II: ADVANCING COGNITIVE BEHAVIORAL THERAPY
Internet-based cognitive behavioral therapy 
According to the cognitive behavioral model of cancer-related fatigue, fatigue has 
been triggered by cancer and/or cancer treatment. Cognitive and behavioral factors are 
responsible for the persistence of fatigue (21). Cognitive behavioral therapy (CBT) for 
severely fatigued cancer survivors targets the following perpetuating factors of cancer-
related fatigue: severe fear of cancer recurrence, poor coping with cancer and cancer 
treatment, a deregulated sleep-wake cycle, deregulation of activity, dysfunctional 
cognitions regarding fatigue and a perceived lack of social support. The intervention 
is  tailored to the individual patient. Patients follow those treatment modules that are 
relevant for them. The intervention consists of 12-14 sessions with a therapist at a 
specialist treatment facility and takes about six months to complete (21).
 An RCT was conducted to determine the efficacy of CBT on severe fatigue in 
cancer survivors compared to a waiting list control condition. Patients  reported a 
significantly larger decrease in fatigue severity and functional impairment following 
CBT than patients in the control condition (21). These findings have been replicated 
(22). A follow-up study showed that the positive effects of CBT on fatigue severity were 
maintained at a two-year follow-up period (23). 
 Although CBT is effective, the availability of the intervention is limited. Therapists 
need training and supervision before they can provide CBT. There are a limited 
number of trained therapists and treatment centers. These treatment locations do not 
cover the Netherlands and treatment capacity is limited.  Besides, CBT is an intensive 
intervention for which patients need to travel to a treatment center. This is quite 
burdensome, especially for severely fatigued patients.
 The field of e-health is growing rapidly and creates new possibilities in the 
development of fatigue-oriented interventions for breast cancer survivors. 
Internet-based interventions are easier accessible for patients in comparison with 
face-to-face interventions: patients do not need to travel to a treatment center and 
can decide for themselves when and where they work on the intervention. Economic 
evaluations have also shown that internet-based interventions can reduce treatment 
time and costs, which may help to increase treatment capacity (24).
 As shown in a theoretical framework for internet interventions of Ritterband et al. 
(25), different factors come into play in internet-based interventions compared with 
face-to-face interventions. Examples of these factors are the appearance and content 
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of a website, the way in which content is delivered, and the program’s ability to engage 
users. These factors are likely to contribute to the effects of the intervention (e.g., 
by increasing patients’ motivation and knowledge) and need to be considered when 
developing a new internet-based intervention (25). 
 Internet-based interventions are a viable option for fatigued breast cancer 
survivors. Generally, 94% of the Dutch inhabitants have internet access, of which 88% 
use the internet regularly (i.e., ≥once a week) (26). Research has shown that about half 
of patients, in particular younger patients with a higher income, use  the internet to 
gather  breast cancer-related information (27, 28).  
According to a recent systematic review and meta-analysis (29), there is an 
increasing number of eHealth interventions for fatigued cancer survivors. Results 
of this meta-analysis showed that the current eHealth interventions are effective in 
improving fatigue in cancer survivors, with small to moderate effect sizes (29). Higher 
effect sizes appeared for therapist-guided interventions compared with self-ma-
nagement interventions, and effects were maintained at a 3- and 6-month follow-up 
(29). An internet-based CBT intervention, specifically aimed at fatigue in breast cancer 
survivors and tested in an RCT, is not available yet.  
Determining the long-term efficacy of CBT
In CBT, cancer survivors learn how to cope with severe fatigue. In the majority 
of patients, this leads to clinically significant improvement of fatigue levels which 
persisted up to a mean of two years after face-to-face CBT (22-24). It is unclear if these 
positive effects are maintained in the long run. A recent long-term follow-up study of 
Janse et al. (30) has shown that long-term maintenance of benefits of CBT for chronic 
fatigue is not self-evident. In patients who were successfully treated with CBT for 
chronic fatigue syndrome, levels of fatigue were deteriorated at long-term follow-up 
(up to 10 years after CBT) (30). It is unknown whether positive effects of face-to-face 
CBT on fatigue severity of cancer survivors will be retained in the long-term, over two 
years of follow-up.  
OUTLINE OF THE DISSERTATION 
To summarize, this thesis aims to advance the current knowledge and treatment of 
severe fatigue in breast cancer survivors, with a focus on cognitive behavioral therapy. 
 In part I (advancing knowledge), we present a meta-analysis to examine the 
prevalence, course, and risk factors of severe fatigue after breast cancer treatment 
(Chapter 2). Additionally, we provide a systematic review to assess the relationship 
of fatigue with quality of life and psychological factors in breast cancer survivors 
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(chapter 3). Next, we show a study on the prevalence and related factors of severe 
fatigue in patients treated for DCIS (chapter 4) and a study on the usability of the 
fatigue item of the Distress Thermometer as screening tool for severe fatigue in cancer 
patients (chapter 5). 
 In part II (advancing cognitive behavioral therapy), we first provide a study protocol, 
describing the development of internet-based cognitive behavioral therapy (ICBT) for 
severe fatigue in breast cancer survivors, and the design of an RCT to examine its 
efficacy (chapter 6). Then, we present results of a randomized controlled trial on the 
efficacy of ICBT for severely fatigued breast cancer survivors, compared with care as 
usual (chapter 7). Last, we show a long-term follow-up study that examined if effects 
of face-to-face CBT on fatigue severity are maintained after two years of follow-up 
(chapter 8).
 We conclude this thesis with a summary and general discussion of the dissertation 
including future directions for CBT in research and clinical practice (chapter 9).
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ABSTRACT
Background: This meta-analysis aimed to (i) examine demographic, disease-related, 
and treatment-related risk factors, (ii) estimate the prevalence, and (iii) describe the 
course of severe fatigue following breast cancer (BC) treatment.
Methods: PubMed, PsycINFO, Cochrane, CINAHL, and Web of Science were systema-
tically searched from inception up to 23 November 2015. Risk factors and prevalence 
rates were analyzed with inverse variance random-effects analyses. Heterogeneity 
was studied with sensitivity analyses. 
Results: Twenty-seven studies were included (N = 12,327). Breast cancer survivors 
(BCS) with a partner were at lower risk for severe fatigue than survivors without a 
partner (RR 0.96, 95% CI 0.93-0.98). Survivors with stage II or III cancer, and survivors 
treated with chemotherapy were at higher risk for severe fatigue than survivors with 
stage 0 or I cancer and without chemotherapy (RR respectively 1.18, 95% CI 1.08-1.28; 
1.12, 95% CI 1.06-1.19). Survivors treated with surgery, radiotherapy, and chemotherapy, 
and survivors with this combination plus hormone therapy were at higher risk than 
survivors with other treatment combinations (RR respectively 1.18, 95% CI 1.05-1.33; 
1.38, 95% CI 1.15-1.66). Survivors treated with surgery and surgery plus radiotherapy 
were at lower risk than survivors with additional treatments (RR respectively 0.83, 95% 
CI 0.70-0.98; 0.87, 95% CI 0.78-0.96). Hormone and targeted therapy were no significant 
risk factors. The pooled prevalence of severe fatigue was 26.9% (95% CI 23.2-31.0), but 
this should be interpreted with caution because of high heterogeneity. A relatively 
large decrease in the prevalence of severe fatigue seemed to occur in the first half year 
after treatment completion.
Conclusions: Approximately one in four breast cancer survivors suffer from severe 
fatigue. Risk factors of severe fatigue were higher disease stages, chemotherapy and 
receiving the combination of surgery, radiotherapy and chemotherapy, both with and 
without hormone therapy. Having a partner, receiving only surgery, and surgery plus 
radiotherapy decreased the risk. 
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INTRODUCTION
Breast cancer (BC) represents one fourth of all cancer cases and is the most common 
tumor type in women worldwide (1). As survival rates have improved due to advances 
in BC treatment, an increased number of women are faced with persistent symptoms 
that are related to the diagnosis and treatment (2,3). Cancer-related fatigue is among the 
most troublesome symptoms, defined by the National Comprehensive Cancer Network 
(NCCN) as “a distressing, persistent, subjective sense of physical, emotional and/or 
cognitive tiredness, related to cancer or cancer treatment, that is not proportional to 
recent activity and interferes with usual functioning (4).”
 The prevalence of fatigue in breast cancer survivors (BCS) was examined in two 
reviews (5,6). Minton et al. reported in a systematic review of 18 studies that fatigue is a 
problem for a significant percentage of BCS (up to 50% in some studies) (5). The overall 
prevalence in this review was not estimated with a meta-analysis. Ganz et al. reported 
in a narrative review that, based on three studies, approximately one in three BCS 
experience fatigue symptoms (6). This prevalence rate was not based on a systematic 
search of the literature. Both reviews did not describe how prevalence rates of fatigue 
after treatment develop over time. Therefore, the prevalence rate and course of fatigue 
in BCS are still unclear. 
To identify which BCS are more likely to develop severe fatigue following treatment, 
it is important to know which demographic, disease and treatment characteristics are 
risk factors. Previous reviews on risk factors for fatigue in cancer survivors did not 
specifically examine these factors in BCS. Prue et al. and Servaes et al. performed a 
systematic review in survivors with various tumor types and included respectively 
24 and 22 studies (7,8). Findings regarding demographic variables and fatigue were 
mixed. About half of studies found no association between the age of BCS and fatigue, 
whereas the other half reported that being younger was associated with fatigue. A 
few studies found that fatigue was associated with marital status and education (7,8). 
Almost all disease characteristics, including stage of disease and lymph node status, 
were not found to be related to fatigue after treatment of various tumor types. In 
addition, almost all treatment characteristics, including type of cancer treatment and 
time since cancer treatment, were not significantly related to fatigue (7,8).
 It is uncertain if these findings can be generalized to BCS, because at least half of 
the study populations in both reviews were survivors with other tumor types (7,8). 
Besides, the literature was searched up to September 2005, while BC treatment has 
evolved during the past decade. The understanding of tumor biology has rapidly 
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developed, generating a range of molecularly targeted drugs of which fatigue is a 
well-known side-effect (9,10). These kinds of changes in BC treatment over time should 
be considered when examining treatment-related risk factors for fatigue. Moreover, 
no meta-analysis was performed before, and sample sizes of individual studies were 
possibly too small to detect significant associations between the prementioned charac-
teristics and fatigue.
 Our meta-analysis focused on clinically relevant severe fatigue, because this level 
of fatigue often has profound negative effects on patients’ daily life, work ability 
and quality of life (11). The aims of this meta-analysis were to (i) determine which 
demographic characteristics (i.e., age, ethnicity, partner status, and education level), 
disease characteristics (i.e., lymph node status, stage of disease and menopausal 
status), and treatment characteristics (i.e., type of cancer treatment, type of surgery, 
breast reconstruction, treatment combinations, and time since cancer treatment) were 
risk factors, (ii) to estimate the prevalence rate and (iii) to describe the course of severe 
fatigue following BC treatment.
METHODS
Protocol and registration
This section is written in accordance with the PRISMA statement for systematic 
reviews and meta-analyses (12). A detailed protocol is published in the International 
Prospective Register of Systemic Reviews (PROSPERO, reference no. CRD42015015768) 
(13). 
Search strategy
PubMed, PsycINFO, Cochrane, CINAHL, and Web of Science were systematically 
searched from inception up to 23 November 2015 for studies on fatigue in disease-free 
BCS. The search strategy existed of three components, used as MeSH-headings and free 
text words: breast cancer, fatigue, and survivors (complete search strategy: Appendix). 
Study selection
Two reviewers (HA and IS) independently assessed the eligibility of articles based on 
title and abstract. If necessary, full text versions were retrieved. In case of disagreement 
about eligibility, consensus was reached by consulting a third reviewer (MG). The 
eligibility criteria were: (i) quantitative data were reported on the prevalence, course, 
or related factors of fatigue in BCS; (ii) only disease-free BCS were examined, defined 
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as patients who had completed curative cancer treatment, except for ongoing adjuvant 
hormone therapy; (iii) sample size was ≥50; (iv) a full-report in English, Dutch, or 
German was provided. 
Data extraction and quality assessment 
All corresponding authors who used a fatigue instrument with published cut-off 
score for severe fatigue were contacted for primary data by e-mail. We asked the 
authors to distinguish between severely fatigued and non-severely fatigued survivors 
in their study. All cut-off scores including its references are reported in Tables 1 and 2. 
We asked the authors to provide us with information on age (continuous), partner status 
(having a partner: yes/no), ethnicity (Caucasian/not Caucasian), and education level 
(≤primary school/>primary school). Three disease characteristics were included: lymph 
node status (positive/negative), menopausal status (premenopausal/postmenopausal), 
and stage of disease (0 or I/ II or III). Guidelines differ with regard to the latter variable 
(14,15). We followed the NCCN guidelines, in which stage 0 was described as early-stage 
BC (15). Eight treatment characteristics were included: treated with chemotherapy 
(yes/no), radiotherapy (yes/no), hormone therapy (yes/no), targeted therapy (yes/no), 
type of surgery (lumpectomy/mastectomy), having had breast reconstruction (yes/no), 
time since cancer treatment (continuous), and treatment modalities (combinations of 
surgery, chemotherapy, radiotherapy, hormone therapy and/or targeted therapy). If the 
corresponding author did not respond within two weeks, one reminder was e-mailed 
to the corresponding author and all co-authors.
 Two reviewers (HA and MG) assessed the methodological quality of the included 
studies using a checklist (16,17), especially designed for studies in psychosocial 
oncology (Table 2). One point was assigned for each criterion that was fulfilled, with 
a maximum score of 14 points. Studies attaining ≥75% of the maximum score (≥11 
points) were considered high-quality studies. Studies with a score of 50-75% (7-11 
points) were considered moderate-quality studies, and studies with a score of <50% (<7 
points) low-quality studies (16,17).
Data synthesis and analyses
Data of both cross-sectional and longitudinal studies were used to plot individual 
study estimates of incidences and proportions. From longitudinal studies, the first 
reported prevalence rate after the period of early survivorship (≥6 months after BC 
treatment (18)) was used to prevent a confounding influence of direct consequences 
of cancer treatment. We used the inverse variance method for pooling the incidences 
and to calculate the corresponding 95% confidence intervals (CIs). As recommended in 
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the Cochrane handbook, we used I² tests to measure heterogeneity. We defined an I² 
value of 50-75% as substantial heterogeneity and an I² value of ≥75% as considerable 
heterogeneity. As we expected heterogeneity between studies, we used random effects 
meta-analyses for the primary analyses. Random effects meta-analysis models assume 
that the estimated effects of the different studies are not identical, but follow some 
distribution. In case of heterogeneity, sensitivity analyses were performed to study 
whether specific groups of patients would provide more homogeneous results. Specific 
groups of patients were composed based on type of study (cross-sectional/longitudinal), 
primary study outcome (fatigue/other outcomes), type of fatigue measure (clinical 
interview/questionnaire/single item), study population (selected with eligibility 
criteria/consecutively screened patient samples), study quality (high/moderate/low), 
and study period (before/after 2007). The latter division was applied, because we know 
from clinical practice that treatment regimens became more intensive since ~ 2007. 
The associations of demographic, disease and treatment characteristics with 
severe fatigue were analyzed with inverse variance analyses, using Review Manager 
5 statistical software (version 5.3). Risk ratios and their corresponding 95% CIs 
were calculated for dichotomous variables and standardized mean differences for 
continuous variables. A separate meta-analysis was performed for each risk factor.
RESULTS
Study selection and data request
The literature search resulted in 5003 hits (flow chart: Figure 1). Duplicates were 
removed (N=1611) and titles were screened (2145 records excluded). The abstracts and/
or full-texts of the remaining 1247 studies were reviewed for eligibility. Studies were 
excluded because: (i) no quantitative data were provided on prevalence, course and/
or related characteristics of fatigue (N=777); (ii) disease-free BCS were not examined 
(N=248); (iii) no full report in English, Dutch, or German was provided (N=96), and (iv) 
sample size was <50 (N=58). 
Altogether, 68 studies were eligible. Useful data for the meta-analysis were reported 
in 15 eligible studies. The other 53 studies were considered for a data request. Twenty 
studies were excluded because: (i) a measure without cut-off point for severe fatigue was 
used (N=16); (ii) study populations were duplicate (N=4), and (iii) authors could not be 
located (N=3) (see also Figure 1). A data request was sent to authors of the remaining 30 
studies. Authors of 21 studies were willing to provide data (70%). However, the authors 
of nine studies had no access to the raw data. Data were provided for the remaining 12 
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studies. Finally, 27 studies (12 327 patients) were included in the meta-analysis. 
Study characteristics 
Sample sizes ranged from 67 to 3088 patients per study. Fourteen different fatigue 
instruments were used. A multi-item questionnaire was used in 14 studies, a diagnostic 
interview in four studies and a single item in nine studies. An unselected population 
(i.e., consecutive patients screened for fatigue) was included in five studies. The other 
22 studies used eligibility criteria to select their study population. Eight studies had a 
longitudinal design (Tables 1 and 2). 
Methodological quality
Ten studies were of high-quality, 13 of moderate-quality and four of low-quality. The 
mean quality score was 9.2 out of 14 (range 4-13; standard deviation=2.33). The most 
common methodological shortcomings were not explaining how the sample size was 
determined (78%) and a lack of a validated questionnaire to measure fatigue (63%) 
(Appendix, Table S1)
Risk factors 
BCS with a partner had a lower risk of severe fatigue than BCS without a partner (RR 
0.96, 95% CI 0.93-0.98; supplementary Figure S1a, Appendix). BCS with stage II or III 
cancer had a higher risk than BCS with stage 0 or I cancer (RR 1.18, 95% CI 1.08-1.28; 
supplementary Figure S1b). The risk was higher in BCS treated with chemotherapy 
than BCS without chemotherapy (RR 1.12, 95% CI 1.06-1.19; supplementary Figure S1c). 
Radiotherapy, hormone therapy and targeted therapy were no significant risk factors. 
Survivors treated with the combination surgery, chemotherapy and radiotherapy 
were at higher risk than other treatment combinations (RR 1.18, 95% CI 1.05-1.33; 
supplementary Figure S1d). If hormone therapy was added to these three treatment 
modalities, the risk was 38% higher than in other treatment combinations (RR 1.38, 
95%, CI 1.15-1.66; supplementary Figure S1e). The risk was decreased in survivors who 
only had received surgery and surgery plus radiotherapy compared to survivors who 
had received additional treatment modalities (RR respectively 0.83, 95% CI 0.70-0.98 
and 0.87, 95% CI 0.78-0.96; supplementary Figures S1f and S1g). All other examined 
risk factors were not significant (Table 3).
Prevalence of severe fatigue
Prevalence rates of severe fatigue in cross-sectional studies ranged from 7% to 52%. 
The pooled prevalence was 26.9% (95% CI 23.2-31.0; Figure 2) in a sample of 12 125 BCS. 
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The heterogeneity in prevalence rates was high (I² = 95). Sensitivity analyses on study 
selection showed a fatigue prevalence of 27.7% (95% CI 22.8-33.2) in studies examining 
consecutively screened patient samples, with a lower level of heterogeneity (I² = 67). 
Sensitivity analyses on type of study (longitudinal/cross-sectional), primary study 
outcome (fatigue/other outcomes), type of fatigue measure (diagnostic interviews/
multi-item questionnaires/single items) and study quality (high/moderate/low) did not 
reduce heterogeneity (supplementary Table S2, Appendix). 
Course of severe fatigue
Given the high heterogeneity in prevalence rates, a meta-analysis on the course of 
severe fatigue after treatment could not be carried out. Visual inspection suggested 
Figure 1. Selection of descriptive studies.
 
Figure 1. Selection of descriptive studies 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1159 results 
PubMed 
 
 
250 results 
PsycINFO 
 
924 results 
CINAHL 
 
402 results 
Cochrane  
 
2268 results 
Web of Science  
5003 search results  
1611 duplicates removed 
3392 records screened  
2145 records excluded based on title 
 
1247 abstracts and/or full 
texts assessed for 
eligibility  
68 eligible articles 
1179 studies excluded 
    777 no quantitative data on prevalence,     
            course and/ or related characteristics of      
            fatigue 
    248 not on disease-free breast cancer 
            survivors after curative treatment 
      96 no original full report in English, Dutch  
           or German  
      58 Sample size <50 
 
 
 
 
 
 
Data request for remaining 53 studies 
23 studies excluded  
     16 used measure without cut-off point for  
           severe fatigue 
       4 duplicate publications       
       3 no locatable authors 
Data request was sent to authors of the other 
30 studies  
    12 extra studies included       
      9 no response from approached authors 
      9 raw data not available anymore 
       
27 articles included in 
 meta-analysis 
Useful data for meta-
analysis reported in 15 
articles 
12 extra articles included 
by data request 
R
is
k 
fa
ct
or
s,
 p
re
va
le
n
ce
 a
n
d
 c
ou
rs
e 
of
 s
ev
er
e 
fa
ti
gu
e:
 a
 m
et
a-
an
al
ys
is
31
a relatively large decrease in the prevalence of severe fatigue in the first half year 
after treatment completion (Figure 3). Afterward, findings on prevalence rates were 
inconsistent and seemed relatively high when assessed approximately five years after 
cancer treatment.
DISCUSSION
In this meta-analysis on severe fatigue in BCS, data of 12 327 BCS were analyzed. 
Results demonstrated that BCS with a partner were at lower risk for severe fatigue. 
In addition, higher stages of BC and chemotherapy increased the risk for severe 
fatigue following cancer treatment. The risk was also increased in BCS treated with 
the combination surgery, chemotherapy, and radiotherapy, and in survivors treated 
with this combination plus hormone therapy. The risk was lower in survivors treated 
with surgery and surgery plus radiotherapy. Reported prevalence rates of severe 
fatigue ranged from 7% to 52%. The pooled prevalence was 27%, but this should be 
interpreted with caution because of high heterogeneity. A relatively large decrease 
in the prevalence of severe fatigue occurred in the first half year after BC treatment. 
Afterwards, findings on prevalence rates were inconsistent. 
 In contrast to our findings, the majority of included studies in previous reviews on 
cancer survivors did not find a significant association between fatigue, and having a 
partner, stage of disease, chemotherapy and cancer treatment modalities. It is likely 
that sample sizes of individual studies in these reviews were too small to detect a 
significant association. However, our finding on having a partner is in line with several 
community-based studies, in which having a partner was also significantly associated 
with being less fatigued (19-21). Notably, hormone therapy was only was a significant 
risk factor if received in addition to surgery, radiotherapy and chemotherapy, in spite of 
the fact that fatigue is often seen as a side-effect of hormone therapy (22). Limited data 
were available on targeted therapy. More studies are needed to determine if targeted 
therapy is associated with severe fatigue after cancer treatment. Clear conclusions on 
the prevalence rate and course of severe fatigue in BCS were not drawn in previous 
reviews. However, our finding that the prevalence of severe fatigue especially 
decreased in the first half year after cancer treatment corresponds with the current 
literature on early survivorship. This time period is known as the re-entry phase, in 
which patients need to adapt to multiple adaptive challenges (18). After this phase, 
only a subgroup of patients experiences persistent symptoms like severe fatigue (23). 
 The major strengths of our study are the large sample size of over 12 000 BCS, the 
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Variables (REF) References Number of 
studies 
Sample size 
(N)
Risk ratio (CI)
Demographic characteristics
Age (SMD (CI)) (28, 30, 32, 33, 35, 36, 38, 40, 
43, 45-48, 50, 54-57)
19 8 678 -.06 (-.14-.03)a
Having a partner (28, 30, 33, 35, 36, 38, 40, 42, 
43, 46, 47, 50, 54-57)
16 9 991 .96 (.93-.98)*
Ethnicity (Caucasian) (26, 28, 30, 33, 35, 36, 43, 45, 
47, 50)
10 4 877 1.00 (.97-1.04)
Education level 
(≤primary school) 
(36, 38, 40, 42, 46, 47, 50, 54, 
55)
8 6 456 1.09 (.99-1.20)
Disease characteristics 
Stage of disease 
(II or III) 
(26, 35, 38, 42, 43, 45-48, 50, 
54, 55)
11 4 093 1.18 (1.08-1.28)*
Negative lymph node 
status 
(26, 43, 45, 46, 48, 54) 6 1 068 .89 (.77-1.03)
Menopausal status 
(pre-/ perimenopausal) 
(26, 33, 36, 43, 45, 47, 50) 9 6 269 .98 (.94-1.02)
Treatment characteristics
Chemotherapy (26, 28, 30, 32, 36, 38, 42, 43, 
45-48, 50, 54-57)
17 10 100 1.12 (1.06-1.19)*
Radiotherapy (26, 28, 30, 32, 36, 38, 43, 45, 
47, 55-57)
12 7 342 1.01 (0.98-1.05)
Hormone therapy (26, 30, 36, 38, 42, 43, 45-48, 
51, 54, 55)
13 9 412 .98 (.93-1.03)
Targeted therapy (46-48) 4 611 .66 (.43-1.00)
Mastectomy (26, 28, 30, 32, 35, 36, 42, 43, 
45-48, 50, 54-56)
16 7 784 1.01 (.96-1.07)
Breast reconstruction (30, 43, 45, 47, 54, 56) 7 1 587 1.02 (.94-1.12)
Time since cancer 
treatment (SMD (CI))
(26, 35, 45, 50, 54, 56) 7 1 260 -.01 (-.14-.11)
Treatment combinations
SU (26,38,42,45,47,56,57) 6 3 028 .83 (.70-.98)*
SU+CT (32,38,42,47,55-57) 7 3 379 1.33 (.97-1.82)
SU+RT (26,32,38,45-48,50,55-57) 11 4 164 .87 (.78-.96)*
SU+HT (38,42,45-47) 4 981 .83 (.57-1.20)
SU+CT+RT (26,32,38,45-48,55-57) 10 3 882 1.18 (1.05-1.33)*
SU+CT+HT (38,42,45-47) 4 981 .99 (.66-1.49)
SU+RT+HT (26,38,45-48) 6 1 264 .89 (.74-1.07)
SU+CT+RT+HT (26,38,45-48) 6 1 264 1.38 (1.15-1.66)*
I2 was <50% in all analyses, unless indicated otherwise. Results are reported as risk ratio (CI), unless indicated otherwise; 
* P < 0.05; a I2 = 55%; SU, surgery; CT, chemotherapy; RT, radiotherapy; HT, hormone therapy; SMD, standardized mean 
difference; SD, standard deviation.
Table 3. Risk factors of severe fatigue in breast cancer survivors
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Event 
rate
Lower 
limit
Upper 
limit
–1.00 –0.50 –0.00 0.50 1.00
Alexander et al (2009) 0.300 0.241 0.367
Andrykowski et al (2010) 0.092 0.064 0.132
Berger et al (2012) 0.241 0.181 0.313
Bower et al (2000) 0.350 0.329 0.372
Crosswell et al (2014) 0.457 0.352 0.566
Dupont et al (2014) 0.352 0.313 0.393
Fu et al (2009) 0.223 0.161 0.300
Goldstein et al (2006) 0.489 0.416 0.562
Goldstein et al (2014) 0.183 0.138 0.240
Hall et al (2014) 0.127 0.089 0.177
Hall et al (2015) 0.214 0.151 0.294
Hong et al (2014) 0.359 0.342 0.377
Jacobsen et al (2007) 0.181 0.136 0.237
Jones et al (2015) 0.426 0.382 0.470
Karakoyun-celik (2010) 0.302 0.225 0.391
Kim et al (2008) 0.320 0.299 0.341
Meeske et al (2007) 0.070 0.054 0.090
Minton et al (2012) 0.395 0.309 0.487
Nieboer et al (2005) 0.171 0.123 0.233
Reidunsdatter et al (2012) 0.300 0.243 0.364
Reinertsen et al (2010) 0.329 0.274 0.390
Schmitz et al (2012) 0.118 0.084 0.162
Servaes et al (2007) 0.380 0.306 0.460
Ventura et al (2013) 0.552 0.475 0.627
Versmessen et al (2012) 0.311 0.234 0.399
Young et al (2006) 0.188 0.113 0.298
Total (random) 0.269 0.232 0.310
Statistices are reported as risk (Cl), unless indicated otherwise. I2= 95.13
Figure 2. Prevalence of severe fatigue in breast cancer survivors.
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wide range of examined risk factors and the specification of our target population 
(i.e., preventing any confounding influence of active, noncurative cancer treatment 
and tumor type on the results). Some potential limitations should also be discussed. 
To start with, cutoff scores of fatigue questionnaires were used to divide BCS in 
severely fatigued and nonseverely fatigued groups. The criteria for severe fatigue 
differ between questionnaires, which probably led to variability between studies 
and could have distorted our results. Second, data of 18 eligible studies could not be 
included in our meta-analysis, mostly because the authors had no access to the raw 
data. Especially, our results on risk factors with small subsets of studies, like targeted 
therapy and time since cancer treatment, might have been different if more eligible 
studies were included. Third, our meta-analysis on the prevalence of severe fatigue 
was limited because of high heterogeneity. Sensitivity analyses showed that the level 
of heterogeneity was only reduced, though still substantial, in studies that screened 
patients consecutively in clinical practice. It is disappointing that no firm conclusions 
Note. Studies that only reported time since diagnosis are shown as dotted lines.
Figure 3. Course of severe fatigue in breast cancer survivors after completion of cancer treatment.
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can be drawn about the prevalence of severe fatigue in BCS after more than 20 years of 
research. Not knowing the scope of the problem makes it unclear what sources have to 
be allocated to follow guidelines for screening and management of severe fatigue (24). 
Fourth, fatigue was described as one unified concept, while fatigue actually consists 
of multiple dimensions like mental fatigue, physical fatigue and the impact of fatigue 
(25). We only had access to the total scores of questionnaires and were not able to select 
specific items that distinguish different dimensions of fatigue. Finally, the patients in 
the included studies were recruited over a period of more than 20 years. It is important 
to note that treatments and diagnostic criteria of cancer have changed in this time 
period. However, a sensitivity analyses on study period (before and after 2007) did not 
show substantial differences in prevalence rates of severe fatigue between both study 
periods. 
 This meta-analysis involves several implications for future research and clinical 
practice. To start with, extra attention should be paid to BCS at increased risk for severe 
fatigue. Our results showed that the risk for severe fatigue is relatively highest in BCS 
treated with a combination of surgery, chemotherapy, radiotherapy, and hormone 
therapy. These patients should especially be monitored closely during follow-up 
examinations. Second, the included studies in our meta-analysis used 14 different 
instruments to measure fatigue, which reflects that a generally accepted definition for 
fatigue in cancer survivors is lacking. Future studies should agree on one definition or 
at least describe which definition is used in their assessment. Besides, future studies 
should acknowledge that fatigue is a multidimensional concept, distinguish different 
domains of fatigue in their assessment, and make more explicit which dimensions 
are studied. This might also help to reduce heterogeneity when estimating the 
prevalence of severe fatigue. Third, insight should be gained in the course of severe 
fatigue after BC treatment. More longitudinal studies that measure severe fatigue 
frequently over longer time periods are needed. This would clarify which patients 
recover spontaneously from fatigue, and which patients remain fatigued and may 
need fatigue-oriented interventions. According to a recent practice guideline of the 
American Society of Clinical Oncology, available evidence-based interventions for 
fatigue in cancer survivors are exercise and psychosocial interventions (i.e. cognitive 
behavioral therapy and psycho-educational therapies). Evidence for the efficacy of 
mind-body interventions (i.e. mindfulness-based approaches, yoga, and acupuncture) 
is limited, and evidence for pharmacologic interventions (i.e. psychostimulants and 
supplements like vitamin D) is lacking (11). Finally, next to demographic, disease, and 
treatment characteristics, other categories of risk factors for severe fatigue in BCS 
should be examined in future studies. For instance, behavioral risk factors should be 
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further examined as there is evidence for behavioral characteristics that maintain 
severe fatigue in cancer survivors (e.g., physical inactivity and deregulated sleep 
patterns) (8,11).
 In conclusion, approximately one in four breast cancer survivors suffer from severe 
fatigue. Risk factors of severe fatigue were higher disease stages, chemotherapy and 
receiving the combination of surgery, radiotherapy and chemotherapy, both with and 
without hormone therapy. Having a partner, receiving only surgery, and surgery plus 
radiotherapy decreased the risk. 
Acknowledgements
We thank Tillema, librarian, for her assistance with the search strategy. Unpublished 
data for this meta-analysis were provided by Antoni (University of Miami, USA), 
Germino (University of North Carolina at Chapel Hill School of Nursing, USA), Hall 
(Massachusetts General Hospital/Harvard Medical School, USA), and Mishel; Crosswell 
(University of California, Department of Psychology, USA); Flatt and Pierce (UC San 
Diego Moores Cancer Center, USA); Fosså and Reinertsen (National Resource Center 
for Late Effects, Department of Oncology, Oslo University Hospital, Norway); Ganz and 
Petersen (Cancer Prevention and Control Research, Jonsson Comprehensive Cancer 
Center, University of California, USA); Jones (Princess Margaret Cancer Centre, Cancer 
Survivorship Program, CAN); Karakoyun-Celik (Celal Bayar University, Department of 
Radiation Oncology, TUR); Minton (St George’s University Hospitals NHS Foundation 
Trust, UK); Paxton (UNT Health Science Center, Department of Behavioral & Community 
Health, USA); Reidunsdatter (Sør-Trøndelag University College, Department of Health 
and Social Sciences, NOR); Schmitz (University of Pennsylvania’s School of Medicine, 
USA), Hayes and DiSipio (Queensland University of Technology, AUS); Servaes (Radboud 
university medical center, Expert Center for Chronic Fatigue, NL); Smith (Outcomes 
Research Branch, Division of Cancer Control and Population Sciences, National Cancer 
Institute, USA), and Vinh-Hung (Department of Radiation Oncology, Vrije Universiteit 
Brussel, BEL).We thank all authors for their cooperation.
R
is
k 
fa
ct
or
s,
 p
re
va
le
n
ce
 a
n
d
 c
ou
rs
e 
of
 s
ev
er
e 
fa
ti
gu
e:
 a
 m
et
a-
an
al
ys
is
41
REFERENCES
1. WHO International Agency for 
Research on Cancer, GLOBOCAN 2012: 
Estimated cancer incidence, mortality 
and prevalence worldwide in 2012 
[Internet]. [Cited 8 September 2015]. 
Available from: http://globocan.iarc.
fr/Pages/fact_sheets_cancer.aspx/
2. Coleman MP, Quaresma M, Berrino 
F, et al. Cancer survival in five 
continents: a worldwide populati-
on-based study (CONCORD). Lancet 
Oncol 2008;9(8):730–56.
3. Stan D, Loprinzi CL, Ruddy KJ. 
Breast cancer survivorship issues. 
Hematol Oncol Clin North Am 
2013;27(4):805–27.
4. Mock V, Atkinson A, Barsevick A, et al. 
NCCN Practice Guidelines for Cancer-
Related Fatigue. Oncology (Williston 
Park) 2000;14(11A):151–61.
5. Minton O, Stone P. How common is 
fatigue in disease-free breast cancer 
survivors? A systematic review of the 
literature. Breast Cancer Res Treat 
2008;112(1):5–13.
6. Ganz PA, Bower JE. Cancer related 
fatigue: a focus on breast cancer and 
Hodgkin's disease survivors. Acta 
Oncol 2007;46(4):474–9.
7. Prue G, Rankin J, Allen J, Gracey J, 
Cramp F. Cancer-related fatigue: 
a critical appraisal. Eur J Cancer 
2006;42(7):846–63.
8. Servaes P, Verhagen C, Bleijenberg 
G. Fatigue in cancer patients during 
and after treatment: prevalence, 
correlates and interventions. Eur J 
Cancer 2002;38(1):27–43.
9. Masters GA, Krilov L, Bailey HH, et 
al. Clinical cancer advances 2015: 
annual report on progress against 
cancer from the American Society 
of Clinical Oncology. J Clin Oncol 
2015;33(7):786-809.
10. Cancer Research UK: Trastuzumab 
(Herceptin) [Internet]. [Cited 2 
October 2015]. Available from: 
http://www.cancerresearchuk.org/
about-cancer/cancers-in-general/
treatment/cancer-drugs/trastuzumab/
11. Bower JE, Bak K, Berger A, et 
al. Screening, assessment, and 
management of fatigue in adult 
survivors of cancer: an American 
Society of Clinical oncology clinical 
practice guideline adaptation. J Clin 
Oncol 2014;32(17):1840-50.
12. Moher D, Liberati A, Tetzlaff J, 
Altman DG. Preferred reporting 
items for systematic reviews and 
meta-analyses: the PRISMA statement. 
Ann Intern Med 2009; 151(4): 264–9.
13. Chien PF, Khan KS, Siassakos D. 
Registration of systematic reviews: 
C
h
ap
te
r 
2
42
PROSPERO. Int J Gynaecol Obstet 
2012;119(8):903–5.
14. Breast cancer: Dutch Guideline, 
version 2.0 [Internet]. [Cited 15 
October 2015]. Available from: http://
www.oncoline.nl/breastcancer/
15. NCCN guidelines for patients: stage 
0 breast cancer [Internet]. [Cited 15 
October 2015]. Available from: http://
www.nccn.org/patients/guidelines/
stage_0_breast/index.html/
16. Daniëls LA, Oerlemans S, Krol 
AD, van de Poll-Franse LV, 
Creutzberg CL. Persisting fatigue 
in Hodgkin lymphoma survivors: 
a systematic review. Ann Hematol 
2013;92(8):1023–32.
17. Mols F, Vingerhoets AJ, Coebergh 
JW, van de Poll-Franse LV. Quality of 
life among long-term breast cancer 
survivors: a systematic review. Eur J 
Cancer 2005;41(17):2613–9.
18. Stanton AL, Ganz PA, Rowland 
JH, Meyerowitz BE, Krupnick JL, 
Sears SR. Promoting adjustment 
after treatment for cancer. Cancer 
2005;104(S11):2608–13.
19. Jing M-J, Wang J-J, Lin W-Q, Lei Y-X, 
Wang P-X. A Community-Based 
Cross-sectional Study of Fatigue in 
Middle-aged and Elderly Women. J 
Psychosom Res 2015;79(4):288-94.
20. Junghaenel DU, Christodoulou C, 
Lai J-S, Stone AA. Demographic 
correlates of fatigue in the US 
general population: Results from 
the patient-reported outcomes 
measurement information system 
(PROMIS) initiative. J Psychosom Res 
2011;71(3):117–23.
21. Kocalevent RD, Hinz A, Brähler E, 
Klapp BF. Determinants of fatigue and 
stress. BMC Res Notes 2011;4(1):238.
22. Cancer Research UK: General side 
effects of hormone therapy [Internet]. 
[Cited 15 October 2015]. Available 
from: http://www.cancerresearchuk.
org/about-cancer/cancers-in-general/
treatment/hormone/general-side-ef-
fects-of-hormone-therapy/
23. Stanton AL. What happens now? 
Psychosocial care for cancer survivors 
after medical treatment completion. J 
Clin Oncol 2012;30(11):1215–20.
24. Berger AM, Mitchell SA, Jacobsen 
PB, Pirl WF. Screening, evaluation, 
and management of cancer-related 
fatigue: Ready for implementation 
to practice? CA Cancer J Clin 
2015;65(3):190–211.
25. Dittner AJ, Wessely SC, Brown RG. 
The assessment of fatigue: a practical 
guide for clinicians and researchers. J 
Psychosom Res 2004;56(2):157–70.
26. Alexander S, Minton O, Andrews 
P, Stone P. A comparison of the 
characteristics of disease-free breast 
cancer survivors with or without 
R
is
k 
fa
ct
or
s,
 p
re
va
le
n
ce
 a
n
d
 c
ou
rs
e 
of
 s
ev
er
e 
fa
ti
gu
e:
 a
 m
et
a-
an
al
ys
is
43
cancer-related fatigue syndrome. Eur 
J Cancer 2009;45(3):384–92.
27. Berger AM, Visovsky C, Hertzog 
M, Holtz S, Loberiza Jr FR. Usual 
and worst symptom severity and 
interference with function in breast 
cancer survivors. J Supp Oncol 
2012;10(3):112–8.
28. Crosswell AD, Lockwood KG, Ganz PA, 
Bower JE. Low heart rate variability 
and cancer-related fatigue in breast 
cancer survivors. Psychoneuroendo-
crinology 2014;45:58–66.
29. Jacobsen PB, Donovan KA, Small BJ, 
Jim HS, Munster PN, Andrykowski 
MA. Fatigue after treatment for 
early stage breast cancer. Cancer 
2007;110(8):1851–9.
30. Dupont A, Bower JE, Stanton AL, Ganz 
PA. Cancer-related intrusive thoughts 
predict behavioral symptoms 
following breast cancer treatment. 
Health Psychol 2014;33(2):155-63.
31. Fu OS, Crew KD, Jacobson JS, et al. 
Ethnicity and persistent symptom 
burden in breast cancer survivors. J 
Cancer Surviv 2009;3(4):241-50.
32. Goldstein D, Bennett B, Friedlander 
M, Davenport T, Hickie I, Lloyd A. 
Fatigue states after cancer treatment 
occur both in association with, and 
independent of, mood disorder: 
a longitudinal study. BMC Cancer 
2006;6(1):240.
33. Hall DL, Mishel MH, Germino 
BB. Living with cancer-related 
uncertainty: associations with fatigue, 
insomnia, and affect in younger 
breast cancer survivors. Support Care 
Cancer 2014;22(9):2489–95.
34. Stover AM, Reeve BB, Piper BF, et 
al. Deriving clinically meaningful 
cut-scores for fatigue in a cohort of 
breast cancer survivors: a Health, 
Eating, Activity, and Lifestyle 
(HEAL) Study. Qual Life Res 
2013;22(9):2279–92.
35. Hall DL, Antoni MH, Lattie EG, et 
al. Perceived fatigue interference 
and depressed mood: comparison of 
chronic fatigue syndrome/myalgic 
encephalomyelitis patients with 
fatigued breast cancer survivors. 
Fatigue 2015;3(3):142–55.
36. Hong S, Bardwell WA, Natarajan L, 
et al. Correlates of physical activity 
level in breast cancer survivors 
participating in the Women’s 
Healthy Eating and Living (WHEL) 
Study. Breast Cancer Res Treat 
2007;101(2):225–32.
37. Ware JE, Kosinski M, Dewey JE, 
Gandek B. SF-36 health survey: 
manual and interpretation guide: 
Quality Metric Inc.; 2000.
38. Jones JM, Olson K, Catton P, et 
al. Cancer-related fatigue and 
associated disability in post-treatment 
cancer survivors. J Cancer Surviv 
C
h
ap
te
r 
2
44
2015;10(1):1–11.
39. Alexander S, Minton O, Stone PC. 
Evaluation of screening instruments 
for cancer-related fatigue syndrome 
in breast cancer survivors. J Clin 
Oncol 2009;27(8):1197–201.
40. Karakoyun-Celik O, Gorken I, Sahin 
S, Orcin E, Alanyali H, Kinay M. 
Depression and anxiety levels in 
woman under follow-up for breast 
cancer: relationship to coping with 
cancer and quality of life. Med Oncol 
2010;27(1):108–13.
41. Storey D, Waters RA, Hibberd CJ, et al. 
Clinically relevant fatigue in cancer 
outpatients: the Edinburgh Cancer 
Centre symptom study. Ann Oncol 
2007;18(11):1861–9.
42. Kim SH, Son BH, Hwang SY, et al. 
Fatigue and depression in disease-free 
breast cancer survivors: prevalence, 
correlates, and association with 
quality of life. J Pain Symptom 
Manage 2008;35(6):644–55.
43. Kluthcovsky ACGC, Urbanetz AA, de 
Carvalho DS, Maluf EMCP, Sylvestre 
GCS, Hatschbach SBB. Fatigue 
after treatment in breast cancer 
survivors: prevalence, determinants 
and impact on health-related 
quality of life. Support Care Cancer 
2012;20(8):1901–9.
44. Meeske K, Smith AW, Alfano CM, et 
al. Fatigue in breast cancer survivors 
two to five years post diagnosis: a 
HEAL Study report. Qual Life Res 
2007;16(6):947–60.
45. Minton O, Alexander S, Stone PC. 
Identification of factors associated 
with cancer related fatigue syndrome 
in disease-free breast cancer 
patients after completing primary 
treatment. Breast Cancer Res Treat 
2012;136(2):513–20.
46. Reidunsdatter RJ, Albrektsen G, 
Hjermstad MJ, Rannestad T, Oldervoll 
LM, Lundgren S. One-year course 
of fatigue after post-operative 
radiotherapy in Norwegian breast 
cancer patients–comparison to 
general population. Acta Oncol 
2013;52(2):239–48.
47. Ventura EE, Ganz PA, Bower JE, 
et al. Barriers to physical activity 
and healthy eating in young breast 
cancer survivors: modifiable risk 
factors and associations with body 
mass index. Breast Cancer Res Treat 
2013;142(2):423–33.
48. Versmessen H, Vinh-Hung V, Van 
Parijs H, et al. Health-related quality 
of life in survivors of stage I-II breast 
cancer: randomized trial of post-ope-
rative conventional radiotherapy and 
hypofractionated tomotherapy. BMC 
Cancer 2012;12(1):495.
49. Young KE, White CA. The prevalence 
and moderators of fatigue in 
people who have been successfully 
R
is
k 
fa
ct
or
s,
 p
re
va
le
n
ce
 a
n
d
 c
ou
rs
e 
of
 s
ev
er
e 
fa
ti
gu
e:
 a
 m
et
a-
an
al
ys
is
45
treated for cancer. J Psychosom Res 
2006;60(1):29–38.
50. Andrykowski MA, Donovan KA, 
Laronga C, Jacobsen PB. Prevalence, 
predictors, and characteristics of 
off-treatment fatigue in breast cancer 
survivors. Cancer 2010; 116(24): 
5740–8.
51. Bower JE, Ganz PA, Desmond KA, et al. 
Fatigue in long-term breast carcinoma 
survivors. Cancer 2006;106(4):751–8.
52. Goldstein D, Bennett BK, Webber K, et 
al. Cancer-related fatigue in women 
with breast cancer: outcomes of a 
5-year prospective cohort study. J Clin 
Oncol 2012;30(15):1805–12.
53. Nieboer P, Buijs C, Rodenhuis S, et 
al. Fatigue and relating factors in 
high-risk breast cancer patients 
treated with adjuvant standard 
or high-dose chemotherapy: a 
longitudinal study. J Clin Oncol 
2005;23(33):8296–304.
54. Reinertsen KV, Cvancarova M, 
Loge JH, Edvardsen H, Wist E, 
Fosså SD. Predictors and course of 
chronic fatigue in long-term breast 
cancer survivors. J Cancer Surviv 
2010;4(4):405–14.
55. Schmitz KH, Speck RM, Rye SA, 
DiSipio T, Hayes SC. Prevalence of 
breast cancer treatment sequelae 
over 6 years of follow-up. Cancer 
2012;118(S8): 2217–25.
56. Servaes P, Gielissen M, Verhagen S, 
Bleijenberg G. The course of severe 
fatigue in disease-free breast cancer 
patients: a longitudinal study. 
Psycho-Oncology 2007;16(9):787–95.
57. Bower JE, Ganz PA, Desmond KA, 
Rowland JH, Meyerowitz BE, Belin TR. 
Fatigue in breast cancer survivors: 
occurrence, correlates, and impact 
on quality of life. J Clin Oncol 
2000;18(4):743–53.
C
h
ap
te
r 
2
46
APPENDICES
Search strategy systematic review 
A. Search strategy Pubmed
("Breast Neoplasms"[Mesh] OR ((breast[tiab] OR mammary[tiab] OR mamma[tiab]) 
AND (cancer[tiab] OR carcinoma*[tiab] OR adenocarcinoma*[tiab] OR tumor[tiab] OR 
tumors[tiab] OR tumour*[tiab] OR maligne[tiab] OR malignant[tiab] OR malignan-
c*[tiab] OR neoplasm*[tiab]))) 
AND 
(("Fatigue"[Mesh] OR fatigue*[tiab] OR asthenia[tiab] OR asthenic[tiab] OR 
astheni*[tiab] OR exhaustion[tiab] OR exhausted[tiab] OR loss of energy[tiab] OR loss of 
vitality[tiab] OR weary[tiab] OR weariness[tiab] OR weakness[tiab] OR apathy[tiab] OR 
apathetic[tiab] OR lassitude[tiab] OR lethargic[tiab] OR lethargy[tiab] OR sleepy[tiab] 
OR sleepiness[tiab] OR drowsy[tiab] OR drowsiness[tiab] OR tired[tiab] OR tirednes-
s[tiab] OR energy loss[tiab] OR vitality loss[tiab]) 
AND 
("Survivors"[Mesh] OR "Disease-Free Survival"[Mesh] OR survivor*[tiab] OR disease 
free[tiab] OR survival[tiab] OR postcancer[tiab] OR post cancer[tiab] OR posttreat-
ment[tiab] OR post treatment[tiab])
B. Search strategy PsycINFO
(Breast neoplasms/ OR ((breast.ti,ab. OR mammary.ti,ab. OR mamma.ti,ab.) AND 
(cancer.ti,ab. OR carcinoma*.ti,ab. OR adenocarcinoma*.ti,ab. OR tumor.ti,ab. OR 
tumors.ti,ab. OR tumour*.ti,ab. OR maligne.ti,ab. OR malignant.ti,ab. OR malignanc*.
ti,ab. OR neoplasm*.ti,ab.)))
AND 
(Fatigue/ OR (fatigue*.ti,ab. OR asthenia.ti,ab. OR asthenic.ti,ab. OR astheni*.ti,ab. OR 
exhaustion.ti,ab. OR exhausted.ti,ab. OR loss of energy.ti,ab. OR loss of vitality.ti,ab. OR 
weary.ti,ab. OR weariness.ti,ab. OR weakness.ti,ab. OR apathy.ti,ab. OR apathetic.ti,ab. 
OR lassitude.ti,ab. OR lethargic.ti,ab. OR lethargy.ti,ab. OR sleepy.ti,ab. OR sleepiness.
ti,ab. OR drowsy.ti,ab. OR drowsiness.ti,ab. OR tired.ti,ab. OR tiredness.ti,ab. OR energy 
loss.ti,ab. OR vitality loss.ti,ab.)) 
AND 
(Survivors/ OR survivor*.ti,ab. OR disease free.ti,ab. OR survival.ti,ab. OR postcancer.
ti,ab. OR post cancer.ti,ab. OR posttreatment.ti,ab. OR post treatment.ti,ab.)
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C. Search strategy Cochrane
#1 MeSH descriptor: [Breast Neoplasms] explode all trees
#2  ((breast or mammary or mamma) and (cancer or carcinoma* or adenocar-
cinoma* or tumor or tumors or tumour* or maligne or malignant or malignanc* or 
neoplasm*)):ti,ab,kw (Word variations have been searched)
#3 #1 or #2 
#4 MeSH descriptor: [Fatigue] explode all trees
#5 fatigue* or asthenia or asthenic or astheni* or exhaustion or exhausted or loss 
of energy or loss of vitality or weary or weariness or weakness or apathy or apathetic 
or lassitude or lethargic or lethargy or sleepy or sleepiness or drowsy or drowsiness 
or tired or tiredness or energy loss or vitality loss:ti,ab,kw (Word variations have been 
searched)
#6    #4 or #5
#7 #3 and #6
#8   MeSH descriptor: [Survivors] explode all trees
#9 MeSH descriptor: [Disease-Free Survival] explode all trees
#10 survivor* or disease free or survival or postcancer or post cancer or 
posttreatment or post treatment:ti,ab,kw (Word variations have been searched)
#11 #8 or #9 or #10
#12    #7 AND #11
D. Search strategy Cinahl 
(MH "Breast Neoplasms+") OR (TI ( breast OR mammary OR mamma ) OR AB ( breast 
OR mammary OR mamma ) AND TI ( cancer OR carcinoma* OR adenocarcinoma* OR 
tumor OR tumors OR tumour* OR maligne OR malignant OR malignanc* OR neoplasm* 
) OR AB ( cancer OR carcinoma* OR adenocarcinoma* OR tumor OR tumors OR tumour* 
OR maligne OR malignant OR malignanc* OR neoplasm* ))
AND
(MH "Fatigue+")  OR TI(fatigue* OR asthenia OR asthenic OR astheni* OR exhaustion 
OR exhausted OR loss of energy OR loss of vitality OR weary OR weariness OR weakness 
OR apathy OR apathetic OR lassitude OR lethargic OR lethargy OR sleepy OR sleepiness 
OR drowsy OR drowsiness OR tired OR tiredness OR energy loss OR vitality loss) OR 
AB(fatigue* OR asthenia OR asthenic OR astheni* OR exhaustion OR exhausted OR 
loss of energy OR loss of vitality OR weary OR weariness OR weakness OR apathy OR 
apathetic OR lassitude OR lethargic OR lethargy OR sleepy OR sleepiness OR drowsy OR 
drowsiness OR tired OR tiredness OR energy loss OR vitality loss)
AND
C
h
ap
te
r 
2
48
Positive if: % of studies that met this criterion
1. A validated, complete questionnaire measuring fatigue 
was used (not only subscales)
34%
2. A description was given of at least three socio-
demographic variables
83%
3. In- and exclusion criteria were described 90%
4. Response rate to the fatigue questionnaire was ≥65 % 41%
5. Information was provided on differences of characteristics 
between responders and non-responders
55%
6. Time since completion of cancer treatment was provided 55%
7. Type of cancer treatment and stage of disease were 
described
41%
8. Data were prospectively gathered 100%
9. The process of data collection was described 92%
10. The sample size determination was explained 21%
11. Missing data were described 55%
12. The results were compared between two groups or more 
(e.g., healthy population, groups with different treatment 
or age and/or compared with at least two time points)
76%
13. Mean, median, standard deviations or percentages were 
reported for the most important clinical outcome measure
93%
14. Limitations of the study were discussed 83%
Table S1. Criteria list for assessing the methodological quality of studies on fatigue in breast cancer survivors
(MH "Survivors+") OR TI ( survivor* OR disease free OR survival OR postcancer OR 
post cancer OR posttreatment OR post treatment ) OR AB ( survivor* OR disease free OR 
survival OR postcancer OR post cancer OR posttreatment OR post treatment )
E. Search strategy Web of Science
((breast OR mammary OR mamma) AND (cancer OR carcinoma* OR adenocar-
cinoma* OR tumor OR tumors OR tumour* OR maligne OR malignant OR malignanc* 
OR neoplasm*))
AND 
(fatigue* OR asthenia OR asthenic OR astheni* OR exhaustion OR exhausted OR 
loss of energy OR loss of vitality OR weary OR weariness OR weakness OR apathy OR 
apathetic OR lassitude OR lethargic OR lethargy OR sleepy OR sleepiness OR drowsy OR 
drowsiness OR tired OR tiredness OR energy loss OR vitality loss) 
AND 
(survivor* OR disease free OR survival OR postcancer OR post cancer OR 
posttreatment OR post treatment)
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Study or Subgroup Risk Ratio Risk Ratio
IV, Random, 95% CI IV, Random, 95% CI
Andrykowski et al (2010) 1.01 [0.79, 1.29]
Bower et al (2000) 0.92 [0.87, 0.98]
Crosswell et al (2014) 0.89 [0.66, 1.20]
Dupont et al (2014) 0.96 [0.86, 1.08]
Hall et al (2014) 0.86 [0,65, 1.15]
Hall et al (2015) 1.04 [0.75, 1.45]
Hong et al (2014) 0.93 [0.89, 0.98]
Jones et al (2015) 0.91 [0.79, 1.04]
Karakoyun-Celik et al (2010) 1.10 [0.89, 1.36]
Kim et al (2008) 0.99 [0.95, 1.04]
Kluthcovsky et al (2012) 1.02 [0.83, 1.25]
Reindunsdatter et al (2012) 0.95 [0.81, 1.12]
Reinertsen et al (2010) 0.89 [0.76, 1.03]
Schmitz et al (2012) 0.92 [0.77, 1.11]
Servaes et al (2007) 0.89 [0.77, 1.03]
Ventura et al (2013) 1.02 [0.85, 1.22]
Total (95% CI) 0.96 [0.93, 0.98]
Severely fatigued BCS Non-severely fatigued BCS
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 12.10, df = 15 (P = 0.67); I2 = 0%
Test for overall effect Z = 3.64 (P = 0.0003)
Figure S1a. Having a partner
S1a. Having a partner 
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Study or Subgroup Risk Ratio Risk Ratio
IV, Random, 95% CI IV, Random, 95% CI
Alexander et al (2009) 1.09 [0.84, 1.43]
Andrykowski et al (2010) 1.14 [0.71, 1.84]
Hall et al (2015) 0.90 [0.52, 1.54]
Jones et al (2015) 1.29 [1.10, 1.51]
Kim et al (2008) 1.05 [0.96, 1.14]
Kluthcovsky et al (2012) 1.17 [0.95, 1.44]
Minton et al (2012) 1.32 [0.81, 2.15]
Reindunsdatter et al (2012) 1.29 [0.93, 1.80]
Schmitz et al (2012) 1.45 [1.14, 1.85]
Ventura et al (2013) 1.35 [1.03, 1.78]
Versmessen et al (2012) 1.06 [0.76, 1.47]
Total (95% CI) 1.18 [1.08, 1.28]
Severely fatigued BCS Non-severely fatigued BCS
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 13.43, df = 10 (P = 0.20); I2 = 26%
Test for overall effect Z = 3.81 (P = 0.0001)
Figure S1b. Stage of disease: II or III
S1b. Stage of disease: II or III 
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Study or Subgroup Risk Ratio Risk Ratio
IV, Random, 95% CI IV, Random, 95% CI
Alexander et al (2009) 1.18 [0.87, 1.59]
Andrykowski et al (2010) 1.31 [0.94, 1.83]
Bower et al (2000) 1.18 [1.06, 1.31]
Crosswell et al (2014) 0.94 [0.72, 1.23]
Dupont et al (2014) 1.20 [1.02, 1.42]
Goldstein et al (2006) 1.18 [0.87, 1.59]
Hong et al (2014) 1.05 [1.00, 1.10]
Jones et al (2015) 1.12 [0.95, 1.31]
Kim et al (2008) 1.02 [0.94, 1.11]
Kluthcovsky et al (2012) 1.23 [1.01, 1.48]
Minton et al (2012) 0.83 [0.55, 1.26]
Reindunsdatter et al (2012) 1.01 [0.72, 1.41]
Reinertsen et al (2010) 1.06 [0.93, 1.20]
Schmitz et al (2012) 1.75 [1.38, 2.22]
Servaes et al (2007) 1.06 [0.84, 1.34]
Ventura et al (2013) 1.13 [0.95, 1.34]
Vermessen et al (2012) 1.37 [0.94, 2.00]
Total (95% CI) 1.12 [1.06, 1.19]
Severely fatigued BCS Non-severely fatigued BCS
Total events
Heterogeneity: Tau2 = 0.01; Chi2 = 31.57, df = 16 (P = 0.01); I2 = 49%
Test for overall effect Z = 3.93 (P = < 0.0001)
Figure S1c. Chemotherapy
S1c. Chemotherapy 
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Study or Subgroup Risk Ratio Risk Ratio
IV, Random, 95% CI IV, Random, 95% CI
Alexander et al (2009) 1.73 [0.25, 11.99]
Bower et al (2000) 1.18 [1.00, 1.39]
Goldstein et al (2006) 1.18 [0.79, 1.75]
Jones et al (2015) 0.95 [0.66, 1.36]
Minton et al (2012) 0.51 [0.05, 4.76]
Reindunsdatter et al (2012) 1.36 [0.56,3.30]
Schmitz et al (2012) 1.43 [1.02, 2.01]
Servaes et al (2007) 1.13 [0.79, 1.62]
Ventura et al (2013) 1.89 [0.51, 7.06]
Vermessen et al (2012) 0.63 [0.14, 2.90]
Total (95% CI) 1.18 [1.05, 1.33]
Severely fatigued BCS Non-severely fatigued BCS
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 4.64, df = 9 (P = 0.86); I2 = 0%
Test for overall effect Z = 2.69 (P = 0.007)
Figure S1d. Treatment combination: surgery, chemotherapy and radiotherapy
S1d. Treatment combination: surgery, chemotherapy and radiotherapy 
0,05 10,2 5 20
Study or Subgroup Risk Ratio Risk Ratio
IV, Random, 95% CI IV, Random, 95% CI
Alexander et al (2009) 1.37 [0.91, 2.05]
Jones et al (2015) 1.35 [0.99, 1.83]
Minton et al (2012) 1.06 [0.50, 2.28]
Reindunsdatter et al (2012) 1.21 [0.69, 2.10]
Ventura et al (2013) 1.37 [0.85, 2.20]
Vermessen et al (2012) 1.97 [1.14, 3.42]
Total (95% CI) 1.38 [1.15, 1.66]
Severely fatigued BCS Non-severely fatigued BCS
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 2.31, df = 5 (P = 0.80); I2 = 0%
Test for overall effect Z = 3.41 (P =  0.0007)
Figure S1e. Treatment combination: surgery, chemotherapy, radiotherapy and hormone therapy
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S1e. Treatment combination: surgery, chemotherapy, radiotherapy and hormone therapy 
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Study or Subgroup Risk Ratio Risk Ratio
IV, Random, 95% CI IV, Random, 95% CI
Alexander et al (2009) 0.60 [0.29, 1.26]
Bower et al (2000) 0.84 [0.70, 1.00]
Jones et al (2015) 0.62 [0.24, 1.61]
Minton et al (2012) 4.57 [0.19, 109.66]
Servaes et al (2007) 0.88 [0.37, 2.07]
Ventura et al (2013) 1.62 [0.31, 8.61]
Total (95% CI) 0.83 [0.70, 0.98]
Severely fatigued BCS Non-severely fatigued BCS
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 2.82, df = 5 (P = 0.73); I2 = 0%
Test for overall effect Z = 2.25 (P = 0.02)
Figure S1f. Treatment combination: surgery only
0.01 10.1 10 100
S1f. Treatment combination: surgery only 
Study or Subgroup Risk Ratio Risk Ratio
IV, Random, 95% CI IV, Random, 95% CI
Alexander et al (2009) 1.30 [0.30, 5.61]
Andrykowski et al (2010) 0.72 [0.44, 1.19]
Bower et al (2000) 0.92 [0.81, 1.04]
Goldstein et al (2006) 0.86 [0.64, 1.16]
Jones et al (2015) 0.63 [0.33,1.18]
Minton et al (2012) 2.30 [0.40, 13.23]
Reindunsdatter et al (2012) 1.00 [0.66, 1.53]
Schmitz et al (2012) 0.56 [0.39, 0.81]
Servaes et al (2007) 0.90 [0.46, 1.73]
Ventura et al (2013) 0.54 [0.09, 3.15]
Vermessen et al (2012) 0.74 [0.08, 6.87]
Total (95% CI) 0.87 [0.78, 0.96]
Severely fatigued BCS Non-severely fatigued BCS
Total events
Heterogeneity: Tau2 = 0.00; Chi2 = 9.96, df = 10 (P = 0.44); I2 = 0%
Test for overall effect Z = 2.74 (P = 0.006)
Figure S1g. Treatment combination: surgery and radiotherapy
S1g. Treatment combination: surgery and radiotherapy
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Relative risk of severe fatigue Level of heterogeneity
RR (95% CI) (I²)
Type of study
Cross-sectional 29.8 (25.0-35.0) 95.04
Longitudinal 21.0 (14.4-29.6) 95.57
Primary study outcome
Fatigue 25.7 (20.8-31.2) 95.67
Other outcomes 29.7 (23.3-37.0) 93.22
Type of fatigue measurement 
Diagnostic interview 22.3 (11.3-39.3) 93.95
Multi-item questionnaire 27.5 (22.2-33.4) 92.11
Single item 27.9 (21.9-34.8) 92.11
Study population
Selected with eligibility criteria 26.8 (22.4-31.8) 95.81
Consecutively screened patient sample 27.7 (22.8-33.2) 67.52
Study quality
High 22.1 (16.0-29.6) 96.49
Moderate 32.6 (26.9-38.9) 91.46
Low 31.2 (22.0-42.2) 89.92
Study period
≥ 2007 30.4 (28.8-32.1) 97.56
< 2007 33.0 (32.0-34.0) 93.11
Table S2. Sensitivity analyses of prevalence rates of severe fatigue in breast cancer survivors
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ABSTRACT   
  
Severe fatigue occurs in one in four breast cancer survivors (BCS). Quality of life 
(QOL) and psychological factors are important in fatigue-oriented interventions for 
BCS, but an up-to-date overview is lacking. The aims of this review were to (i) provide 
a comprehensive overview of the relationship of fatigue with QOL and psychological 
factors in BCS and (ii) determine the strength of evidence for these relationships. A 
systematic literature search was conducted to find studies on fatigue after curative 
breast cancer treatment. Fatigue-related factors of 57 eligible studies were extracted 
and the level of evidence was determined. Factors regarding QOL (ie, general QOL, 
functioning, work ability, pain, and mental health) had a negative relationship with 
fatigue (moderate to strong evidence). This underlines the severity of cancer-related 
fatigue and its negative consequences on patients’ lives. Psychological factors were 
divided into the subcategories emotional problems, sleep, activity regulation, coping 
with cancer, dysfunctional cognitions, and social support. Moderate to strong evidence 
appeared for a relationship of fatigue with depressive symptoms, anxiety, distress, 
sleep disturbances, lower physical activity levels, difficulties with coping with cancer, 
and catastrophizing about symptoms. These factors are points of attention for existing 
and future psychological interventions for fatigue in BCS. 
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INTRODUCTION 
     
Breast cancer is by far the most prevalent type of cancer among women, affecting 
one in eight women during their lifetime (1, 2). As populations throughout the world are 
growing and aging, the number of new breast cancer diagnoses is rising. Meanwhile, 
survival rates have been improved due to advances in the detection and treatment of 
breast cancer, resulting in an increasing number of breast cancer survivors (BCS) (3).
    A subgroup of BCS experience troublesome and debilitating symptoms after curative 
cancer treatment. Cancer-related fatigue is one of the most common sequelae of cancer 
treatment, defined by the National Comprehensive Cancer Network as ‘a distressing, 
persistent, subjective sense of physical, emotional and/ or cognitive tiredness, related 
to cancer or cancer treatment, that is not proportional to recent activity and interferes 
with usual functioning’ (4, 5).
A recent meta-analysis of our research group on severe fatigue in BCS showed a 
pooled prevalence rate of severe fatigue of 27%. Regarding the course of severe fatigue 
over time, there seemed to be a relatively large decrease in the prevalence in the first 
six months after breast cancer treatment. Higher disease stages, chemotherapy and 
certain combinations of cancer treatment modalities were identified as potential risk 
factors for fatigue in BCS, whereas having a partner and receiving surgery with or 
without radiotherapy decreased this risk  (6). 
If fatigue in cancer survivors is caused by an underlying somatic condition (eg, 
anemia), treatment can be directed at this cause. However, this is only the case in 
a minority of patients. Mostly, a somatic etiology cannot be found and non-medical 
interventions are indicated (7, 8). In the current guidelines for fatigue in cancer 
survivors, a main category of recommended interventions concerns psychological 
interventions (eg, psycho-education and cognitive (behavioral) therapy), focusing on 
behavioral and psychosocial factors that contribute to the maintenance of fatigue over 
time (9-11). 
Insight in the relationship of fatigue with quality of life (QOL) and psychological 
factors in BCS would help us to identify target factors and outcomes for existing and 
future psychological interventions. There is a growing body of literature on cancer-
related fatigue (8), but to the best of the authors’ knowledge, no systematic review has 
specifically focused on fatigue-related QOL and psychological factors in BCS yet. Two 
systematic reviews summarized the psychosocial and behavioral correlates of fatigue 
in cancer survivors with mixed cancer diagnoses. Fatigue-related QOL of life and 
psychological factors that appeared from this review concerned depression, anxiety, 
C
h
ap
te
r 
3
60
distress, pain, poorer sleep quality, lower physical activity, catastrophizing, and worse 
physical functioning (12, 13). However, besides a lack of a specific focus on BCS, these 
reviews date from 10 to 15 years ago, and did not determine a level of evidence for the 
relationships of fatigue with QOL and psychological factors. 
In this systematic review, we aimed to (i) provide a comprehensive overview of the 
relationship of fatigue with QOL and psychological factors in BCS and (ii) determine the 
strength of evidence for these relationships, in order to detect target factors for fatigue-
oriented interventions. This knowledge could be used to guide the development of new 
interventions, or to optimize the efficacy of existing interventions aimed at fatigue in 
BCS.
METHOD
A systematic review protocol has been published in the International Prospective 
Register of Systemic Reviews (PROSPERO, reference no. CRD42015015768). Review 
methods are in accordance with the PRISMA statement for systematic reviews and 
meta-analyses (14). 
Search strategy and selection criteria
A systematic search of the databases Pubmed, PsycINFO, Cochrane, CINAHL and 
Web of Science was conducted. The search strategy consisted of the main components 
‘breast cancer’, ‘fatigue’, and ‘survivors’, included as MeSH-headings and free text 
words. The complete search strategy is provided in Appendix A. 
The literature search consisted of two parts. The first part were the results of an 
original search, which were reported in a recent meta-analysis of our research group, 
described in the Introduction section (6). This search included all studies from inception 
up to November 23, 2015 that had reported the prevalence, socio-demographic, and/or 
medical related factors of fatigue in BCCS. The eligibility of the 1247 full texts that had 
resulted from this search were re-evaluated for the purpose of the current systematic 
review (ie, fatigue-related QOL and psychological factors in BCS). The second part of 
the literature search was a full-update search from November 23, 2015 up to April 5, 
2017. 
In both parts of the search, studies were eligible if: (a) only included BCS who had 
completed curative cancer treatment (except for ongoing adjuvant hormone therapy) 
were included; (b) quantitative data (obtained through questionnaires) were reported 
on fatigue-related QOL and/or psychological factors; (c) the study consisted of at least 
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50 participants, and (d) a full-report in English, Dutch or German was provided.
We used the definition of the World Health Organization for QOL: “individuals' 
perception of their position in life in the context of the culture and value systems in 
which they live and in relation to their goals, expectations, standards and concerns.” 
This is a broad ranging concept, which also incorporates individuals’ physical health 
and mental health (15).  We defined psychological factors as “variables which relate to 
behaviors, feelings, thoughts and attitudes which would be modifiable for the purposes 
of intervention, or which may moderate the effects of treatment” (16). 
Data extraction and synthesis
Study titles and abstracts were screened for eligibility independently by two 
reviewers. Full text versions were retrieved if necessary. Only fatigue-related factors 
that were examined in at least two unique study populations, or at least two time points 
in one study population, were reported. Findings must be based on univariate analyses 
(mean or frequency comparisons, correlations, univariate regression analyses) and/or 
multivariate analyses (multivariate regression and modeling analyses). If univariate 
and multivariate analyses were both conducted for a certain variable in one study 
population, only the multivariate results were reported. Related factors of fatigue 
were categorized based on conceptual similarity, determined by consensus between 
all authors. 
Study quality
The methodological quality of the included studies was assessed by two reviewers 
(H.A. and M.G.) with a checklist for psychosocial oncology studies, consisting of 14 
criteria  (Table A.1, Appendix). One point was assigned to each fulfilled criterion, after 
which studies were divided into high (≥11 points), moderate (7-11 points), and low (<7 
points) quality studies (6, 17, 18). 
Level of evidence
The criteria of a previous review that summarized determinants of fear of cancer 
recurrence (19) were used to assess the level of evidence: (a) strong evidence: consistent 
finding in at least five studies, with a non-significant finding in less than half of the 
selected studies; (b) moderate evidence: consistent finding in the same direction in at 
least three studies or at least half of studies reporting a non-significant relationship; (c) 
insufficient evidence: a significant relationship was only found in one or two studies 
(19). Findings of low quality studies were not included in the determination of the level 
of evidence. 
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RESULTS 
Search results  
The records that resulted from the original and full-update search are described 
separately in the flow-chart of study selection (Figure 1). The search strategy resulted 
in a total number of 5.662 hits. After removing 1.723 duplicates and excluding 2.457 
records based on title and/or abstract, the full texts of 1.482 studies were assessed for 
eligibility. A total of 1.424 studies were excluded, because: (a) the analyses contained 
survivors with other tumor types or survivors who were not disease-free (n=416); (b) 
no quantitative data were reported on fatigue-related QOL and/or psychological factors 
(n=839); (c) the sample size was below 50 participants (n=72), and (d) a full-report in 
English, Dutch or German was lacking (n=98). Finally, 57 eligible studies remained. 
Study characteristics
The design of 40 of 57 included studies was cross-sectional, whereas the 17 other 
studies were longitudinal with a mean of 3 (range 2 to 6) measurement points. Sample 
Notes. Number of records from original search (OR) plus full-update search (UPD) are reported. 
WOS=Web of Science.
Figure 1 Selection of descriptive studies
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pubmed 
1159 (OR) + 
166 (UPD) 
 
 
  
 
 
 
 
PsycINFO 
250 (OR) +  
30 (UPD) 
 
 
CINAHL 
924 (OR) + 
106 (UPD) 
 
Cochrane 
402 (OR) + 
16 (UPD) 
WOS 
2268 (OR) + 
341 (UPD) 
Search results 
5003 (OR) + 659 (UPD) 
Duplicates removed 
1611 (OR) + 112 (UPD) 
 
 
 
 
  Records screened 
3392 (OR) + 547 (UPD) 
 
 
Records excluded on title/ abstract 
2145 (OR) + 312 (UPD) 
 
 
 Full texts assessed for 
eligibility 
1247 (OR) + 235 (UPD) 
Eligible articles 
48 (OR) + 9 (UPD) 
Records excluded based on 
full text 
1199 (OR) + 226 (UPD) 
 
 
 
 
 
 
Reasons 
(a) No data on disease-free breast 
cancer  
      survivors after curative cancer  
      treatment: 248 (OR) + 168 (UPD)   
(b) No quantitative data on psychosocial      
      and/ or behavioral related factors of    
      fatigue: 797 (OR) + 42 (UPD) 
(c) Sample size<50: 58 (OR) + 14 (UPD) 
(d) No original full report in English,   
      Dutch or German: 96 (OR) + 2 (UPD) 
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sizes at start of the studies ranged from 59 to 3088 BCS. Four studies used a diagnostic 
interview, whereas the other 53 studies used questionnaires to measure fatigue. 
Twenty-one different questionnaires were used to measure fatigue in BCS. The most 
frequently used questionnaires to assess fatigue were the Fatigue subscale of the 
EORTC QOL questionnaire-C30 (n=6), the Vitality subscale of the RAND SF-36 (n=6) and 
the Fatigue subscale of the Profile of Mood States (POMS) (n=6). The mean time since 
cancer treatment was reported in 21 studies and was 20 months (SD=21; range=0-64 
months), while 21 studies only reported the mean time since diagnosis (42 months; 
SD=25; range=10 to 90 months). Study quality was high in 18 studies, moderate in 33 
studies, and low in six studies (Table 1). 
The relationship between fatigue and QOL in BCS
There was strong evidence for a negative relationship between patients’ level of 
fatigue and their QOL in general (11 studies). Twelve other factors with regard to QOL of 
BCS have been examined. These factors were divided into the subcategories functioning 
and mental health. The evidence on each included factor (none, insufficient, moderate, 
or strong) is described in Table 2. Only the factors with moderate to strong evidence 
will be discussed in the text. 
Functioning 
Evidence was strong for a relationship between fatigue and physical functioning (9 
out of 11 studies), role functioning (8 out of 10 studies), cognitive functioning (7 out of 
9 studies), emotional functioning (10 studies), social functioning (9 out of 11 studies), 
and pain (7 out of 10 studies). Moderate evidence appeared for a relationship of fatigue 
with sexual functioning (3 out of 4 studies) and work ability (3 out of 4 studies). Higher 
levels of fatigue were found to be related to more pain, lower levels of functioning and 
a lower work ability. 
Mental health
There was moderate evidence for a relationship of higher fatigue levels with lower 
mental health (3 studies), and for the absence of a relationship with a history of a 
DSM-IV axis I diagnosis (not significant in 4 studies). 
The relationship between fatigue and psychological factors in BCS
In total, 16 psychological factors were examined and divided into the subcategories 
emotional problems, sleep, activity regulation, coping with cancer diagnosis, 
dysfunctional cognitions, and social support. The evidence on the included factors 
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is described in Table 3. Only the factors with moderate to strong evidence will be 
discussed in the text.
Emotional problems
Higher levels of fatigue were related with more  emotional problems (moderate 
to strong evidence), which concerned  symptoms (not psychiatric disorders). The 
identified problems were depressive symptoms (22 out of 25 studies), anxiety (7 out of 
10 studies), and distress (4 out of 5 studies).
Sleep
There was strong evidence for a relationship between higher fatigue levels and 
sleep disturbances (9 out of 14 studies). Mostly, this concerned a relationship between 
fatigue and insomnia (5 out of 9 studies). Insufficient data were available for a further 
specification of the types of sleep disturbances. Moderate evidence appeared for the 
relationship between higher fatigue levels and a lower sleep quality (4 out of 5 studies).
Activity regulation
Lower activity levels were found to be related to higher fatigue levels, with a strong 
level of evidence (7 out of 11 studies). 
Coping with cancer diagnosis
Moderate evidence was found for a relationship between a higher level of fatigue 
and a more negative body image (4 studies), and a more negative future perspective 
(ie, more worries about future health) (3 studies).
Dysfunctional cognitions
There was strong evidence (5 out of 6 studies) for a positive relationship between 
fatigue and catastrophizing about symptoms, which reflects a tendency to engage 
in negative self-statements and overly negative thoughts about the future regarding 
fatigue. 
Study quality
Findings of the six low quality studies were not included in the determination of 
the levels of evidence. If these studies would be included, the level of evidence would 
remain unchanged for all factors except mental health. The level of evidence of both 
factors for a relationship with fatigue would change from moderate into strong.  
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DISCUSSION
Summary of findings
The aims of this systematic review were to provide a comprehensive overview of 
fatigue-related QOL and psychological factors in BCS and to determine the strength 
of evidence for these relationships. There was moderate to strong evidence for the 
conclusion that higher levels of fatigue in BCS go together with a lower QOL, a lower level 
of functioning (in the physical, role, cognitive, emotional, social, and sexual domain), 
a lower work ability, more pain, and lower mental health. Looking at psychological 
factors, moderate to strong evidence appeared for the relationship of fatigue in BCS 
with depressive symptoms, anxiety, distress, sleep disturbances, a lower sleep quality, 
lower levels of physical activity, components of coping with cancer (ie, body image and 
worries about future health), and catastrophizing about symptoms.
Strengths and limitations
This is the first systematic review that provides a comprehensive overview of fatigue-
related QOL and psychological factors in BCS. Strengths include the structured and 
thorough search of the literature and the determination of the level of evidence. Our 
choice to limit our review to breast cancer survivors removes a potentially confounding 
influence of tumor type and active cancer treatment. Thus far, research on fatigue in 
cancer survivors has predominantly been focused on BCS (20). This means that our 
findings represent the majority of the current literature on fatigue in cancer survivors. 
A limitation of this review is the lack of sufficient data from longitudinal studies 
to distinguish causes and consequences of fatigue. It should also be mentioned that 
we could only draw broad conclusions from group data. Individual patient data 
would have enabled us to provide more detailed insights, for instance by analyzing if 
related factors of fatigue differ between certain subgroups of patients (ie, regarding 
age or type of cancer treatment) (21). Another limitation concerns the heterogeneity 
of the measurements in the included studies. Questionnaires that measured fatigue 
and related psychological factors differed, and may (partly) have involved different 
concepts. The use of 21 different questionnaires in the 57 included studies reflects 
a lack of consensus on the measurement and definition of fatigue in BCS. Achieving 
more consensus is required to be able to integrate research results and optimize the 
scientific knowledge on cancer-related fatigue. 
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Recommendations for future research
Our findings are in accord with previous systematic reviews on fatigue in cancer 
survivors with mixed diagnoses. The fatigue-related QOL and psychological factors that 
were reported in these reviews were also identified in our review on BCS: depression, 
anxiety, distress, pain, poorer sleep quality, lower physical activity, catastrophizing 
about symptoms, and worse physical functioning (12, 13). Future reviews should verify 
if the strength of evidence for these factors and the other fatigue-related factors (ie, 
components of coping with cancer, different domains of functioning, and work ability) 
can also be extrapolated to cancer survivors with other tumor types.  
The identified fatigue-related psychological factors from our review may influence 
effects of interventions aimed at fatigue in BCS. It would be valuable to explore the 
potentially mediating role of these factors. To date, the mechanisms behind cancer-
related fatigue are not fully understood, which is seen as a major barrier to enhance 
symptom control (8). Identifying potential mediators of effects of fatigue-oriented 
interventions could help to clarify which intervention elements work for whom. In 
turn, this could improve the tailoring of interventions to individual patients, which 
could (further) improve its efficacy. Integration of different types of interventions 
might be beneficial, like combining exercise interventions with elements of cognitive 
behavioral therapy or mindfulness. 
 Our review revealed some important gaps in the knowledge on fatigue in BCS. 
Factors with insufficient evidence require further research. This is the case for four 
types of dysfunctional cognitions (other than catastrophizing about symptoms) that 
were only assessed in one population of BCS at multiple time points: (i) self-efficacy (ie, 
patients’ sense of control regarding fatigue), (ii) psychological attributions regarding 
fatigue (ie, patients’ tendency to attribute fatigue complaints to ruminating or sleep 
disturbances), (iii) focusing on symptoms (ie, preoccupation with symptoms), and 
(iv) accommodating to illness (ie, patients’ tendency to organize their lives to avoid 
overexertion and control stress). Research has shown that changing dysfunctional 
cognitions helped to decrease fatigue severity in other patient populations: a decrease 
in focusing on symptoms and an increase in self-efficacy partly mediated effect of 
cognitive behavioral therapy on fatigue in patients with chronic fatigue syndrome and 
type 1 diabetes (22, 23).
 Strong evidence appeared for the relationship between higher levels of fatigue with 
higher levels of anxiety, but fear of cancer recurrence was only examined in three 
studies (24-26). Future studies should examine the relationship of fatigue with anxiety 
in BCS, and particularly fear of cancer recurrence, in further detail. It also needs to 
be examined how to integrate fear of cancer recurrence in interventions for fatigue 
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in BCS. For instance, our research group has developed an evidence-based cognitive 
behavioral therapy for fatigue in cancer survivors, in which decreasing high levels of 
fear of cancer recurrence is seen as a perpetuating factor of fatigue and included as 
one of the treatment modules (9). 
Only two studies took patients’ social environment into account and concluded 
that dissatisfaction with social support was related to a higher level of fatigue (27, 
28). Together with the strong and consistent evidence on the negative relationship of 
fatigue with social functioning, this shows an area of interest for future research on 
fatigue in BCS. 
Few studies focused on sexual functioning and fatigue in BCS (29-32). Sexual 
dysfunctions resulting from cancer treatment are common and occur in 37 to 51% 
of BCS (33). Given the high prevalence of both fatigue and sexual dysfunctions, the 
interrelatedness between these two sequelae of cancer treatment should be examined 
in further detail. It is likely to hypothesize that a decrease in fatigue severity may 
improve sexual dysfunctions,  which makes it worthwhile to explore the influence of 
fatigue-oriented interventions on sexual functioning.  
Finally, attention should be paid to the relationship of fatigue in BCS with protective 
psychological factors, like optimism and mindfulness. So far, the main focus has been 
on factors that are likely to have a negative influence on fatigue. However, it would 
be valuable to know which skills are helpful to cope with cancer-related fatigue and 
may prevent it from becoming chronic. Protective psychological factors may also 
mediate effects of fatigue-oriented interventions. An example was shown in a study on 
a stress reduction intervention for cancer patients, in which self-reported mindfulness 
(ie, self-regulation of awareness towards present mental states, and a non-evaluative 
acceptance towards moment-to-moment experiences) mediated the positive effect on 
psychological well-being (34).  
Clinical implications
The consistent evidence for the relationship of fatigue in BCS with lower scores 
regarding QOL, all functioning domains, work ability, and mental health reflects 
the severity of the symptom and its negative consequences on patients’ lives. This 
underlines the importance of interventions that target fatigue in BCS. Our systematic 
review highlights important areas of attention for existing and future fatigue-oriented 
interventions: depressive symptoms, anxiety, distress, sleep disturbances, lower 
physical activity levels, difficulties with coping with cancer, and catastrophizing about 
symptoms. 
Findings of this review showed that fatigue and depressive symptoms go 
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hand-in-hand. As depressive symptoms were by far the most frequently studied 
psychological variable, the evidence for its positive relationship with fatigue was the 
strongest of all variables. It is important to screen for a depressive disorder in fatigued 
BCS. In that case, fatigue is one of the symptoms (35), and the depressive disorder 
should be treated first. Once the depressive disorder has been treated successfully, 
levels of fatigue may decrease at the same time. If not, a fatigue-oriented intervention 
can be provided afterwards. 
 Fatigue and depressive symptoms seem to be interdependent: depressive symptoms 
were shown to be a predictor of fatigue and vice versa. A consistent correlation 
between depression and fatigue was also found in another systematic review that 
focused on cancer patients in all phases of the curative and palliative trajectory of 
cancer treatment (36).  Recently, it was shown that a decrease in depressive symptoms 
influenced the effect of CBT on fatigue in patients with type 1 diabetes. Although patients 
with a depressive disorder were excluded from this study, depressive symptoms were 
still identified as one of the mediators of the reduction in fatigue (Menting, Tack, et al., 
submitted; (37). Elements of psychological interventions like changing dysfunctional 
cognitions and improving sleep patterns might decrease fatigue and depressive 
symptoms simultaneously. Directly addressing depressive symptoms may contribute 
to a further reduction of fatigue. The role and place of depressive symptoms in fatigue-
oriented interventions for BCS should be further examined.   
 Two factors regarding patients’ functioning that need attention in treatment of 
cancer-related fatigue are return to work and pain. Findings of our review showed 
moderate evidence for a relationship of fatigue and patients’ work ability. This 
relationship was also found in a systematic review of Duijts e.a. on survivors with 
mixed cancer diagnoses. As the group of occupationally active BCS is expanding and 
work is important for social integration and participation (38), return to work should be 
addressed in interventions aimed at fatigue. Besides, future studies should investigate 
the effects of fatigue-oriented interventions on the work ability of BCS. 
Strong evidence emerged from our review regarding a positive relationship between 
pain and fatigue. More detailed conclusions (eg, on the influence of different locations 
and causes of pain) cannot be drawn but should be examined future research. Pain 
resulting from cancer treatment is often complex and difficult to diagnose (39). There 
is a diversity of pain syndromes in cancer survivors, and a consistently effective 
pharmacological treatment is lacking (40). Studies have shown a positive relationship 
of pain with a passive coping style and catastrophizing, which shows potential for 
psychological coping interventions to improve pain control (39). Integrating coping 
interventions for pain into interventions for cancer-related fatigue has potential 
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benefit that needs to be explored in future research. 
 
CONCLUSIONS
Higher levels of fatigue go together with a worse QOL, lower functioning and work 
ability, more pain, and lower mental health of BCS. This underlines the importance 
of interventions that decrease this debilitating symptom. The moderate to strong 
evidence for the relationship of fatigue with depressive symptoms, anxiety, distress, 
sleep disturbances, lower physical activity levels, difficulties with coping with cancer, 
and catastrophizing about symptoms reflects important points of attention for 
interventions aimed at fatigue in BCS. Future research is needed to identify mediators 
of treatment effects, which could help to explore what intervention elements work 
for which patients. It also needs to be examined how to integrate pain and return to 
work into fatigue-oriented interventions. This could guide the development of new 
interventions, or help to optimize the efficacy of existing interventions aimed at fatigue 
in BCS.
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APPENDIX
Positive if:
1. A validated, complete questionnaire measuring fatigue was used (not only subscales)
2. A description was given of at least three socio-demographic variables
3. In- and exclusion criteria were described 
4. Response rate to the fatigue questionnaire was reported and ≥65 %
5. Information was provided on differences of characteristics between responders and 
nonresponders
6. Time since completion of cancer treatment was provided 
7. Type of cancer treatment and stage of disease were described
8. Data were prospectively gathered 
9. The process of data collection was described
10. The sample size determination was explained 
11. Missing data were described
12. The results were compared between two groups or more (e.g., healthy population, groups with 
different treatment or age and/or compared with at least two time points)
13. Mean, median, standard deviations or percentages were reported for the most important clinical 
outcome measure
14. Limitations of the study were discussed
Supplementary Table 1. Criteria list for assessing the methodological quality of studies on fatigue in breast cancer 
survivors
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ABSTRACT
Purpose: Severe fatigue after treatment of ductal carcinoma in situ (DCIS) has not 
been studied before. The current study examined (i) the prevalence of severe fatigue 
in DCIS patients versus breast cancer survivors (BCS) and healthy controls (HC), (ii) 
quality of life and functioning of severely versus non-severely fatigued DCIS patients 
and BCS, and (iii) the association of fatigue with psychosocial and behavioral factors 
in DCIS patients. 
Methods: 89 patients treated for DCIS were matched on age and gender to 67 BCS 
and 178 HC (ratio 1:1:2). Fatigue was measured with the Fatigue Severity subscale of 
the Checklist Individual Strength.
Results: 23% of DCIS patients, 25% of BCS, and 6% of HC were severely fatigued 
(DCIS versus HC: P < .001). Severely fatigued DCIS patients had a lower quality of life 
and were more impaired in all domains of functioning than non-severely fatigued DCIS 
patients. Sleep problems, dysfunctional cognitions regarding fatigue, avoidance of 
activities, all-or-nothing behavior, perceived lack of social support, DCIS-related coping 
problems, and fear of future cancer occurrence were related to fatigue. 
Conclusions: The prevalence of severe fatigue in DCIS patients was similar to BCS, 
but higher than in HC. Severely fatigued DCIS patients had a lower quality of life 
and more functional impairments. The psychosocial and behavioral fatigue-related 
factors in DCIS patients are known to perpetuate fatigue in BCS. These factors can be 
targeted in interventions for cancer-related fatigue. Our findings suggest that the same 
treatment elements might be applicable to severely fatigued DCIS patients.
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INTRODUCTION
Since the introduction of breast cancer screening programs in western countries 
in the nineties, the number of detected cases of ductal carcinoma in situ (DCIS) has 
increased rapidly (1). Nowadays, an estimated proportion of 1 in 33 women will be 
diagnosed with DCIS in her lifetime (2). It cannot be predicted in which cases DCIS will 
be harmless, and in which cases it will develop into breast cancer (3). To prevent any 
progression, DCIS is generally treated with a mastectomy or breast-conserving surgery 
followed by radiotherapy (4). 
 This means that although DCIS is non-invasive, it is treated with the same treatment 
modalities as breast cancer. This paradox can make DCIS a confusing diagnosis for 
patients (5). So far, the influence of DCIS on patients’ lives has been examined in a 
limited number of studies. A recent large study showed that the overall quality of 
life does not differ between DCIS patients and age-matched women without a history 
of a breast disease (6). Nevertheless, the diagnosis and treatment of DCIS can have 
significant impact on psychosocial functioning.  
 A subgroup of DCIS patients has increased distress levels and poor mental health 
during and after treatment completion, and coping problems frequently occur (7-9). 
Patients are often unsure about their diagnosis, for example about whether DCIS is 
cancer (9). Despite the favorable prognosis of DCIS, many patients overestimate their 
actual risk on the occurrence of breast cancer or metastases (8, 10, 11). Anxiety plays a 
main role in this overestimation (8). 
 In contrast to the limited number of studies on sequelae of DCIS treatment, numerous 
studies examined this subject in breast cancer survivors (BCS). In these studies, severe 
fatigue emerged as one of the most troublesome cancer-related symptoms, occurring 
in approximately one in four BCS and diminishing patients’ quality of life (12, 13). Thus 
far, the prevalence of severe fatigue and its consequences have not been studied in 
DCIS patients.
 Guidelines on cancer-related fatigue assume that fatigue is related to cancer and 
its treatment (13). However, these triggers are no longer present after treatment 
completion. At that point, factors that maintain fatigue come into play (14). There is 
evidence for multiple psychosocial and behavioral factors that can perpetuate fatigue 
in cancer survivors: sleep problems, perceived lack of social support, low physical 
activity levels, dysfunctional cognitions regarding fatigue, heightened fear of cancer 
recurrence, and poor coping with the diagnosis cancer and being treated for cancer (14, 
15). Though DCIS-related coping problems and worries about future cancer occurrence 
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are also common in DCIS patients (8, 10, 11), it is unknown if these factors are related 
to fatigue. The other factors and their association with fatigue have not been explored 
in DCIS patients yet.  
  In this study, we examined (i) the prevalence of severe fatigue in DCIS patients 
compared to BCS and healthy controls (HC), (ii) quality of life and functioning of 
severely versus non-severely fatigued DCIS patients and BCS, and (iii) the association 
of fatigue with psychosocial and behavioral factors in DCIS patients. 
METHODS
Participants and procedure
A cross-sectional study was conducted in two general hospitals in the Netherlands: 
hospital Gelderse Vallei (Ede) and hospital Pantein (Boxmeer). All patients who were 
treated for DCIS or breast cancer between January 2010 and September 2015 were 
registered in anonymous patient registries. DCIS patients and BCS were selected from 
these registries. Ethical approval was obtained from the medical ethic committees of 
both hospitals.
 DCIS patients were eligible if treatment for DCIS was completed up to five years 
ago. DCIS patients were excluded if (i) a current or former malignant tumor, or (ii) 
a somatic comorbidity that can cause severe fatigue was reported in their medical 
records. All eligible DCIS patients were selected from the patient registries, and invited 
to participate by mail. If they were willing to participate, they were asked to return 
a participation form and to indicate if they preferred to complete the questionnaires 
by e-mail or by mail. Subsequently, participants received the questionnaires in the 
preferred way, as well as an informed consent with a self-addressed envelope by mail. 
 To determine if the prevalence of fatigue in DCIS patients differed from women 
who have had a malignant breast tumor and healthy women, two control groups were 
selected. Each DCIS patient was matched to one BCS and two HC (ratio 1:1:2) with 
respect to gender and age, based on categories of 5-year strata. Matched BCS were 
selected from the patient registries of the participating hospitals. All matched BCS 
(i) had completed breast cancer treatment up to five years ago (except for hormone 
therapy), (ii) were disease-free, and (iii) had no somatic comorbidities that could cause 
severe fatigue according to their medical records. To equalize type of treatment, DCIS 
patients were only matched to BCS who had not received chemotherapy. A recent 
meta-analysis of our research group indicated chemotherapy as a potential risk factor 
for severe fatigue in BCS (12). For this reason, BCS who had received chemotherapy 
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were excluded. Matched BCS received questionnaires by mail. They were asked to 
return the questionnaires and an informed consent if they were willing to participate. 
 Matched HC were derived from CentERdata, a cohort of over 2000 Dutch adults who 
represent the general Dutch population (16). Precision matching on age and gender 
was performed with the procedure Coarsened  Exact Matching (CEM) using STATA/
SE 12.1. Being healthy was defined as zero days of sick leave in the past month, and 
no self-reported limitations in daily activities, social activities and work due to health 
problems.
Measures 
Data on the clinical variables stage of DCIS, type of surgery, radiotherapy, and date 
of diagnosis were retrieved from medical records. Data on the latter two variables 
were also available in BCS. Data on the socio-demographic variables partner and work 
status, educational level, medical problems, and recent significant life events were 
gathered with self-report questionnaires. Educational level was also available in HC 
and categorized into low, medium and high, according to the Dutch national public 
health compass (17). 
 The level of fatigue was measured in DCIS patients, BCS and HC with the subscale 
Fatigue Severity of the Checklist Individual Strength (CIS-fatigue; 8 items, 7-point scale, 
range 8-56) (18, 19). Higher score indicate higher levels of fatigue. The established 
cut-off score for severe fatigue is 35 or higher, which is two standard deviations above 
the mean score in HC (18, 19). The CIS-fatigue has good psychometric properties (20, 
21), and was used in previous research on cancer patients and survivors (14, 15, 22).
 Quality of life and functioning were measured in DCIS patients and BCS with 
the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC-QLQ-C30; 30 items, 4-point scale) (23). This questionnaire 
consists of function scales (physical, social, cognitive, emotional, and role functioning) 
and a global quality of life scale. Higher scores indicate better functioning. The 
EORTC-QLQ-C30 has adequate validity and reliability (24).  
 Questionnaires on behavioral and psychosocial factors were only administered in 
DCIS patients. Sleep quality was measured with the Sleep/Rest subscale of the Sickness 
Impact Profile-8 (SIP-8). Higher scores indicate more sleep problems (25). 
 Activity patterns were assessed with the two subscales of the Cognitive and 
Behavioral Responses to Symptoms Questionnaire (CBRSQ): avoidance of activities and 
fluctuating activity patterns (i.e., all-or-nothing behavior). Higher scores indicate a 
more dysfunctional activity pattern (26).  
 Cognitions regarding fatigue were measured with the Self-Efficacy Scale (SES). 
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Higher scores indicate a lower sense of control with regard to fatigue (27). Focusing 
on fatigue was measured with the Illness Management Questionnaire (IMQ). Higher 
scores indicate a higher tendency to focus on fatigue (28).
 Fear of cancer occurrence was measured with an adapted version of the Cancer Worry 
Scale (CWS). The word ‘again’ was removed from all items to adapt this questionnaire 
for DCIS patients. Higher scores indicate more worries about cancer (29).
 Coping with DCIS was assessed with the Impact of Event Scale (IES), which measures 
patients’ responses to having had DCIS and being treated for DCIS with the two 
dimensions intrusion and avoidance. Higher scores indicate more coping problems 
(30).
 Discrepancies in social support were measured with the shortened version of the 
Social Support List Discrepancy (SSL-D). Lower scores indicate more discrepancies 
between the level of desired and actual social support (31).
Statistic analyses
Descriptive statistics were used to report socio-demographic and clinical charac-
teristics of study participants. Available characteristics of the control groups were 
compared to DCIS patients using chi-square tests for independence and independent 
samples T-tests. These methods were also used to compare characteristics of severely 
and non-severely fatigued DCIS-patients. 
 DCIS patients, BCS and HC were divided in severely versus non-severely fatigued 
patients, using the cut-off score of 35 of the CIS-fatigue. Chi-square tests for independence 
and independent samples T-tests were used to compare fatigue prevalence rates 
and mean fatigue scores between DCIS patients and BCS, and DCIS patients and HC. 
Independent samples T-tests were used to compare quality of life and functioning 
between severely and non-severely fatigued DCIS patients, and between severely and 
non-severely fatigued BCS. Differences on the EORTC-QLQ-C30 subscales of at least 10 
points were considered to be clinically relevant (32). 
 Pearson correlations were used to assess if fatigue severity was related to psychosocial 
and behavioral factors. Spearman’s rank correlation coefficients were used for ordinal 
variables. Correlations were interpreted following of Cohen’s guidelines (0.1-0.29 = 
weak, 0.3 - 0.49 = moderate, ≥0.5 = strong (33)). P-values of .05 were considered as 
statistically significant, and SPSS version 22 was used for all analyses.
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RESULTS
Sample characteristics 
Figure 1 illustrates the flow chart of patient inclusion. Between January 2010 and 
September 2015, 156 patients were diagnosed with DCIS in the two participating 
hospitals. Twenty-eight patients were excluded, because they had a somatic comorbidity 
that could cause severe fatigue (N = 11), a current or former malignant tumor (n=6), 
were deceased (N = 5), not locatable (N = 4), or had cognitive impairments (N = 2). 
 In total, 128 DCIS patients were eligible. Thirty-nine patients did not participate 
in the study, of which 11 patients actively declined to participate. Questionnaires 
were completed by 89 patients (response rate of 70%). Non-participants did not differ 
significantly from participants regarding age at diagnosis, stage of DCIS, and type of 
DCIS treatment. Socio-demographic and clinical characteristics of study participants, 
and severely versus non-severely fatigued DCIS-patients are reported in Table 1. None 
of the characteristics differed significantly between these two groups.
 Regarding the control groups, 67 of 89 BCS completed the questionnaires on fatigue 
and QOL (response rate of 75%), and 178 HC were retrieved from the CentERdata 
cohort. Mean time since diagnosis was significantly longer in BCS than in DCIS patients 
(respectively 49 months (SD = 10) and 35 months (SD = 19); P < .001). All BCS and 
Figure 1. Flow chart of patient inclusion.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
156 patients treated for DCIS at the 
two treatment centers between 
January 2010 and September 2015 28 patients excluded 
     11 somatic comorbidity that can cause            
           severe fatigue 
        6 invasive tumor after treatment of DCIS 
        5 deceased    
        4 no contact information available           
        2 incompetent to participate  
128 patients were eligible and 
invited to participate in the study 
   39 Non-participants 
      11 active declines 
      28 non-responders 
89 patients completed the 
questionnaires (70%) 
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DCIS patients were treated with surgery. The number of patients who had received 
radiotherapy did not differ significantly between BCS and DCIS patients. Educational 
level did not differ significantly between DCIS patients and HC. 
Prevalence of severe fatigue 
In total, 20 of 88 DCIS patients (23%), 17 of 67 BCS (25%) and 11 of 178 HC (6%) were 
severely fatigued. One DCIS patient was excluded from the analyses because of missing 
values on the CIS-fatigue. The proportion of severely fatigued patients did not differ 
significantly between DCIS patients and BCS (P = 0.847), but was significantly higher 
in DCIS patients than in HC (P < 0.001). Mean fatigue severity scores were 24.7 (SD 
13.2; range 8-56) in DCIS patients, 26.5 (SD 12.8; range 8-56) in BCS and 17.7 (SD 8.6; 
range 8-48) in HC. Mean fatigue severity scores did not differ significantly between 
DCIS patients and BCS (P = 0.397), but were significantly higher in DCIS patients than 
in HC (p< 0.001).
Quality of life and functioning in severely versus non-severely fatigued 
patients 
Severely fatigued DCIS patients scored significantly lower on global quality of life, 
and physical, role, emotional, cognitive, and social functioning than non-severely 
fatigued DCIS patients. Mean differences were at least 10 points in all domains, which 
indicates that all differences were clinically relevant. This pattern of results was similar 
when comparing severely and non-severely fatigued BCS (Table 2). 
Relationship of fatigue with psychosocial and behavioral factors
There were strong correlations between fatigue, and focusing on fatigue (IMQ; r 
= 0.62, P < 0.001) and avoidance of activities (CBRSQ; r = 0.52, P < 0.001). There were 
moderate correlations between fatigue and sleep problems (SIP; r=.45, p<.001), all-or-
nothing behavior (CBRSQ; r = 0.42, P < 0.001), problems with coping with the diagnosis 
DCIS and its treatment (IES intrusion; r = 0.33, P = 0.002; IES avoidance; r = 0.32, P = 
0.003), and perceived lack of social support (SSL-D; r = 0.33, P = 0.002). There was a 
weak correlation between fatigue, and sense of control regarding fatigue (SES; r = -0.26, 
P =0.015) and fear of future cancer occurrence (CWS; r = 0.24, P = 0.025).
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Total samplea Severely fatigued 
patientsa
Non-severely 
fatigued 
patientsa
Difference
P-valueb
(n=89) (n=20) (n=68)
Socio-demographic characteristics
Age at diagnosis in years
    Mean ± SD, range 61.2 ± 9.0 (40-79) 58.7 ± 8.8 (42-72) 61.8 ± 9.0 (38-75) 0.18
Education level
     Low 37 (42) 7 (37) 29 (44) 0.72
     Middle 25 (28) 7 (37) 18 (27)
     High 24 (27) 5 (26) 19 (29)
Having a partner 
     Yes 76 (85) 17 (90) 59 (87) 1.003
     No 11 (12) 2 (10) 9 (13)
Having a paid job 
     Yes 34 (38) 9 (47) 43 (63) 0.57
     No 54 (61) 10 (53) 25 (37)
Clinical characteristics
Time since diagnosis in months
    Mean ± SD, range 35 ± 19 (5-100) 34 ± 17 (5-61) 36 ± 19 (5-100) 0.64
Stage of disease
     I 5 (6) 2 (10) 3 (4) 0.08
     II 29 (33) 10 (50) 19 (28)
     III 55 (62) 8 (40) 45 (68)
Type of surgery
     Lumpectomy 56 (63) 13 (65) 42 (62) 1.00c
     Lumpectomy + breast 3 (3) 0 (0) 3 (4) 1.00c
        reconstruction 
     Mastectomy 13 (15) 3 (15) 10 (15) 1.00c
     Mastectomy + breast   17 (19) 4 (20) 13 (19) 1.00c
        reconstruction
Type of adjuvant treatment     
     Radiotherapy 57 (64) 12 (60) 44 (65) 0.90
Self-reported medical problems (≥1)
49 (55) 10 (53) 28 (41) 0.53
Notes. Total sample numbers differ because of missing data.
a Results are shown as n (%), unless indicated otherwise.
b Difference between severely and non-severely fatigued DCIS patients; *P < .05.
c Fisher's exact test was used because of violation of the assumption of minimum expected cell frequency.
Table 1. Characteristics of DCIS patients.
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DISCUSSION
This was the first study that examined the prevalence of severe fatigue in DCIS patients 
with a validated fatigue measure. The prevalence of severe fatigue in DCIS patients of 
23% was similar to BCS, but higher than in HC. Severely fatigued DCIS patients had a 
lower quality of life and were more impaired in all domains of functioning compared to 
non-severely fatigued DCIS patients. Differences in quality of life and functioning were 
similar between severely and non-severely fatigued BCS, which replicates previous 
research (34). Besides, fatigue was related to the psychosocial and behavioral factors 
known to perpetuate fatigue in BCS (15).
 Severe fatigue is a common and troublesome symptom in DCIS patients, just as in 
BCS. Given its adverse consequences on quality of life and functioning, this symptom 
needs to be taken seriously. Clinicians should pay attention to fatigue in DCIS patients in 
daily practice, in the same manner as in cancer patients and survivors. In accordance 
with the NCCN guidelines for cancer-related fatigue, it seems appropriate to screen all 
DCIS patients for fatigue in clinical practice (35).
 The similarities in DCIS patients and BCS concerning the prevalence, consequences 
and possible perpetuating factors of fatigue suggest that a breast disease does not need to 
be malignant to induce severe fatigue. Triggers of severe fatigue might be equal in DCIS 
patients and BCS (e.g., being diagnosed with a potentially serious medical condition, 
and being treated with surgery and/or radiotherapy). Once treatment of breast cancer 
of DCIS is completed, these triggers are no longer involved. After treatment completion, 
more generic factors are related to fatigue in both patient groups (e.g., sleep problems, 
DCIS patients P value BCS P value
EORTC-QLQ-C30 
subscales
Severe 
fatigue 
(n=20)
No severe  
fatigue 
(n=68)
Severe 
fatigue 
(n=17)
No severe 
fatigue 
(n=50)
Global quality of life 63.2 ± 16.3 84.1 ± 13.0 < 0.001* 53.9 ± 20.4 81.0 ± 14.0 < 0.001*
Physical functioning 80.0 ± 15.0 90.8 ± 11.6 0.001* 64.2 ± 19.0 87.8 ± 14.0 < 0.001*
Role functioning 64.8 ± 22.8 94.1 ± 13.4 < 0.001* 54.9 ± 28.7 90.0 ± 18.4 < 0.001*
Emotional functioning 64.9 ± 23.3 88.7 ± 14.1 < 0.001* 65.1 ± 21.1 82.0 ± 19.0 0.004*
Cognitive functioning 70.2 ± 21.2 91.4 ± 14.0 < 0.001* 69.6 ± 20.6 87.3 ± 17.4 0.001*
Social functioning 69.3 ± 25.0 93.9 ± 11.5 < 0.001* 79.2 ± 25.5 93.3 ± 13.0 0.047*
Notes. Scores are reported as mean ± SD. Higher scores indicate better functioning. *P < 0.05. Abbreviations: DCIS = 
ductal carcinoma in situ, BCS = breast cancer survivors.
Table 2. Mean scores on the EORTC-QLQ-C30
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low physical activity levels, and dysfunctional cognitions regarding fatigue). 
 These factors are targeted in evidence-based interventions for fatigue in cancer 
survivors. For example, physical activity levels can be increased in exercise 
interventions, and adjustment of dysfunctional cognitions regarding fatigue is part of 
cognitive behavioral therapy (13). Our findings suggest that these interventions may 
also be applicable to DCIS patients. However, the interventional approach needs to 
be adapted to this patient group. In this case, attention should be paid to common 
DCIS-specific problems, like coping problems regarding the diagnosis (36). Further 
research is needed to adapt current interventions for fatigue in cancer survivors to 
DCIS patients, and to examine the efficacy of these interventions.   
 Only 6% of our HC were severely fatigued, which is a low prevalence rate compared 
to other studies that retrieved HC from the CentER dataset. These studies found 
prevalence rates ranging from 7 to 22% using different criteria for health (37-39). Our 
criteria for being healthy were relatively strict, as all women with any limitations 
caused by health problems were excluded. Therefore, the prevalence of fatigue in our 
HC sample possibly is an underestimation. Moreover, some baseline characteristics 
of the two control groups are unknown (e.g., partner and work status). However, due 
to the applied matching procedure, the three research groups were comparable with 
regard to gender and age. Besides, the fact that recruitment procedures were identical 
for DCIS patients and BCS enhances the comparability of these two groups.  Another 
limitation of this study is a lack of information on when patients became fatigued and 
how long they were fatigued. Therefore, the diagnosis and treatment of DCIS have not 
necessarily been the only triggers of fatigue. Future studies should take the length and 
starting point of fatigue symptoms into account.
 Participants in this study were diagnosed between 2010 and 2015. In this five-year 
period, Dutch breast cancer guidelines had been revised once (40). It is possible that 
cancer treatment has changed after this guideline revision. A sensitivity analysis 
was conducted to compare fatigue levels between DCIS patients treated before and 
after the guideline change in 2012. The same analysis was conducted for BCS. Fatigue 
levels did not differ significantly between the two treatment periods in both patient 
groups (p-values respectively 0.187 and 0.732). This suggests that our results were not 
influenced by changes in cancer treatment during the five-year study period.
 This study was a first attempt to identify factors that were associated with fatigue 
in DCIS patients. However, the related factors of fatigue will probably be interrelated, 
and causality could not be determined. The sample size of our study was too small 
to conduct more advanced analyses like a multiple regression or a cluster analysis. 
Future studies with larger sample sizes are needed to further examine related factors 
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of fatigue in DCIS patients.
 In conclusion, this study showed that severe fatigue is a common symptom 
that occurs in almost a quarter of DCIS patients, and influences quality of life and 
functioning adversely. Fatigue was related to psychosocial and behavioral factors 
that perpetuate fatigue in cancer survivors. Evidence-based interventions for fatigue 
in cancer survivors target these perpetuating factors, and might also be applicable to 
DCIS patients. However, it should be examined if the interventional approach needs to 
be adapted, taking DCIS-specific coping problems into account. 
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ABSTRACT
Objective: Internationally, the Distress Thermometer and associated Problem List 
are increasingly used in oncology as screening tools for psychological distress. Cancer-
related fatigue is common but often overlooked in clinical practice. We examined if 
severe fatigue in cancer patients can be identified with the fatigue item of the Problem 
List.
Methods: Newly diagnosed breast (N = 334) and colorectal (N = 179) cancer patients 
were screened for severe fatigue, which was defined as having a positive score on 
the fatigue item of the Problem List. The Fatigue Severity subscale of the Checklist 
Individual Strength was used as gold standard measure for severe fatigue.
Results: In total, 78% of breast cancer patients and 81% of colorectal cancer patients 
were correctly identified with the fatigue item. The sensitivity was 89% in breast cancer 
patients and 91% in colorectal cancer patients. The specificity was 75% in breast cancer 
patients and 77% in colorectal cancer patients. The positive predictive value was 53% 
in breast cancer patients and 64% in colorectal cancer patients, whereas the negative 
predictive value was 95% in both tumor types.
Conclusions: The fatigue item of the Problem List performs satisfactorily as a quick 
screening tool for severe fatigue. However, a positive screen should be followed up 
with a more thorough assessment of fatigue, i.e., a questionnaire with a validated 
cut-off point. Given time pressure of clinicians, this already implemented and brief 
screening tool may prevent severe fatigue from going undetected in clinical practice. 
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BACKGROUND
The Distress Thermometer (DT) and associated Problem List (PL) are increasingly 
used for routine screening in oncology practice, as recommended in the clinical practice 
guideline for distress management of the National Comprehensive Cancer Network 
(NCCN) (1, 2). The aim of this short self-report questionnaire is to detect psychological 
distress and related problems in cancer patients (3). As the time per patient in clinical 
visits is limited, screening tools like the DT can prevent important needs of patients 
from being overlooked. Given the emerging international implementation of the DT 
and associated PL, it is worthwhile to assess the potential of this screening tool for other 
screening purposes. For example, Hegel et al. already showed that a cut-off score of 7 
on the DT has good sensitivity and specificity to detect depression in newly diagnosed 
breast cancer (BC) patients (4). 
Another common and disabling symptom in cancer patients is cancer-related 
fatigue, defined by the NCCN as “a distressing, persistent, subjective sense of physical, 
emotional and/or cognitive tiredness, related to cancer or cancer treatment, that is not 
proportional to recent activity and interferes with usual functioning” (5). Severe fatigue 
can cause impairments in daily functioning and diminish quality of life (6). According 
to current international guidelines (7), cancer patients should be screened routinely 
for the presence of fatigue in clinical practice using brief, quantitative self-report 
measures with empirically established cutoff scores. However, fatigue screening is not 
common in many clinical settings due to barriers of clinicians (eg, time limitations 
or not recognizing fatigue as a problem) or patients (eg, not wanting to complain or 
assuming that cancer-related fatigue is normal and permanent) (5). 
 The use of the already implemented DT and associated PL as a screening tool for 
severe fatigue might improve the detection of severe fatigue in cancer patients. The PL 
includes 1 fatigue item, in which patients are asked if fatigue is a problem for them. 
The aim of the current study was to examine the usability of this fatigue item of the 
PL to detect severe fatigue in newly diagnosed BC and colorectal cancer (CC) patients. 
METHODS
Procedure
All patients who attended an intake session before the start of their cancer treatment 
filled out a psychosocial screening at the outpatient clinic of the oncological center of 
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hospital Gelderse Vallei (Ede, the Netherlands). This screening was administered by a 
nurse practitioner as part of routine clinical care for BC and CC patients, and consisted 
of a DT with associated PL and the subscale Fatigue Severity of the Checklist Individual 
Strength (CIS-fatigue). Administration of the DT is in accordance with the Dutch 
guideline “Detection of need for psychosocial care (8).” The CIS-fatigue was added 
to screen for severe fatigue because evidence-based cognitive behavioral therapy 
for severe fatigue (9) is part of routine care in hospital Gelderse Vallei. Data from 
screenings administered between December 2009 and January 2013 were available for 
the current study. Approval of a medical ethical committee was not required because 
all available patient data were deidentified and collected as part of routine clinical 
care.
Study population
Data from patients who (i) were newly diagnosed with breast or colorectal cancer, 
(ii) were scheduled for cancer treatment with curative intent, and (iii) filled out a 
psychosocial screening questionnaire prior to cancer treatment were included.
Measures
Distress Thermometer (DT) 
The DT consists of a thermometer and a PL, in which patients are asked which 
problems or symptoms they experienced in the past week. The problems in this 
checklist are divided into 5 categories: practical problems, family problems, emotional 
problems, spiritual/ religious concerns, and physical problems (10). In the current 
study, only the fatigue item (yes/ no) of the category “Physical problems” of the PL was 
used.
Checklist Individual Strength (CIS)
The subscale Fatigue Severity (8 items, 7-point scale, range 8-56) of the CIS (CIS-fatigue) 
measures the level of fatigue over the past 2 weeks. The CIS-fatigue was originally 
developed to measure severe fatigue in patients with chronic fatigue syndrome (11,12). 
The established cutoff score for severe fatigue is 35 or higher (11). The CIS-fatigue has 
been shown to be sensitive to change in fatigue levels over time in previous studies on 
cancer patients during curative and palliative treatment, and in cancer survivors who 
had completed cancer treatment (9,13-16). 
 Previous studies have shown that the psychometric quality of the CIS-fatigue is 
adequate. In the current study, the reliability of the CIS-fatigue was excellent (Cronbach’s 
α = .93). This was also the case in other studies in which this questionnaire was used 
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(11,12,17). In addition, previous research has demonstrated that the CIS-fatigue has 
good to excellent convergent, discriminative, and divergent validity (11,12,17). Besides, 
the CIS-fatigue has been found to be able to discriminate between severely and 
non-severely fatigued subjects in study populations of patients with chronic diseases 
(eg,  chronic fatigue syndrome, rheumatoid arthritis, multiple sclerosis, neuromuscular 
diseases, and type 1 diabetes) and healthy populations (eg, healthy controls and 
different occupational groups) (17-21). 
Analysis 
The test variable was fatigue according to the fatigue item of the PL. The CIS-fatigue 
(cutoff ≥ 35) was used as gold standard measure for severe fatigue. Sensitivity analyses 
were performed to assess the usability of the fatigue item of the PL as screening tool 
for severe fatigue. Based on our gold standard measure, fatigue scores were defined 
as true positive (TP; correctly identified as case of severe fatigue), true negative 
(TN; correctly identified as noncase of severe fatigue), false positive (FP; incorrectly 
identified as case), and false negative (FN; incorrectly identified as noncase). The 
following psychometric properties of the fatigue item were calculated: (i) the number 
of severely fatigued cancer patients who were correctly identified with the fatigue item 
(overall test accuracy, [TP+TN]/[TP+TN+FP+FN]); (ii) the probability that the fatigue 
item will be positive when severe fatigue is present (true positive rate/sensitivity, TP/
[TP+FN]); (iii) the probability that the fatigue item will be negative when severe fatigue 
is absent (true negative rate/specificity, TN/[TN+FP]); (iv) the probability that a patient 
is truly severely fatigued when the fatigue item is positive (positive predictive value, 
TP/[TP+FP]), and (v) the probability that a patient is not truly severely fatigued when 
the fatigue item is negative (negative predictive value, TN/[TN+FN]). 
RESULTS
Patient characteristics
The eligibility of all patients who filled out a psychosocial screening (N = 592) was 
assessed. Seventy-nine patients were excluded because they were scheduled for cancer 
treatment with palliative intent 
(N = 42), had a benign tumor (N = 18), were previously treated for cancer (N = 14), 
or had already received neo-adjuvant chemotherapy (N = 5). This resulted in a study 
sample of 513 patients: 334 BC and 179 CC patients. Demographic and clinical characte-
ristics are shown in Table 1. The population of BC patients was primarily female (98%) 
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with a mean age of 60 years (SD = 14), and half of patients had early-stage BC. About 
half of the population of CC patients was male (56%), the mean age was 69 years (SD = 
12), and the stage of cancer (I-III) was equally divided. 
Screening for severe fatigue with the fatigue item 
In total, 80 BC patients (24%) and 54 CC patients (30%) were severely fatigued 
according to the gold standard CIS-fatigue. The mean CIS-fatigue score at intake was 25 
(SD = 13) in BC patients and 26 
(SD = 15) in CC patients. The results of the sensitivity analyses are shown in Table 
2. Five patients were excluded from these analyses due to missing data. The overall 
accuracy of the fatigue item of the PL to detect severe fatigue was 78% in BC survivors 
and 81% in CC survivors. There were 9 missed cases of severe fatigue (false negatives) 
in BC patients and 5 false negatives in CC patients. Given these false negatives, the 
probability that the fatigue item is positive when severe fatigue is present (sensitivity) 
was 89% in BC and 91% in CC patients. There was false alarm in 63 BC patients and in 
28 CC patients because they were incorrectly identified as cases of severe fatigue (false 
positives). Given these false positives, the probability that the fatigue item is negative 
when severe fatigue is absent (specificity) was 75% in BC and 77% in CC patients. In 
addition, the probability that a patient is truly severely fatigued when the fatigue 
Breast cancer patients Colorectal cancer patients
(N=334) (N=179)
N (%) N (%)
Demographic characteristics
Age
    (Mean ± SD, range) 59.7 ± 13.5, 29-92 69.3 ± 11.5, 29-92
Gender
     Female 328 (98) 78 (44)
     Male 6 (2) 101 (56)
Clinical characteristics
Stage of disease
     I 172 (51) 54 (30)
     II 123 (37) 60 (34)
     III 36 (11) 63 (35)
     Unknown 3 (1) 2 (1)
Table 1 Patient characteristics
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item is positive (positive predictive value) was 53% in BC and 64% in CC patients. The 
probability that non-cases of severe fatigue are indeed not severely fatigued when the 
fatigue item is negative (negative predictive value) was 95% in both tumor types. 
CONCLUSIONS
This study showed that the fatigue item of the PL of the DT performs satisfactorily 
to screen quickly for severe fatigue in newly diagnosed cancer patients. However, a 
positive screen should be followed up with a more thorough assessment of fatigue (i.e., 
a questionnaire with a validated cutoff point) to confirm that the patient is severely 
fatigued. Given time pressure of clinicians, brief screening tools like the DT could 
prevent significant problems like severe fatigue from going unnoticed. As the DT and 
PL are increasingly used in daily clinical practice, this screening tool for severe fatigue 
can easily be integrated in regular care for cancer patients.
 International guidelines recommend the use of brief self-report measures for routine 
screening of cancer-related fatigue in clinical practice (7). The current study showed 
that the fatigue item of the PL, with a mean sensitivity of 90% and a mean specificity 
Breast cancer patients Colorectal cancer patients
(N=330) (N=178)
Outcomes, N (%)
True positives 70 (21) 49 (27)
True negatives 188 (56) 96 (54)
False positives 63 (19) 28 (16)
False negatives 9 (3) 5 (3)
Psychometric properties
Accuracy 0.782 0.815
Sensitivity 0.886 0.907
Specificity 0.749 0.774
Positive predictive value 0.526 0.636
Negative predictive value 0.954 0.950
Table 2. Detecting severe fatigue with the fatigue item of the Problem List
C
h
ap
te
r 
5
112
of 76%, can reliably be used for this purpose. This also applies to other single-item 
screening instruments for cancer-related fatigue. For instance, Butt et al. examined 
the usability of an eleven-point scale item “How would you rate your fatigue at its 
worst over the past three days?” This item was based on the NCCN Clinical Practice 
Guidelines for Supportive Care, and had an optimal cutoff score of 5 with a sensitivity of 
69% and a specificity of 71% (22). Another examined single-item screening instrument 
concerns the four-point scale item “I get tired for no reason” of the Zung Self-Rating 
Depression Scale. Kirsh et al. showed that this item had an optimal cutoff score of 2, 
with a sensitivity of 79% and a specificity of 88% (23). These findings indicate that 
single-items can be quick and yet accurate screening tools for cancer-related fatigue.
 It is important to detect severe fatigue as early as possible. A recent study of our 
research group showed that fatigue severity before start of cancer treatment strongly 
predicts the severity of persistent post-treatment fatigue (13). This indicates that 
screening for cancer-related fatigue may already start before initiation of cancer 
treatment. The current study showed that screening prior to treatment can quickly 
and reliably be performed with the Fatigue item of the PL. 
 Screening should continue during and after cancer treatment, as recommended by 
the NCCN guidelines for cancer-related fatigue (5). Previous studies with breast cancer 
survivors have identified different individual trajectories of fatigue symptoms, like (i) 
fatigue that is only present during cancer treatment, (ii) persistent fatigue that starts 
during cancer treatment and continues after cancer treatment, and (iii) delayed-onset 
fatigue that starts after conclusion of adjuvant therapy (16,24,25). In addition to these 
different trajectories of cancer-related fatigue, patients can value their levels of fatigue 
differently throughout treatment (16). These response shifts and individual variations 
in fatigue trajectories over time imply that fatigue is a dynamic symptom that warrants 
repeated screening throughout treatment. 
 Once patients have been identified as severely fatigued, it is warranted to monitor 
them. However, only detecting severe fatigue is not sufficient. In case of severe fatigue, 
a focused history and physical examination is needed, as recommended in the NCCN 
guidelines for cancer-related fatigue. For instance, the clinician should examine 
whether the fatigue is a symptom of recurrence of malignancy for cancer survivors 
who were assumed to be disease-free, or if the patient has non-cancer comorbidities 
that can explain severe fatigue (5). 
 Fatigue should also be discussed with patients. Previous research on cancer survivors 
has shown that severe fatigue, measured with the CIS-fatigue, often goes hand in hand 
with impairments in multiple domains of daily functioning (26,27). However, fatigue is 
a subjective experience that is experienced differently by each patient (5), and patients 
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can be severely fatigued but this does not necessarily mean that this is a problem to 
them. The Fatigue item of the PL is an easy way to detect severe fatigue quickly, but 
clinicians need to find out whether fatigue bothers patients and whether support is 
required to manage it. 
 Referral to fatigue-oriented interventions should be considered in case of 
persistent high levels of fatigue. Available evidence-based interventions during cancer 
treatment are physical exercise interventions (28,29). For patients with severe fatigue 
after cancer treatment, evidence-based psychosocial interventions (i.e., cognitive 
behavioral therapy and psycho-educational therapies) are also available in addition to 
physical exercise interventions. There is also, albeit limited, evidence for mind-body 
interventions for fatigue in cancer survivors (i.e., mindfulness-based approaches, 
yoga, and acupuncture) (7).
 Strengths of the current study were the large sample size and the representati-
veness of the two samples of newly diagnosed cancer patients. In a previous study 
of Goedendorp et al, the prevalence of severe fatigue according to the CIS-fatigue 
was 20% in newly diagnosed BC and 28% in newly diagnosed gastrointestinal cancer 
patients, which is comparable to the prevalence rates in our two patient samples (30). A 
limitation was the assessment of the psychometric properties of the fatigue item prior to 
cancer treatment. As our study was cross-sectional, future research is needed to assess 
if the fatigue item of the Distress Thermometer can also be used to screen for severe 
fatigue during and after cancer treatment. However, there are no reasons to assume 
that the moment of screening influences the psychometric quality of the fatigue item. 
Additionally, although the psychometric properties of the CIS-fatigue have proven to 
be adequate and although the CIS-fatigue is sensitive to change in cancer patients, its 
cutoff score for severe fatigue has not specifically been validated in cancer patients yet. 
In conclusion, the fatigue item of the Problem List performs satisfactorily as a quick 
screening tool for severe fatigue. However, a positive screen should be followed up 
with a questionnaire with a validated cutoff point. This tool can, in a time sensitive 
manner, prevent severe fatigue from being overlooked in clinical practice.
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ABSTRACT
Background: About one third of breast cancer survivors suffer from persistent 
severe fatigue after completion of curative cancer treatment. Face-to-face cognitive 
behavioral therapy (F2F CBT) especially designed for fatigue in cancer survivors 
was found effective in reducing fatigue. However, this intervention is intensive and 
treatment capacity is limited. To extend treatment options, a web-based version of CBT 
requiring less therapist time was developed. This intervention is aimed at changing 
fatigue-perpetuating cognitions and behaviors. The efficacy of web-based CBT will be 
examined in a multicenter randomized controlled trial.
Methods: In total, 132 severely fatigued breast cancer survivors will be recruited 
and randomized to either an intervention condition or care as usual (ratio 1:1). 
Participants will be assessed at baseline and six months thereafter. The intervention 
group will receive web-based CBT, consisting of three F2F sessions and maximally eight 
web-based modules over a period of six months. The care as usual group will be on a 
waiting list for regular F2F CBT. The total duration of the waiting list is six months. The 
primary outcome of the study is fatigue severity. Secondary outcomes are functional 
impairments, psychological distress and quality of life. 
Discussion: If web-based CBT is effective, it will provide an additional treatment 
option for fatigue in breast cancer survivors. Web-based CBT is expected to be less 
time-consuming for therapists than regular F2F CBT, which would result in an increased 
treatment capacity. Moreover, the intervention would become more easily accessible 
for a larger number of patients, and patients can save travel time and costs.
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BACKGROUND
Worldwide, breast cancer is the most common malignancy in women. About 1.7 
million new cases were diagnosed in 2012 (1). In the last decades, survival rates 
have been improved due to early detection by screening programs and advances in 
oncological treatments (2, 3). Since the number of breast cancer survivors increases, 
concerns are raised about their long-term well-being. After completion of curative 
cancer treatment, side-effects can become chronic. One of these persistent side-effects 
is cancer-related fatigue (3). The National Comprehensive Cancer Network defined 
cancer-related fatigue as “a distressing, persistent, subjective sense of physical, 
emotional and/or cognitive tiredness, related to cancer or cancer treatment, that is 
not proportional to recent activity and interferes with usual functioning” (4). Once the 
malignancy is successfully treated, the fatigue is expected to decrease. Nevertheless, 
severe fatigue becomes a chronic condition in approximately one-third of breast 
cancer survivors (5-8).
Interventions for fatigue in cancer survivors
Since persisting severe fatigue interferes with daily functioning and has profound 
effects on quality of life, it should not be left untreated (5, 9). The evidence of available 
interventions was recently evaluated in a practice guideline of the American Society 
of Clinical Oncology (10). It was concluded that there is evidence for the efficacy of 
physical and psychosocial interventions. Initiating or maintaining adequate levels 
of physical activity (11-19), (cognitive) behavioral therapy (20-25), and (psycho)
educational interventions (20, 25, 26) can reduce fatigue. In addition, there is some 
evidence for the efficacy of mindfulness-based approaches (21, 27, 28), yoga (29, 30), 
and acupuncture (31, 32). 
The current study focuses on one of these evidence-based interventions: cognitive 
behavioral therapy (CBT). A CBT protocol for fatigue in cancer survivors with mixed 
diagnoses was developed and tested in a randomized controlled trial (RCT) at our 
treatment center, the Expert Center for Chronic Fatigue of the Radboud university 
medical center (Radboudumc) (22). This RCT showed that patients reported a clinically 
significant reduction in fatigue and functional impairments following CBT (22). These 
effects were maintained at a two-year follow-up (33). The efficacy of the CBT protocol 
was recently replicated in a RCT of Prinsen et al. (34). The CBT protocol is based on a 
model of precipitating and perpetuating factors of fatigue (22). According to this model, 
the malignancy and its treatment are the precipitating factors that induced fatigue. 
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However, other factors are responsible for the persistence of severe fatigue after cancer 
treatment (22). These fatigue-perpetuating factors and the overall explanatory model 
are captured in Figure 1. Each fatigue-perpetuating factor is addressed in a module of 
the CBT protocol, offered as regular face-to-face (F2F) therapy. However, this F2F CBT 
is intensive for both therapists and patients, since it consists of twelve to fourteen F2F 
sessions over a period of six months. Therapists need to invest considerable time to 
deliver these sessions and a limited number of trained cognitive behavioral therapists 
provide this F2F therapy. Besides, patients need to travel to a treatment center to attend 
the sessions. The development of web-based CBT would reduce the therapist time 
needed to deliver the intervention and increase treatment accessibility for severely 
fatigued breast cancer survivors. 
Web-based CBT
The fast-growing field of e-health has created new possibilities in the development of 
web-based interventions. Web-based CBT has been developed and examined for a wide 
range of mental health problems, and so far, results are promising. Multiple studies 
have shown that web-based CBT can be effective in reducing mental health problems 
(35). To extend treatment options for severely fatigued breast cancer survivors, we 
have developed a web-based version of our F2F CBT protocol for severely fatigued 
cancer survivors, named “On the road to recovery”. The efficacy of this intervention 
will be examined in a RCT, named “the CHANGE-study”.      
The right time to intervene
In our previous RCT’s examining regular F2F CBT for severely fatigued cancer 
Figure 1. Explanatory model of the CBT protocol.
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survivors, the intervention was offered at least one year after completion of cancer 
treatment (22, 34). However, recent research has shown that fatigue does not decrease 
further after three months following curative cancer treatment (36), and fatigue-per-
petuating factors can already be identified at three months following cancer treatment 
(37). Therefore, it might be possible to treat fatigue in cancer survivors at an earlier 
stage. To examine if this is the case, the web-based CBT will be offered at least three 
months after completion of cancer treatment. 
Aims of the CHANGE study
1. To examine the efficacy of web-based CBT for severely fatigued breast cancer 
survivors on fatigue severity compared to care as usual. 
2. To examine the efficacy of web-based CBT for severely fatigued breast cancer 
survivors on functional impairments, psychological distress, and quality of life 
compared to care as usual.
3. To examine if time since completion of cancer treatment moderates the efficacy 
of web-based CBT with respect to fatigue severity.
METHODS
The method section of this study protocol is written in accordance with the CONSORT 
statement for reporting parallel group randomized trials (38) and the CONSORT 
e-health criteria for reporting web-based interventions (39). 
Design 
A non-blinded multicenter RCT (the CHANGE study) will be conducted to evaluate 
the efficacy of web-based CBT compared to care as usual for severely fatigued breast 
cancer survivors. 
Recruitment 
1. Referrals by medical professionals
Patients will be recruited by medical professionals (physicians and nurses) at the 
outpatient clinic of the departments of surgery and/or oncology of eight hospitals in 
the Netherlands (Radboudumc, Nijmegen; Canisius Wilhelmina hospital, Nijmegen; 
hospital Gelderse Vallei, Ede; hospital Bernhoven, Uden; hospital Pantein, Boxmeer; 
VieCuri medical center, Venlo; Elkerliek hospital, Helmond; Slingeland hospital, 
Doetinchem). Physicians and nurses will inform eligible patients about the study 
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during regular medical follow-up consults and give them an information leaflet. If a 
patient agrees to be informed about the study by the researcher, the nurse practitioner 
will fill out a participation form and send it to the researcher (HA). Subsequently, the 
researcher will call the patient to give a detailed explanation about the study and to 
address questions. 
 As a second recruitment strategy, nurse practitioners from selected participating 
hospitals will identify cohorts of eligible patients through medical records. They will 
inform these cohorts by mail. Patients will receive an information leaflet with an 
accompanying letter. In this letter, patients are asked to contact the researcher if they 
want to participate in the study.
2. Self-referrals
Patients will also be informed about the study by leaflets and notifications on social 
media of patients’ associations and the Radboudumc (e.g. Facebook and Twitter). 
Patients can complete a participation form, integrated in an informative website. 
Subsequently, the researcher will contact the patient by phone to inform her about the 
study and to address questions. 
Participants
All patients who want to participate in the study will first be screened for eligibility. 
The in- and exclusion criteria are shown in Table 1. To verify the medical criteria 
(criterion 2, 3, and 4) of self-referrals, patients will send a copy of the most recent 
report of their medical follow-up examination to the researcher. The researcher will 
administer an online screening questionnaire to verify the other criteria. All patients 
will sign informed consent before filling out this online screening. The Checklist 
Individual Strength (40) will be used to screen for severe fatigue (criterion 6). The 
Beck Depression Inventory for Primary Care (BDI-PC) (41, 42) will be used to screen 
for a depressive disorder (criterion 9). If the score on the BDI-PC is ≥4, the researcher 
will administer the Depression module of the Mini-International Neuropsychiatric 
Interview (M.I.N.I.) (43) by phone to assess the presence of a major depression. If 
patients meet the criteria for major depression, they will be advised to contact their 
general practitioner for an appropriate referral. 
Procedure
If patients are eligible and have signed written informed consent, they will start with 
a baseline assessment (T0). Following T0, participants will be randomized to either the 
intervention condition (web-based CBT) or the control condition (care as usual). After 
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six months, all participants will be assessed again (T1). For participants assigned to the 
web-based CBT, this will be the post-intervention assessment. The overall study design 
is shown in Figure 2. A test assistant will perform T0, T1 and the randomization.
Randomization 
Stratified randomization will be based on time since completion of cancer treatment 
(three months up to one year versus ≥ one year) and type of referral (referrals by medical 
professionals versus self-referrals). After T0, randomization will be performed by a test 
assistant in the presence of the patient. A computerized randomization tool, built by 
an independent statistical expert, will be used to randomly allocate patients to either 
intervention or control condition. The allocation ratio will be 1:1 and block-randomi-
zation will be used with a block size of six. The test assistant, the researcher and the 
participants will be blinded to the allocation sequence. They will not be blind for the 
randomization outcome, because this is not possible in psychological treatments. 
Intervention
Development 
On the road to recovery is built in a web portal, designed with technical guidance 
from the Psychological and Psychiatric Care Innovation (Utrecht, The Netherlands) (44). 
Experts in the field of fatigue in cancer survivors developed the content of this web 
Inclusion criteria
1. Women who are 18 years or older
2. Treated for breast cancer with curative intent
3. Breast cancer treatment (surgery, chemo- and/ or radiotherapy) must be finished at least three 
months previously. There is no upper limit for the time since completion of cancer treatment. 
Patients who currently receive hormone and/ or targeted therapy are eligible.
4. Disease-free at entry of the study, defined by the absence of somatic disease activity parameters
5. Able to speak, read, and write Dutch
6. Severely fatigued, defined by a score of ≥35 on the fatigue severity subscale of the Checklist 
Individual Strength 
7. Having access to a computer with internet 
Exclusion criteria
8. Presence of a co-morbidity that explains the presence of severe fatigue
9. A depressive disorder, assessed with the BDI-PC and the M.I.N.I.
10. Current psychological treatment for a psychiatric disorder
11. Current CBT for fatigue
Table 1. In- and exclusion criteria
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portal. Trained, experienced cognitive behavioral therapists (HK, TB) and researchers 
(MGI, HA) wrote the texts and assignments. In total, the web portal consists of thirteen 
texts and twenty-six assignments. A graphic designer developed the lay-out of On the 
road to recovery, and a videographer made thirteen videos together with a therapist 
(HK) and the researcher (HA). These videos are integrated in the web portal. In the 
first video, a medical oncologist (SV) explains the rationale of the CBT. The other twelve 
videos are interviews of three cancer survivors. These patients are recovered from 
fatigue after receiving F2F CBT, and tell about their experiences with the CBT modules. 
A screenshot of the web portal is provided in Figure 3. For this occasion, the text is 
translated into English. 
Usability testing
Five severely fatigued breast cancer survivors, who were following F2F CBT, 
participated in a test pilot. The usability of the web portal was tested by using a “think 
aloud procedure” (45). Participants were asked to think aloud while independently 
completing the modules. In the meanwhile, the researcher (HA) noted obstacles they 
encountered (i.e. usability problems and problems with text readability). Afterwards, 
all participants filled out a feedback form. They were asked about the sufficiency of 
information provided, text readability, and the lay-out and usability of the web portal. 
The findings of the usability testing were used to optimize the final version of the web 
portal. 
T0 = baseline assessment; T1 = second assessment
Figure 2. Overall study design. 
Recruitment and 
screening
T0
Randomization
Web-based CBT
T1
Usual care
T1
6 months
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Intervention condition: On the road to recovery 
All participants in the intervention condition will follow On the road to recovery, 
a web-based version of the regular F2F CBT for severely fatigued cancer survivors. 
Participants will start with two F2F sessions with their therapist. In these sessions, the 
CBT model for fatigue in cancer survivors (Figure 1) will be explained and a treatment 
plan will be made. Thereafter, participants will follow On the road to recovery online. 
The web-based CBT consists of eight treatment modules. All participants will start with 
setting their treatment goals (module 1). Then, they will work on the fatigue-perpe-
tuating factors that are applicable to them: (1) poor coping with breast cancer and 
breast cancer treatment; (2) high fear of cancer recurrence; (3) dysfunctional fatigue-
related cognitions; (4) a deregulated sleep-wake rhythm; (5) a deregulated activity 
pattern; and/or (6) negative social interactions and low social support. Each of these 
six fatigue-perpetuating factors coincides with a treatment module (module 2-7). At 
baseline assessment, it is decided which modules are relevant for each participant. 
Finally, all participants will complete the therapy by realizing their treatment goals 
(module 8). On the road to recovery is tailor-made. Assessment tools are used to assess 
which fatigue-perpetuating factors are present and to determine which treatment 
modules patients need to follow (Table 2). All treatment modules consist of three 
parts: psycho-education (“READING”), assignments in which participants work on 
fatigue-perpetuating factors (“DOING”) and a final assignment, in which participants 
evaluate their progress (“REVIEW”). The content of the eight treatment modules is 
described in more detail in Appendix 1. 
  Therapists will contact patients two-weekly by e-mail to give feedback on their 
progress and to answer questions. Therapists can also initiate video sessions with a 
secured video consultation system (Facetalk) (46). These video sessions are in particular 
recommended for the modules “Fear of cancer recurrence” and “Coping with cancer 
and cancer treatment”. The guideline is to plan maximally two video sessions. The 
maximum duration of On the road to recovery is six months. Therapists will be blinded 
for the level of fatigue severity (primary outcome measure). Only after the post-tre-
atment assessment (T1), they will be informed about the levels of fatigue severity on 
T0 and T1. The outcomes with respect to fatigue severity and other disabilities will 
be discussed with the participant in a final F2F session. In this session, the therapist 
and patient will determine if the patient is recovered from severe fatigue. If patients 
are not recovered from severe fatigue, F2F therapy will be offered outside the study 
context. 
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Treatment integrity
On the road to recovery will be given by licensed cognitive behavioral therapists. 
All therapists are experienced in working with the F2F CBT protocol for severe fatigue 
in cancer survivors. They will participate in a weekly supervision, in which cases 
are discussed in the presence of senior clinical psychologists (HK, TB). Changes in 
individual treatment plans will be made according to the study protocol and to the CBT 
principles for severely fatigued cancer survivors.   
   At the end of the study, a random five percent of the e-mail messages send 
to the patients will be evaluated. An experienced clinician (HK) and researcher (HA) 
will determine whether the web-based CBT was delivered according to the predefined 
treatment protocol. To determine if web-based CBT is less time consuming than F2F 
CBT, therapists will register the invested time for each patient.
Control condition: care as usual
Participants in the control condition will be on a waiting list for regular F2F CBT for 
fatigue in cancer survivors. The total duration of the waiting list is six months. In this 
period, patients will receive care as usual. The usual care for breast cancer survivors 
in the Netherlands consists of follow-up examinations conform the Dutch guidelines 
for oncology care (47). The frequency of these follow-up examinations depends on 
age, time since diagnosis and a possible BRCA1/2 mutation. In general, there will be a 
three-month follow-up in the first year, a biannual follow-up in the second year, and an 
annual follow-up in the following years up to five years after diagnosis. 
Figure 3. Screenshot of On the road to recovery
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  Recently, a guideline for the management of psychosocial distress in breast 
cancer survivors is implemented (48).  According to this guideline, psychosocial 
problems are identified and patients should be referred to specialized care providers. 
Participants may therefore be referred to other fatigue-oriented interventions during 
the study (e.g. psychosocial interventions, a rehabilitation trajectory, or physical 
therapy). At T1, all participants will be asked if they have received any treatment for 
fatigue during the study, and if so, they are asked to describe this treatment.
Outcomes 
Primary outcome
Fatigue severity, measured by the subscale Fatigue Severity (8 items, 7-point Likert 
Scale) of the Checklist Individual Strength (CIS) (49). This subscale consists of eight 
items, scored on a 7-point Likert scale. The range of scores is 8 to 56, with a higher 
score indicating a higher level of fatigue. The cut-off score for severe fatigue is ≥35 (49). 
The CIS has been established as a valid and reliable measure (50, 51), which showed 
sensitivity to detect change in previous studies investigating fatigue in cancer survivors 
[22,33,52,53]. 
 
Secondary outcomes
Functional impairments, measured by the Sickness Impact Profile 8 (SIP) (54,55). 
This questionnaire addresses the level of disability in eight domains: alertness 
behavior, sleep/ rest, homemaking, leisure activities, mobility, social interactions, 
ambulation, and work. The weighted total score on these eight domains will be used to 
assess functional disability, with higher scores indicating more disabilities. The SIP is a 
reliable measure with sufficient content validity (56).
 Psychological distress, measured by the total score on the Brief Symptom Inventory 
18 (BSI-18) (57). This multidimensional questionnaire consists of eighteen items, scored 
on a 5-point Likert scale. The range of scores is 0 to 72, with a higher score indicating 
more psychological distress. The BSI-18 is a shortened version of the Symptom Checklist 
90 (SCL-90) (58). The BSI-18 has high levels of sensitivity and specificity (59).
 Quality of life, measured by the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) (60). 
This questionnaire consists of thirty items that cover five function scales (physical, 
role, cognitive, emotional and social functioning), three symptom scales (fatigue, pain, 
and nausea and vomiting), and a global health and quality of life scale. All scales are 
scored on a 4-point Likert scale. The EORTC-QLQ-C30 has been established as a valid 
and reliable measure (61). 
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Other variables
Demographic variables will be assessed by using a self-report questionnaire at 
T0. The instruments used to determine the relevant fatigue-perpetuating factors are 
shown in Table 2. 
Power
The sample size calculation is based on the guidelines of Borm et al. (2007) for 
analysis of covariance (ANCOVA) in RCT’s (72). A clinically relevant difference of 
six points is expected for the primary outcome (fatigue severity subscale of the CIS) 
between the intervention and control condition. This difference is based on a study 
of Knoop et al. (73), in which the efficacy of a minimal intervention for patients with 
chronic fatigue syndrome was examined (73). A minimum number of 60 patients per 
condition would be needed for a t-test with an alpha of .05, a two-sided significance 
level and a power of .85. According to Borm et al. (72), this number of patients needs to 
be multiplied by a “design factor” to calculate the needed sample size for an ANCOVA 
(60). This factor is one minus the squared correlation coefficient between the baseline 
and outcome measure of fatigue severity. In our previous study examining the efficacy 
of F2F CBT for fatigue in cancer survivors, the correlation of the baseline and outcome 
measure was .36 (22, 33). This leads to a factor of .87 (1 - .362 = .87). Thus, the minimal 
number of patients in each condition is 53 (60*.87=52.2). The drop-out rate in our first 
RCT examining F2F CBT for fatigue in cancer survivors was 13% (22, 33). In the current 
study, patients might experience less support from their therapist in the web-based 
CBT. Therefore, the drop-out in the current RCT is estimated to be 50% higher than 
in the first RCT (1,5*13=19,5%) Therefore, a margin of 19,5% for drop-out is added to 
the minimal number of 53 patients per condition. This results in a sample size of 132 
severely fatigued breast cancer survivors. 
Intended statistical analyses
The primary objective of the study is to examine the effects of web-based CBT 
on reducing fatigue severity compared to care as usual. Therefore, an analysis 
of covariance (ANCOVA) will be used with the CIS-fatigue score at T1 as dependent 
variable, the CIS-fatigue score at T0 as covariate and condition as fixed factor (39). The 
clinical importance of the treatment effect will be determined. Differences between 
the intervention and control condition on the amount of change in fatigue severity 
will be calculated on T0 and T1. Clinically meaningful change will be defined as a 
reliable change index of more than 1.96 and a decrease of the fatigue level to a normal 
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range (i.e. a score of <35 on the fatigue severity subscale of the Checklist Individual 
Strength). The effects of web-based CBT on the secondary outcomes of the study 
(functional impairments, psychological distress and quality of life) compared to care 
as usual will be determined with ANCOVA’s. For each secondary outcome measure, an 
ANCOVA will be performed with the score of the outcome measure at T1 as dependent 
variable, the score at T0 as covariate and condition as fixed factor. The third objective 
of the study is to examine if time since completion of cancer treatment moderates 
the effects of web-based CBT. This will be analyzed with an ANCOVA with time since 
completion of cancer treatment (3 months-1 year versus ≥1 year) as covariate. The 
CIS-fatigue score at T1 will be the dependent variable, and the fatigue score at T0 will 
be the second covariate. All data analyses will be based on intention to treat. Missing 
values on primary and secondary outcome measures will be replaced with multiple 
imputation using fully conditional specification with at least five imputations. In case 
of statistically significant differences, a sensitivity analysis will be performed, based on 
different assumptions about the values of missing data.
Ethical approval
This study has been reviewed and approved by the Medical Ethical Committee of the 
Radboudumc (reference no. 2013/167). The study has also been approved by the local 
ethical committees of each participating hospital (Radboudumc, Canisius Wilhelmina 
hospital, hospital Gelderse Vallei, hospital Bernhoven, hospital Pantein, VieCuri 
medical center, Elkerliek hospital and Slingeland hospital). The study is registered in 
the Dutch Trial Registry (reference no. NTR4309, date registered: December 6, 2013).
DISCUSSION
The CHANGE study will examine the efficacy of a web-based version of an eviden-
ce-based CBT protocol for severe fatigue in breast cancer survivors. The efficacy of the 
intervention on fatigue, functional impairments, psychological distress and quality of 
life will be examined as well. Web-based CBT has several advantages over F2F CBT; (i) 
e-mail contacts are expected to be less time consuming for therapists than F2F contacts, 
which would result in an increased treatment capacity; (ii) the intervention becomes 
more easily accessible for a larger number of patients, and (iii) the burden for patients 
can be reduced, because they can save travel time and costs to the treatment center. 
Besides, patients can work on the intervention at their own pace, at any preferred time. 
 After completion of the patient inclusion, the CHANGE study will be extended to 
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form a non-inferiority trial. In this trial, stepped care will be compared to F2F CBT 
for severely fatigued breast cancer survivors. The first step in the stepped care 
condition will be web-based CBT. If patients are not recovered from severe fatigue 
after completion of web-based CBT, additional F2F CBT sessions will be offered. We 
will examine whether the effects of stepped care on fatigue severity are noninferior to 
regular F2F CBT after a waiting period. We will also determine whether stepped care 
requires less therapist time than regular F2F CBT. The non-inferiority trial is registered 
in the Dutch Trial Registry (reference no. NTR5179).
   In conclusion, if web-based CBT is effective, it would provide an additional 
treatment option that is easily accessible for breast cancer survivors suffering from 
severe fatigue.
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APPENDIX
Overview of the treatment modules of On the road to recovery
The CBT protocol for fatigue in cancer survivors is aimed at changing fatigue-related 
cognitions and behaviors. On the road to recovery consists of eight treatment modules. 
All patients will start with module 1 (goal setting) and finish with module 8 (realizing 
of goals). The intermediate six modules coincide with six fatigue-perpetuating factors, 
and can differ between patients depending on their baseline assessment. Assessment 
tools are used to determine which factors are applicable (Table 2). Each patient will 
work on at least one fatigue-perpetuating factor. All treatment modules are illustrated 
in Figure 4. In total, patients will follow from three up to eight treatment modules: 
Module 1: Goal setting
This module starts with an explanation of the web portal and the rationale of On the 
road to recovery. The cognitive behavioral model of fatigue in cancer survivors (Figure 
1) is explained to patients. This model assumes that the fatigue is induced by the cancer 
and cancer treatment, but other factors cause the fatigue to persist. Subsequently, 
patients are asked to set concrete treatment goals. The overall goal of the intervention 
is no longer being severely fatigued and no longer being disabled by fatigue. Concrete 
goals are the activities patients would do (and do not do now), if they were no longer 
limited by severe fatigue. 
Module 2: Coping with cancer and cancer treatment 
Being treated for cancer can be a traumatic event. If patients keep reliving or actively 
avoiding memories of this period in their life, they might suffer from posttraumatic 
symptoms that can perpetuate fatigue. The aim of this module is to help patients with 
the processing of their experiences. To this end, patients will first complete a targeted 
writing assignment. They will write about the events, their experiences and its impact 
from breast cancer diagnosis up to now [74]. After writing it down, patients will repeat 
reading their story until they no longer feel distressed when thinking of the cancer and 
cancer treatment. Talking about their story with their therapist (using Facetalk), their 
spouses or with significant others can be part of this process as well.
Module 3: Fear of cancer recurrence 
Fear of disease recurrence is normal after completion of cancer treatment. It is also 
normal that anxious thoughts increase in particular situations, like upcoming medical 
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follow-up examinations. However, in some patients, fear of cancer recurrence is 
continuously and excessively elevated. These heightened levels of fear can perpetuate 
severe fatigue. In this module, patients will first get insight in the triggers of their 
anxiety. They will rank several situations that can provoke anxiety, and define their 
coping strategies in these situations. Then, patients will be helped to identify the 
cognitions underlying their fear. They will define what they are scared of, and the 
extent to which this corresponds with reality. If needed, patients are advised to talk 
with their physician to get insight in their actual risk of cancer recurrence. Finally, 
patients will learn to adopt helpful cognitions that can decrease their worrying. An 
example of a helpful cognition is: “It makes no sense to worry about the cancer coming 
back. This does not help me and only makes me feel bad”. 
Module 4: Helpful thinking
Dysfunctional fatigue-related cognitions can perpetuate severe fatigue. Examples 
are catastrophizing (i.e. having a highly negative orientation towards fatigue), a low 
self-efficacy (i.e. not feeling able to influence fatigue) and somatic attributions (i.e. 
attributing the fatigue mainly to the cancer and cancer treatment). These cognitions 
make patients feel like they have no control over their fatigue. In this module, patients 
will first assess their thoughts when feeling tired, and identify the subsequent feelings, 
behaviors and its consequences. Then, they will learn to replace dysfunctional thoughts 
with more realistic, helpful cognitions that can increase their self-efficacy. An example 
Figure S1. Overview of the treatment modules of On the road to recovery.
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
FATIGUE 
2. Coping with cancer 3. Fear of recurrence 
4. Cognitions 
regarding fatigue 5. Sleep-wake rhythm 6. Activity regulation 7. Social support 
1. Goal setting 
8. Realizing goals 
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is: “I accept that I am tired, that is just how it is NOW. It does not have to stay like this, 
I am able to do something about the fatigue.” 
  Another part of this module is learning to focus less on fatigue. Patients will 
learn how to shift their attention, for example by focusing on other activities or on the 
environment. Patients are advised to stop using fatigue as an indicator for what they 
can and cannot do, and no longer talk about their fatigue. 
Module 5: Sleep-wake rhythm 
Irregular sleep patterns are common in fatigued cancer survivors and can perpetuate 
severe fatigue. Keeping irregular bedtimes and wake-up times, and lying down or 
sleeping during the day can lead to a disrupted circadian pattern. In this module, a 
consistent sleep-wake pattern will be established. Patients will be temporarily asked to 
get up and go to bed at fixed times each day. They will also be asked not to sleep or lie 
down during the day. In this way, patients can (re)set their “biological clock”. Advices 
for adequate sleep-hygiene practices are given (i.e. adopt a regular going-to-bed ritual 
and avoid drinking any caffeinated drinks or alcohol before going to sleep). 
Module 6: Activity regulation
After completion of cancer treatment, activity patterns can be deregulated. The 
activity patterns of all participants will be measured and divided in one of two 
categories: 
1. Relatively active: these patients have fluctuating activity levels with bursts of 
activities followed by periods of inactivity (“all-or-nothing behavior”).
2. Low active: these patients have a continuous low level of physical activity. This 
may be habit, or patients may avoid activities out of fear of getting tired. 
Both activity patterns can perpetuate severe fatigue. Relatively active patients will 
first learn to evenly distribute their activities, leaving sufficient space for unforeseen 
circumstances. Subsequently, they will gradually increase their (physical) activity level. 
Patients choose a physical activity that they can perform daily (walking or cycling). 
They gradually and systematically build up the duration of this physical activity. Low 
active patients will immediately start with this graded activity program. When patients 
are able to increase their physical activity level, their self-efficacy with respect to 
fatigue and being active often increases as well. This module finishes with optional 
assignments for building up mental and social activities, and resumption of work (if 
applicable). 
Module 7: Social support
C
h
ap
te
r 
6
146
Severely fatigued breast cancer survivors can experience negative social interactions 
regarding their fatigue, like overly concerned responses or a lack of understanding 
of significant others. In this module, patients will learn how to communicate about 
their fatigue with significant others. They will also learn how to be more assertive, for 
example by setting clear limits concerning the information they want to share. Some 
patients might still expect the same amount of support from their environment as 
during their illness. When the expectations of patients with regard to social support are 
unrealistic, patients will learn to adopt a different attitude towards their environment 
and to modify their expectations.
Module 8: Realizing goals
When patients have finished building up their physical activity level, they are advised 
to start realizing the treatment goals they set in the first module. They will make an 
action plan and realize their pre-set goals step-by-step. Another part of this module 
is letting go of the regular sleep-wake rhythm and even distribution of activities. In 
this way, patients learn how to cope with disruptions in their sleep-wake rhythm and 
activity pattern. Finally, patients will evaluate the overall progress they have made 
during the treatment program On the road to recovery. Part of this evaluation is to 
determine if they consider themselves as recovered from severe fatigue.
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ABSTRACT 
                 
Background: Severe fatigue is a common and distressing symptom affecting 
approximately one in four survivors of breast cancer. The current study examined 
the efficacy of Internet-based cognitive behavioral therapy (ICBT) for severe fatigue in 
survivors of breast cancer compared with care as usual (CAU).
Methods: The authors conducted a parallel-group randomized controlled trial. 
Severely fatigued, disease-free survivors of breast cancer who had completed cancer 
treatment at least 3 months previously were eligible. Participants were randomly 
allocated to ICBT or CAU using computer-generated stratified block randomization. 
The primary outcome of fatigue severity was assessed at baseline and after 6 months, 
as were the secondary outcomes of functional impairment, psychological distress, 
and quality of life. Statistical effects were tested with analyses of covariance (intenti-
on-to-treat analysis).
Results: Participants were recruited between January 2014 and March 2016 and 
assigned to ICBT (66 patients) or CAU (66 patients). Compared with the participants 
who had received CAU, those who had received ICBT reported lower fatigue scores at 
6 months (mean difference [D], 11.5; 95% confidence interval [95% CI], 7.7-15.3) and 
a large effect size (Cohen d = 1.0), with the majority of patients (73%) demonstrating 
clinically significant improvement. ICBT also was found to lead to lower functional 
impairment (D, 297.8; 95% CI, 145.5-450.1) and psychological distress scores (D, 5.7; 
95% CI, 3.4-7.9) and higher quality-of-life scores (D, 11.7; 95% CI, 5.8-17.7) compared 
with CAU, with medium to large effect sizes (Cohen d = 0.6-0.8).
Conclusions: ICBT appears to be effective in reducing severe fatigue and related 
symptoms and meets the current need for easy accessible and more efficient eviden-
ce-based treatment options for severely fatigued survivors of breast cancer.
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BACKGROUND            
 
Severe fatigue is a common and distressing symptom that is reported by 
approximately one in four of survivors of breast cancer (1). Severely fatigued survivors 
report a lower quality of life (QOL) and more functional impairment compared with 
survivors without severe fatigue (2). Given these serious consequences, it is important 
to treat severe fatigue effectively. However, having evaluated the current management 
of cancer-related fatigue, experts recently concluded that the availability of eviden-
ce-based interventions such as graded exercise and cognitive behavioral therapy (CBT) 
is too limited. E-Health approaches could improve their accessibility (3). 
The results of an integrative review by Post and Flanagan (4) support the feasibility 
and acceptability of Web-based platforms for survivors of breast cancer. The authors 
also evaluated the efficacy of Internet-based interventions in this patient population, 
and concluded that the strongest data have been provided by studies on Internet-based 
CBT (ICBT) interventions (4).
To our knowledge to date, the ICBT interventions that have been evaluated for 
survivors of breast cancer have not specifically been aimed at fatigue. However, the 
effects of other types of Web-based interventions aimed at fatigue in cancer survivors 
are promising. A randomized controlled trial (RCT) by Yun et al (5) demonstrated that a 
Web-based self-management education program led to greater improvements in fatigue 
in cancer survivors compared with care as usual (CAU) (5). In addition, explorative 
analyses of a feasibility RCT by Foster et al (6) demonstrated that a Web-based self-ma-
nagement intervention enhanced the self-efficacy of cancer survivors in managing 
fatigue compared with a patients with a control condition who only received an 
information leaflet. However, this effect was not sustained at a follow-up of 12 weeks, 
and no positive effect on fatigue severity was found (6). 
Another type of intervention for fatigue in cancer survivors is a Web-based, mindful-
ness-based cognitive therapy intervention developed by Bruggeman-Everts et al (7). 
The results of an uncontrolled pilot study indicated that this intervention was effective 
in reducing fatigue severity (7). This intervention currently is being tested in an RCT, 
but to our knowledge the results have not been published to date (8). Another relevant, 
ongoing RCT concerns a pilot study by Corbett et al examining an online self-ma-
nagement intervention with CBT elements (9). Finally, 2 RCTs by Willems et al (10) 
and van den Berg et al (11) demonstrated that a general Web-based self-management 
intervention for psychosocial adjustment in cancer survivors (without a specific focus 
on fatigue) led to improvements in fatigue compared with a nonactive control group, 
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with small effect sizes (Cohen’s d of 0.2 and 0.3, respectively) (10,11). 
Because to the best of our knowledge an evidence-based ICBT intervention for 
severe fatigue in survivors of breast cancer was lacking, we translated an eviden-
ce-based, face-to-face CBT intervention into a Web-based format. A previous review of 
Andersson et al (12) demonstrated the potential of this translation by concluding that, 
if guided by a therapist, the effects of ICBT and face-to-face CBT were equivalent for a 
range of psychiatric and somatic disorders (12). 
The efficacy of the face-to-face intervention was shown in 2 trials aimed at severe 
fatigue in cancer survivors with various diagnoses, with effects being maintained at a 
follow-up of 2 years (13-15). Generally, the delivery of face-to-face CBT is challenging. 
It is an intensive intervention with a mean of 13 face-to-face sessions (13), thereby 
limiting treatment capacity while being demanding for patients. ICBT makes 
treatment accessible to more patients because it reduces travel time and dependence 
on scheduled appointments with a therapist. A Web portal with information and 
assignments, supported by E-mail contact with a therapist, enables patients to complete 
the intervention online and might reduce therapist time.
 The main objective of the current study was to examine whether ICBT is superior 
to CAU in reducing severe fatigue in survivors of breast cancer. Secondary outcomes 
were functional impairment, psychological distress, and quality of life (QOL). We 
hypothesized that ICBT would be more effective than CAU in reducing fatigue, 
functional impairment, and psychological distress and in improving QOL.
METHODS AND MATERIALS
Study design and participants 
In a parallel-group multicenter RCT, we compared the efficacy of ICBT for severely 
fatigued survivors of breast cancer with CAU at the Radboud University Medical Center 
in Nijmegen, the Netherlands.
Eligible survivors of breast cancer were recruited from 8 hospitals located in the 
eastern and southern parts of the Netherlands using various recruitment strategies: 
physicians and nurses introduced the study to eligible patients during a regular 
follow-up consultation, nurse practitioners informed cohorts of eligible patients about 
the study by mail (ie, clinician-referred participants), or patients were approached by 
patients’ associations and participating hospitals via social media such as Facebook 
and Twitter (ie, self-referrals). If interested, patients were invited to sign up for the 
study on a dedicated Web site.
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All participants were enrolled by the primary researcher (H.J.G.A.). Patients who 
signed up for participation received verbal and written information regarding the 
study and patient questions were addressed, after which interested patients were 
screened for eligibility.
Female patients were eligible if they were aged ≥18 years, free of disease, and had 
completed treatment for breast cancer with curative intent at least 3 months previously 
(barring hormone and targeted therapy) as verified by their general practitioner, 
oncologist, or surgeon. If potential participants were able to speak, read, and write 
Dutch and had access to a computer and the Internet, they were screened online for 
being severely fatigued (defined as a score of ≥35 on the Fatigue Severity subscale of 
the Checklist Individual Strength [CIS-Fatigue Severity]) and having basic Internet 
skills (eg, having an E-mail address and being able find information online).
Exclusion criteria were: 1) comorbidity that could explain the severe fatigue (as 
assessed by a medical oncologist [C.V.]); 2) a depressive disorder (as assessed with the Beck 
Depression Inventory for Primary Care and, in the case of a score of ≥4, the Depression 
module of the Mini-International Neuropsychiatric Interview); 3) undergoing current 
psychological treatment for a psychiatric disorder; and 4) undergoing current CBT for 
fatigue. At the start of the study, patients aged ≥65 years also were excluded. However, 
to increase the number of eligible patients, this maximum age restriction was lifted 
during the study. 
 After providing written informed consent, the survivors of breast cancer who were 
enrolled in the trial completed a baseline assessment at the study treatment center, 
after which they were randomized (allocation ratio of 1:1) to either the intervention 
condition comprising ICBT or the control condition consisting of CAU. After 6 months, 
participants completed the second assessment online. Further details regarding the 
study design have been published in a protocol article (16). 
The RCT was reviewed and approved by the Arnhem-Nijmegen Medical Research 
Ethics Committee (NL43781.091.13) and the ethics committees of the participating 
hospitals. The study was recorded in the Netherlands Trial Registry (no. NTR4309).
Randomization
Randomization was in blocks of 6 and stratified based on time since cancer treatment 
(3-12 months vs ≥12 months) and type of referral (clinician-referred participants vs 
self-referrals). The computer-generated allocation sequence was prepared by an 
independent statistician, whereas a test assistant who performed the randomization 
informed individual participants about the allocation by telephone. The primary 
researcher and the test assistant were not blinded for allocation after randomization 
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because of practical constraints. Statistical analyses were conducted by an independent 
researcher who was blinded for the allocation.
Intervention Condition
ICBT for severely fatigued survivors of breast cancer was developed from an 
evidence-based, face-to-face CBT protocol for severely fatigued cancer survivors with 
mixed cancer diagnoses (13-15). The protocol is based on a cognitive behavioral model 
of precipitating and perpetuating factors of fatigue, in which it is assumed that the 
malignancy and its treatment induce the fatigue whereas cognitive behavioral factors 
(eg, a deregulated sleep-wake cycle or dysfunctional cognitions regarding fatigue) 
maintain the fatigue (13).
ICBT consisted of a total of 3 face-to-face sessions and a maximum of 8 Web-based 
modules. Participants initiated ICBT with 2 face-to-face sessions, after which they 
followed their treatment online, in which they were guided by licensed cognitive 
behavioral therapists through electronic consultations (ie, E-mail contacts and 
a maximum of 2 telephone or video consultations). Six therapists delivered the 
intervention, which was tailored to the individual patient. The intended duration of 
ICBT was 6 months and the intervention was completed with a face-to-face evaluation 
session. All participants first set their treatment goals (module 1). They then worked 
on the fatigue-perpetuating factors that were applicable to them: 1) poor coping with 
breast cancer (treatment); 2) high fear of cancer recurrence; 3) dysfunctional fatigue-
related cognitions; 4) a deregulated sleep-wake rhythm; 5) a deregulated activity 
pattern; and/or 6) negative social interactions and low social support. Each of these 
6 fatigue-perpetuating factors corresponded with a treatment module (modules 2- 7). 
Finally, participants realized their treatment goals (module 8).
The intervention was tailored to the individual patients. At baseline, it was decided 
which modules were relevant to them. Assessment tools were used to assess which 
fatigue-perpetuating factors were present and which treatment modules patients 
needed to follow. A detailed description of these assessment tools and cutoff scores has 
been provided in the protocol article (16).
Control Condition
Participants in the control condition received CAU, which meant that they were 
placed on a 6-month waiting list for face-to-face CBT, which was the regular waiting 
time at the treatment center because of limited treatment capacity. CAU also comprised 
oncological follow-up examinations and a referral for psychosocial care, if pertinent. 
There were no restrictions regarding the use of fatigue interventions for the duration 
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of the study, but all participants were requested to report these at 6 months.
Outcome Measures
Primary outcome
The primary outcome was fatigue severity as assessed with the 8-item CIS-Fatigue 
Severity (7-point Likert scale [range, 8-56]). The CIS-Fatigue Severity measures the 
patient’s fatigue levels over the past 2 weeks, with higher scores indicating higher 
levels of fatigue. The cutoff score for severe fatigue is ≥35 (17). Previous studies have 
shown the reliability and validity of the subscale to be good to excellent (17-19). It has 
been used before in intervention studies with cancer survivors (7,11,13,14).
Secondary outcomes
Secondary outcomes were: 1) functional impairment, as assessed with the Sickness 
Impact Profile 8 (8 subscales [range, 0-5799]), with higher scores indicating more 
disabilities (20); 2) psychological distress, as assessed with the Brief Symptom Inventory 
18 (18 items on 5-point Likert scale [range, 0-72]), with higher scores indicating 
more psychological distress (21); and 3) QOL, as assessed with the global QOL scale 
of the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC-QLQ-C30; 2 items on a 7-point Likert scale [range, 0-100]) 
(22). All 3 questionnaires have been established as reliable and valid measures (23-25).
Evaluation of ICBT
Two raters (H.J.G.A. and an independent researcher) screened a random selection 
of 5% of all E-mails sent by the therapists to determine treatment integrity in terms of 
the percentage of intervention elements that were in accordance with the treatment 
protocol. The percentage of scores that were rated equally by the 2 raters (interrater 
agreement) also was calculated. Participants were defined as ICBT starters if they had 
filled in their treatment goals on the Internet portal, which was a prerequisite to gain 
access to the other modules. 
Participants were defined as treatment dropouts if they had agreed with their 
therapist to discontinue ICBT prematurely. Criteria to determine which modules 
were indicated for each patient have been reported in the protocol article (16). The 
percentages of indicated modules were calculated, as well as the percentages of 
patients who had opened these modules. 
Therapists recorded the time they spent on each patient during ICBT. At 6 months, 
all ICBT completers rated their satisfaction with ICBT on a scale of 1 to 10, with 10 being 
the most positive score.
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Statistical Analysis
Sample size calculation
A sample of 120 participants was needed for a Student t test with an α of .05, a 
2-sided significance level, and a power of 0.85 (16). Based on a study that examined 
the efficacy of a minimal intervention for patients with medically unexplained chronic 
fatigue, we assumed a clinically relevant difference in fatigue severity between the 
intervention and control condition of 6 points (26). To calculate the required sample 
size for an analysis of covariance, this sample size wasmultiplied with the factor (1- r2), 
in which r was 0.36 (27). This resulted in a minimal number of 53 patients in each 
condition. Because we expected treatment dropout to be 50% higher than the rate 
recorded in the 2006 RCT examining the efficacy of face-to-face CBT (13%) because 
of decreased therapist involvement, we included a dropout margin of 19.5% in the 
sample size calculation (13,16). This resulted in a sample size of 132 participants.
Statistical effects
Descriptive statistics, chi-square tests, and independent-sample Student t tests were 
used to confirm the comparability of the baseline characteristics of the intervention 
and control groups. Analyses of covariance were conducted to assess the efficacy 
of ICBT on fatigue severity, functional impairment, psychological distress, and QOL 
compared with CAU. Condition was entered as the fixed factor and baseline scores on 
the corresponding questionnaires as the covariates. Standardized effect sizes (Cohen 
d) were calculated by subtracting the unadjusted mean scores of the intervention and 
control condition at 6 months, divided by the pooled standard deviation (SD) of both 
groups at 6 months. Effect sizes of 0.2 to 0.5 were considered small, those of 0.5 to 0.8 
as moderate, and those ≥0.8 as large (28). All analyses were based on intention to treat 
for all participants. SPSS statistical software (version 22; IBM Corporation, Armonk, 
NY) was used for all analyses.
Sensitivity analyses
We conducted multiple imputation for missing values for the primary and secondary 
outcomes at 6 months based on the assumption that data were missing at random, 
using fully conditional specification with 20 imputations (29). A sensitivity analysis 
was conducted to assess the robustness of our findings for missing data. We computed 
whether findings would be maintained in the case of no change in missing values in 
the intervention condition at 6 months using the last observation carried forward. We 
assumed improvement in the control condition because regression toward the mean is 
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likely to occur (30). Because lower scores indicate more improvement, we subtracted 
the mean change score of the controls (ie, baseline score minus score at 6 months) from 
the baseline score for missing values in the CAU condition. With regard to QOL, for 
which higher scores indicate better functioning, we added the mean change score of 
the controls to the score at 6 months. In addition, we conducted a post hoc per-protocol 
analysis including all ICBT completers and all participants who had not received any 
additional treatment for their fatigue during the trial.
Clinical significance
A clinically significant improvement was defined as a reliable change index of at least 
-1.96 and a fatigue level within the normal range (CIS-Fatigue Severity <35) (17,31). In 
addition, participants rated improvement at 6 months using a single question to which 
they could respond with “I am no longer bothered by fatigue,” “I feel much better,” 
“I experience the same level of fatigue,” or “the fatigue has worsened in the past 6 
months,” in which the first 2 response options were considered to indicate self-rated 
improvement (13). We used chi-square tests to compare the percentages of clinically 
significant and self-rated improvement in the ICBT group with the percentages in the 
control group.
RESULTS
Sample Characteristics
Between January 2014 and March 2016, a total of 291 survivors of breast cancer 
indicated they wished to be informed about the study, of whom the primary researcher 
excluded 70 (24%) women, whereas 89 women (31%) declined participation. In total, 
132 patients (45%) were included and randomized to ICBT (66 patients) and CAU 
(66 patients). Figure 1 shows the flow chart of patient inclusion, with reasons for 
ineligibility and nonparticipation. 
The baseline characteristics of the participants are shown in Table 1. None of these 
characteristics differed significantly between the 2 conditions. We recorded 2 serious 
adverse events during the trial. Both concerned cancer recurrence in 2 participants 
in the CAU condition, 1 of whom withdrew from the study. Of the 66 women assigned 
to ICBT, 3 (5%) did not initiate the intervention and 2 (3%) discontinued treatment 
prematurely (see Fig. 1 for further details).
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CBT indicates cognitive behavioral therapy; CIS, Checklist Individual Strength (Fatigue Severity subscale); ICBT, Inter-
net-based cognitive behavioral therapy.
Figure 1. Flow chart of patient selection and participation. 
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Assessed for eligibility (n=291) 
   Referred by medical professionals (n=184)  
   Self-referrals (n=107) 
Randomised (n=132) 
   Referred by medical professionals (n=76) 
   Self-referrals (n=56) 
 
x 
 
 
 
 
Allocated to ICBT (n=66) 
 
Allocated to care as usual (n=66) 
Non-starters (n=3) 
   Intervention took too much time (n=2) 
   Intervention did not meet participant’s  
   expectations (n=1) 
Declined to participate (n=89) 
   Not interested (n=57) 
   Travel distance to treatment centre    
      (n=23) 
   Time investment (n=9) 
Not meeting inclusion criteria (n=70) 
   Co-morbidity that explains the fatigue (n=26) 
   Not severely fatigued (CIS<35) (n=15) 
   Not disease-free (n=7)    
   Treated for ductal carcinoma in situ (n=6) 
   No Internet literacy or access (n=6) 
   Current CBT for fatigue (n=5) 
   Current psychiatric treatment (n=3) 
   Depressive disorder (n=1) 
   Male (n=1) 
 
Completers 6-month assessment (n=64) 
Completers 6-month assessment (n=66) 
 
Completers ICBT intervention (n=61) 
Withdrawals (n=2) 
   Not interested in further    
      participation (n=1) 
   Metastases (n=1) 
 
 
Treatment dropouts (n=2) 
   Intervention did not meet participant’s         
   expectations (n=2) 
Intention to treat  
 
 
Completers 
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Characteristic ICBT (n=66) CAU (n=66)
Sociodemographic characteristics
Mean age at entry (SD), y 52.5 (8.2) 50.5 (7.6)
Education levela
    Low 17 (26%) 14 (21%)
    Middle 24 (36%) 31 (47%)
    High 25 (38%) 21 (32%)
Having a partner (yes) 57 (86%) 54 (82%)
Having children (yes) 52 (79%) 56 (85%)
Having a paid job (yes) 37 (56%) 40 (61%)
Medical characteristics
Stage of disease at diagnosisb
   I 32 (49%) 31 (47%)
   II 25 (38%) 26 (39%)
  III 9 (14%) 9 (14%)
Type of cancer treatment
    Surgery 5 (8%) 3 (5%)
    Surgery and radiotherapy 7 (11%) 10 (15%)
    Surgery and chemotherapy 15 (23%) 14 (21%)
    Surgery and radiotherapy and chemotherapy 39 (59%) 39 (59%)
Hormone therapy
    During study participation      38 (58%) 44 (67%)
    Prior to study participation 11 (17%) 5 (8%)
Targeted therapy
    During study participation      2 (3%) 2 (3%)
    Prior to study participation 9 (14%) 9 (14%)
Mean time since diagnosis (SD), mo 43.7 (31.0) 39.0 (25.5)
Time since completion of cancer treatment, mo 37.1 (30.8) 32.5 (25.1)
     3-12 16 (24%) 14 (21%)
     >12 50 (76%) 52 (79%)
Abbreviations: CAU, care as usual; ICBT, Internet-based cognitive behavioral therapy; mo, months; SD, standard deviation; 
y, years.
Data are shown as the number (%) unless otherwise indicated. Baseline characteristics did not differ significantly be-
tween the 2 groups (P >.05).
a Level of education was categorized as low, middle, or high according to the Dutch National Public Health Compass.
b Stage of disease was determined according to the 6th edition of the TNM classification of malignant tumors.
Table 1. Baseline characteristics of the study participants
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Efficacy of ICBT
Primary outcome
The results of the intention-to-treat analyses of the primary and secondary 
outcomes at 6 months are shown in Table 2. Participants randomized to ICBT reported 
significantly lower fatigue scores compared with those who received CAU. The effect 
size was large (Cohen =  1.0; 95% confidence interval [95% CI], 0.6-1.3).
Secondary outcomes
Compared with the CAU patients, participants in the ICBT condition reported less 
functional impairment and psychological distress, and a better QOL at the 6-month 
assessment. Effect sizes were moderate (Cohen d of 0.6, 0.8, and 0.7, respectively).
Clinical significance
The percentage of survivors of breast cancer with clinical improvement of fatigue 
severity was significantly higher after ICBT (73%) than after CAU (27%), as was the case 
with self-rated improvement (85% in the ICBT group vs 31% in the CAU condition) (Table 
2). The change in fatigue scores for each individual participant is depicted in Figure 
2 (32); the figure also shows whether the change between baseline and the 6-month 
assessment was clinically significant and reliable or reliable only, and whether there 
was no change or a deterioration in fatigue. There was more often clinically significant 
and reliable change noted in the ICBT condition, and more often no change observed 
in the control condition.
Sensitivity Analyses
Scores of 2 participants (2%) in the CAU condition were missing for all outcome 
measures at the 6-month assessment, whereas 4 of the 132 survivors of breast cancer 
(3%) had only completed the primary outcome measure at 6 months. The results of the 
sensitivity analyses demonstrated the robustness of the findings of the current study 
for missing data (see Supporting Information Table S1).
In the per-protocol analysis, 3 ICBT nonstarters, 2 treatment dropouts, and 12 
participants who received treatment for their fatigue other than ICBT during the study 
were excluded. The effect sizes computed for the remaining participants were higher 
(fatigue severity: d = 1.2; functional impairment: d = 0.7; psychological distress: d = 0.9; 
and QOL: d = 0.9) (see Supporting Information Table S2).
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ICBT (n=66) CAU (n=66) Mean 
difference
(95% CI)
P-value Effect size
(95% CI)a
Primary outcome
Fatigue severity (CIS-fatigue, range 8-56)b
    Baseline 45.2 (7.0) 44.9 (7.5)
    6 mo 27.7 (12.2) 39.1 (11.3) 11.5 (7.7 to 
15.3)
<0.0001c 1.0 (0.6 to 1.3)
Clinically significant improvement (no., %)d
48 (73%) 18 (28%) <0.0001c
Self-rated improvement (no., %)e
50 (85%) 18 (31%) <0.0001c
Secondary outcomes
Functional impairment (SIP-8, range 0-5799)b
    Baseline 1039.0 (617.6) 1127.5 (598.5)
    6 mo 490.2 (552.3) 841.8 (592.1) 297.8 (145.5 to 
450.1)
<0.0001c 0.6 (0.3 to 1.0)
Psychological distress (BSI-18, range 0-72)b
    Baseline 11.5 (9.2) 12.4 (8.2)
    6 mo 6.9 (6.9) 13.1 (8.8) 5.7 (3.4 to 7.9) <0.0001c 0.8 (0.4 to 1.1)
Quality of life (EORTC-QOL-C30, range 0-100)f
    Baseline 60.1 (17.7) 56.6 (18.3)
    6 mo 77.1 (16.5) 63.9 (20.1) 11.7 (5.8 to 
17.7)
<0.0001c 0.7 (0.4 to 1.1)
Abbreviations: 95% CI, 95% confidence interval; BSI-18, Brief Symptom Inventory 18; CAU, care as usual; CIS-Fatigue 
Severity, Checklist Individual Strength-Fatigue Severity subscale; EORTC-QLQ-C30, European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire Core 30; ICBT, Internet-based cognitive behavioral therapy; Mo, 
months; QOL, quality of life; SIP-8, Sickness Impact Profile 8.
Data are shown as the mean (standard deviation), unless otherwise indicated. P values were calculated using analyses of 
covariance with adjustment for baseline scores.
a Cohen d.
b Higher scores indicate more symptoms or impairment.
c P<.05.
d Reliable change index >1.96 and cutoff value for CIS-Fatigue Severity <35; the data regarding 2 patients (2%) were 
missing.
e Based on the responses “I have completely recovered” or “I feel much better but still experience some symptoms”; the 
data regarding 15 patients (11%) were missing.
f Higher scores indicate a better QOL.
Table 2. Results of the intention-to-treat analysis for all outcomes from baseline to the 6-month assessment
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Evaluation of ICBT
With regard to treatment integrity, a mean of 95% of the interventions in the E-mails 
sent by therapists were delivered in accordance with the ICBT protocol, with an 
interrater agreement of 99%. The mean self-reported therapist time for ICBT completers 
(face-to-face sessions and electronic consultations) was 7.1 hours (SD, 2.5 hours; 
range, 3.6-16.6 hours). The mean duration of ICBT was 25 weeks (SD, 4 weeks). The 
mean number of electronic consultations was 11, with an average of 10 E-mails and 1 
telephone/video consultation. Supporting Information Table S3 shows the percentages 
of modules that were indicated and opened during ICBT, which ranged from 63% to 
100%. The vast majority of ICBT completers (85%) gave their overall satisfaction with 
ICBT a score of ≥7 of 10, with a mean score of 7.6.
The horizontal and vertical lines indicate the Checklist Individual Strength (CIS)-Fatigue Severity subscale cutoff score 
for severe fatigue (35). The diagonal line indicates no change in fatigue severity between baseline and the 6-month 
assessment. The dashed parallel lines indicate the 95% confidence intervals for the Reliable Change Index. Figures were 
created using the Leeds Reliable Change Index calculator.32 Two patients were not included due to missing data on the 
CIS-Fatigue Severity subscale at baseline. The CIS-Fatigue Severity score already dropped below the cutoff score for severe 
fatigue (CIS-Fatigue Severity <35) between screening and baseline in 5% of participants.
CAU, care as usual; ICBT, Internet-based cognitive behavioral therapy.
Figure 2. Changes in fatigue scores from baseline to the 6-month assessment.
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DISCUSSION
To our knowledge, the current study is the first RCT to examine the efficacy of an 
ICBT intervention specifically aimed at decreasing severe fatigue in survivors of breast 
cancer. Compared with participants who had received CAU, participants in the ICBT 
condition reported significantly less fatigue, with a large effect size and the majority 
demonstrating clinically significant and self-rated improvement. ICBT also was found 
to lead to significantly less functional impairment and psychological distress and a 
better QOL compared with CAU.
The Web-based intervention was based on our center’s treatment protocol for 
face-to-face CBT for severe fatigue, the efficacy of which was demonstrated in 2 
previous RCTs (13,14). Comparing the effect sizes, we found that both treatment 
formats appeared to be equally effective in reducing severe fatigue (effect size for 
ICBT: 1.0 [95% CI, 0.6-1.3] vs effect size for face-to-face CBT: 1.0 [95% CI, 0.6-1.5]) (13). 
This is in keeping with a previous meta-analysis that demonstrated that the effects 
of face-to-face CBT and therapist-guided ICBT also were equivalent in patients with 
various psychiatric and somatic disorders (12).
The effects of the current ICBT intervention on fatigue were found to be large 
compared with other Webbased interventions for fatigue in cancer survivors. The 
results of the RCT by Yun et al (5) on a Web-based selfmanagement education program 
demonstrated rates of clinically relevant improvement for fatigue outcomes ranging 
from 47% to 56% in the intervention condition and from 33% to 45% in the control 
condition (5). In addition, the pilot study by Bruggeman-Everts et al (7) demonstrated 
that Web-based, mindfulness-based cognitive therapy led to a clinically relevant 
improvement in 35% of participants (7). The effects of general self-management 
interventions on fatigue in the RCTs of Willems et al and van den Berg et al were small 
(Cohen’s d of 0.2 and 0.3, respectively) compared with the current study (10,11).
In the current study, approximately 73% of patients demonstrated clinically 
significant improvement regarding fatigue compared with 28% of patients in the CAU 
condition, and the Cohen’s d effect size of 1.0 was large. These positive findings may 
be explained in part by the fact that the intervention was based on an evidence-based 
face-to-face protocol, and guided by experienced therapists who worked at a specialized 
tertiary treatment center.
Although ICBT seems to be a relatively more effective intervention, it should be 
determined whether the efficiency of the intervention can be improved. The mean 
duration of the intervention of 24 weeks is long compared with other Web-based 
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interventions for fatigue. For example, the duration of the Web-based self-management 
education program of Yun et al was 9 weeks (5), and the Web-based, mindfulness-based 
cognitive therapy intervention of Bruggeman-Everts et al took 12 weeks (7). In future 
research, it should be examined whether the duration of ICBT can be shortened 
without losing efficacy. In addition, ways to decrease therapist involvement need 
to be examined to further improve treatment capacity. Integration of computerized 
automated feedback into the intervention could be useful to realize this objective.
Not all indicated modules were opened by patients who followed ICBT. Therapists 
guided patients through the Web site by E-mail, and suggested which modules patients 
should read. However, this was only suggested as advice, and none of the modules 
were stated to be mandatory to follow. In addition, patients had access to optional 
modules that were not indicated for them. This made it difficult to define proper 
adherence criteria. We had predicted that minimal therapist involvement would lead 
to more participants dropping out of ICBT (an estimated 20%) than generally is the 
case for face-to-face interventions. Surprisingly, only 8% of patients discontinued ICBT 
prematurely. 
The expectation that less therapist involvement is required for ICBT appears to be 
confirmed by the results of the current study: the mean therapist time per participant 
was 7.1 hours (range, 3.6-16.6 hours) for ICBT compared with 12.5 hours (range, 5-26 
hours)(13) in face-to-face CBT. Although the results of the current study suggest that 
ICBT is more time-efficient, a note of caution is in order because the 2 treatment formats, 
although based on the same protocol, were studied in different patient samples.
In the current study protocol, we planned to determine whether ICBT already could 
be provided from 3 months (instead of the regular 12 months) after cancer treatment. 
We wanted to compare the efficacy of ICBT between patients who had completed 
cancer treatment 3 to 12 months previously with those who had completed treatment 
>12 months previously. However, conclusions could not be drawn because the current 
analysis was underpowered (only 23% of participants fell into the first category).
Limitations of the current study are a lack of blinding of the outcome assessors 
(due to practical constraints) and a lack of an active control condition. The clinically 
significant improvement in fatigue noted in 28% of the survivors in the control 
condition is remarkable because cancer-related fatigue generally is considered to 
be a persistent symptom. Assuming that in some of these survivors the fatigue had 
been transitory, it would be better to offer the intervention only to those patients with 
chronic fatigue symptoms (ie, those indicating a duration of persistent fatigue of at 
least 6 months) to avoid patients being treated unnecessarily. Another limitation of 
the current study concerns the fact that we could not determine the long-term effect 
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of ICBT. Controlled follow-up assessments could not be incorporated into the design of 
the current study because patients in the CAU condition were placed on a waiting list 
to receive face-to-face CBT directly after the 6-month assessment.
Given the limited budgets in mental health care, future studies need to determine 
the cost-effectiveness of ICBT (33). We propose that combining our ICBT program for 
cancer-related fatigue with a stepped-care model is likely to further increase treatment 
efficiency. Toward this end, we will extend the current study to a noninferiority trial 
(Dutch Trial Registry trial no. NTR5179), in which survivors of breast cancer will be 
offered face-to-face sessions in addition to ICBT, if possible. Outcomes again will be 
compared with usual care (ie, face-to-face CBT after a 6-month waiting period). If the 
Web-based, stepped-care intervention is not found to be inferior to usual care, broader 
implementation will be considered. 
It also should be noted that with a mean age of 51.5 years, the participants in the 
current study were relatively young, whereas breast cancer is most prevalent among 
women aged 60 to 75 years (34). This limits the generalizability of the current study 
results and may indicate that ICBT in particular attracts younger women, but we must 
not overlook those severely fatigued survivors of breast cancer whose Internet literacy 
skills are deficient or who reject online interventions. It is important that face-to-face 
CBT remains available for these women. Moreover, the current study should be 
replicated among cancer survivors with different tumor types because we are unsure 
whether the results of the current study can be generalized to these patient populations.
Requiring less therapist involvement than face-to-face CBT without losing efficacy, 
ICBT appears to be a logical next step in the development of more accessible, minimally 
intensive psychological interventions for severely fatigued survivors of breast cancer.
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APPENDICES
ICBT (n=66) CAU (n=66) Mean difference 
(95% CI)
P-value Effect size 
(95% CI)a
Primary outcome
Fatigue severity (CIS-fatigue, range 8-56)b
     Baseline 45.2 (7.0) 44.9 (7.5)
     6 months 27.7 (12.2) 39.3 (11.2) 11.7 (7.9 to 15.5) <0.0001c 1.0 (0.6 to 1.4)
Secondary outcomes
Functional impairment (SIP-8, range 0-5799)b
     Baseline 1039.0 (617.6) 1127.5 (598.5)
     6 months 494.9 (554.5) 856.4 (596.9) 306.2 (156.2 to 456.2) <0.0001c 0.6 (0.3 to 1.0)
Psychological distress (BSI-18, range 0-72)b
     Baseline 11.5 (9.2) 12.4 (8.2)
     6 months 6.9 (6.8) 13.1 (8.8) 5.7 (3.5 to 7.8) <0.0001c 0.8 (0.4 to 1.1)
Quality of life (EORTC-QOL-C30, range 0-100)d
     Baseline 60.1 (17.7) 56.7 (18.3)
     6 months 76.0 (17.5) 63.4 (20.0) 10.9 (5.1 to 16.8) <0.0001c 0.7 (0.3 to 1.0)
Data are mean (SD), unless otherwise indicated. P-values were calculated using analyses of covariance with adjustment 
for baseline scores. 
Abbreviations: CAU=Care as usual; ICBT=internet-based cognitive-behavioural therapy; CIS-fatigue=Checklist Individual 
Strength, Fatigue Severity subscale; SIP=Sickness Impact Profile; BSI-18=Brief Symptom Inventory-18; EORTC-QLQ-
C30=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. 
aCohen’s d.
bHigher scores indicate more symptoms or impairment. 
c P<0.05
d Higher scores indicate a better quality of life
Table S1. Results of the sensitivity analysis of missing values for all outcomes at the 6-month assessment
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ICBT (n=58) CAU (n=56) Mean difference 
(95% CI)
P-value Effect size 
(95% CI)a
Primary outcome
Fatigue severity (CIS-fatigue, range 8-56)b
     Baseline 45.2 (7.0) 44.9 (7.5)
     6 months 25.6 (10.8) 38.8 (11.2) 13.4 (9.5 to 17.3) <.0001c 1.2 (0.8 to 1.6)
Secondary outcomes
Functional impairment (SIP-8, range 0-5799)b
     Baseline 1039.0 (617.6) 1127.5 (598.5)
     6 months 459.3 (551.4) 829.6 (554.5) 360.9 (211.7 to 510.2) <.0001c 0.7 (0.3 to 1.1)
Psychological distress (BSI-18, range 0-72)b
     Baseline 11.5 (9.2) 12.4 (8.2)
     6 months 6.1 (6.3) 13.3 (8.8) 6.6 (4.3 to 8.8) <.0001c 0.9 (0.5 to 1.3)
Quality of life (EORTC-QOL-C30, range 0-100)d
     Baseline 60.1 (17.7) 56.7 (18.3)
     6 months 79.8 (13.3) 63.9 (20.4) 14.6 (8.5 to 20.7) <.0001c 0.9 (0.5 to 1.3)
Data are mean (SD), unless otherwise indicated. Values of one participant in the ICBT and one participant in the CAU con-
dition were missing on all secondary outcomes. P-values were calculated using analyses of covariance with adjustment 
for baseline scores. 
Abbreviations: CAU=Care as usual; ICBT=internet-based cognitive-behavioural therapy; CIS-fatigue=Checklist Individual 
Strength, Fatigue Severity subscale; SIP=Sickness Impact Profile; BSI-18=Brief Symptom Inventory-18; EORTC-QLQ-
C30=European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. 
a Cohen’s d. 
b Higher scores indicate more symptoms or impairment. 
c P<0.05
d Higher scores indicate a better quality of life
Table S2. Results of per protocol analysis for all outcomes at the 6-month assessment
Treatment module % patients for whom the module 
was indicated
% patients that opened the 
indicated module
Sleep-wake rhythm All participants 60/61 (98%)
Fatigue-related cognitions All participants 57/61 (93%)
Activity pattern All participants 57/61 (93%)
Fear of cancer recurrence 46/61 (75%) 27/46 (59%)
Coping with cancer 24/61 (39%) 15/24 (63%)
Social environment 24/61 (40%) 15/24 (63%)
Table S3. Usage of the web-portal
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ABSTRACT
Purpose: Cognitive behaviour therapy (CBT) reduces cancer-related fatigue (CRF) 
in cancer survivors in the short-term. We examined fatigue levels up to 14 years after 
CBT.
Methods: Eligible participants of two randomized controlled trials who had 
completed CBT for CRF and a post-treatment assessment were contacted (n=81). 
Fatigue was assessed with the subscale ‘fatigue severity’ of the Checklist Individual 
Strength (CIS-fatigue). The course of fatigue over time was examined with linear mixed 
model analyses. Fatigue levels of participants were compared to matched population 
controls at long-term follow-up. We tested with multiple regression analysis if fatigue 
at follow-up was predicted by patients’ fatigue level and fatigue perpetuating factors 
directly after CBT (post-CBT). 
Results: Seventy-eight persons completed a follow-up assessment (response-
rate=96%, mean time after CBT=10 years). The mean level of fatigue increased from 
23.7 (SD=11.1) at post-CBT, to 34.4 (SD=12.4) at follow-up (p<0.001). Population controls 
(M=23,9, SD=11.4) reported lower fatigue levels than participants.  Half of patients 
(52%) who were recovered from severe fatigue at post-CBT (CIS-fatigue<35) were still 
recovered at long-term follow-up. Patients with lower fatigue levels at post-CBT were 
less likely to show relapse.
Conclusion: Despite initial improvement after CBT, levels of fatigue deteriorated 
over time. Half of patients who were recovered from severe fatigue after CBT still 
scored within normal ranges of fatigue at long-term follow-up. 
Implications for cancer survivors: It should be explored how to help patients with 
a relapse of severe fatigue following an initially successful CBT. They may profit from 
CBT again, or another evidence-based intervention for fatigue could be more beneficial 
(like mindfulness or exercise therapy). Future research to gain insight into reasons for 
relapse is warranted.
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INTRODUCTION 
Fatigue is one of the most common and distressing consequences of cancer and 
cancer treatment. Cancer-related fatigue (CRF), defined by the National Comprehensive 
Cancer network (NCCN) as ‘a persistent, subjective sense of tiredness related to cancer 
or cancer treatment that interferes with usual functioning, arises over a continuum, 
ranging from tiredness to exhaustion. When compared to the tiredness felt by a healthy 
individual, cancer-related fatigue is perceived of greater magnitude, disproportionate 
to activity and exertion, and not completely relieved by rest (1).’ CRF has negative 
effects on patients’ quality of life. Prevalence rates of CRF vary, approximately 25-30% 
of cancer survivors report persistent fatigue after cancer treatment (2,3). 
The cognitive-behavioural model of CRF makes a distinction between precipitating 
and perpetuating factors of fatigue. It is assumed that cancer and its treatment trigger 
fatigue, but that cognitive and behavioural factors perpetuate it. Six perpetuating 
factors are distinguished: 1) Insufficient coping with the experience of cancer, 2) 
excessive fear of disease recurrence, 3) dysfunctional cognitions concerning fatigue, 
4) deregulation of sleep-wake pattern, 5) deregulation of activity or low activity, 6) 
perceived lack of social support and negative social interactions (4). 
Cognitive behaviour therapy (CBT) for CRF is aimed at these fatigue perpetuating 
cognitions and behaviours. The efficacy of CBT for CRF has been tested in several 
randomized controlled trials (RCT’s) (4-6). It was found that CBT led to significant 
reduction of fatigue and functional impairment in severely fatigued cancer survivors. 
Positive effects of CBT were maintained up to 2 years after completion of CBT (7), with 
the majority of patients reporting a level of fatigue within normal range following 
treatment.
It is unclear if treatment effects are maintained in the long-term; there are no 
studies on CBT in cancer survivors that expanded the scope of the follow-up beyond 
the aforementioned period of two years. Studies on the long-term effect of CBT for 
fatigue in other patient populations have shown that sustainment of treatment effect is 
not self-evident. For example, Janse et al. (8) recently reported on the long-term effect 
of CBT for chronic fatigue syndrome (CFS). Patients with CFS suffer from medically 
unexplained, severe fatigue leading to substantial disability. The 583 participants 
of previously published studies on the effects of CBT for CFS were contacted for a 
long-term follow-up assessment. Positive effects of CBT for CFS were sustained up to 
18 months after CBT,64% of the patients had fatigue scores in the normal range. At 
long-term follow-up, up to 10 years after end of treatment, fatigue severity had again 
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increased significantly, and at long-term follow-up 37% of the participants had a 
fatigue score in the normal range. Similar results were found by Van Akker et al. (9), 
their study showed a positive effect of CBT on fatigue in patients with multiple sclerosis 
directly following treatment, which was also not sustained at follow-up.
The main objective of this study was to determine whether the positive effects of 
CBT on fatigue severity in cancer survivors were sustained at long-term follow-up. 
We defined long-term follow-up as more than 2 years after finishing CBT for CRF. 
The second objective of this study was to determine predictors of fatigue at long-term 
follow-up. More specifically, we examined whether the level of fatigue at long-term 
follow-up could be predicted by the fatigue perpetuating factors and patients’ level of 
fatigue directly after CBT.
MATERIAL AND METHODS
Study design and participants 
A total of 93 patients derived from two previous RCT’s of Gielissen et al. (4) and 
Prinsen et al. (5) were invited to participate in our long-term follow-up study:
• In the RCT of Gielissen et al. (4), a total of 112 patients were randomized to 
either CBT or waiting list condition. . Patients from both conditions received 
CBT, either directly after randomization or after the waiting list period. Of the 
112 patients, 98 started CBT and 70 completed the post-treatment assessment. 
These 70 patients were invited to participate in the current follow-up study. 
• In the RCT of Prinsen et al. (5), 50 patients were randomized in the study. 
Follow-up measurements of the patients still undergoing CBT were incomplete 
because of logistic reasons. Therefore, the study was stopped prematurely, and 
only 23 randomized patients from the intervention condition were included 
in the analyses to determine the efficacy of CBT (5). We only invited these 23 
patients for the current follow-up study. 
The initial RCT’s had the following inclusion criteria: (1) being severely fatigued 
at baseline (operationalized as a score of 35 or higher on the fatigue subscale of the 
Checklist Individual Strength (CIS); (2) no known somatic cause for the fatigue; (3) 
completion of curative treatment for cancer at least 1 year ago; (4) a minimal age at 
disease onset of 18 years; (5) no evidence of disease recurrence and (6) not being older 
than 65 years (4,5). In the current follow-up study, we excluded patients who had 
metastatic cancer and/or received treatment for cancer in the six months prior to the 
follow-up assessment. 
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Because general populations surveys have shown that fatigue increases with 
advancing age (10), we examined if fatigue levels of our participants at long term 
follow-up differed from the level of fatigue in an age-matched control group that 
represented the general Dutch population.  A sample of general population controls was 
derived from a research panel of CentERdata, a research institute at Tilburg University. 
CentERdata has access to a large panel of participants for surveys. The panel reflects 
the distribution of the Dutch population with respect to age, sex, education level and 
socio-economic status. For each participant in our study, three controls were derived 
from the research panel. The control group was matched to our study population based 
on age and gender with the procedure Coarsened Exact Matching (CEM) using STATA/
SE12.1. 
Intervention 
Participants in our study originated from two RCT’s testing the efficacy of CBT for 
CRF in cancer survivors with mixed cancer diagnoses (4,5). In both RCT’s, patients 
were significantly less fatigued and functionally impaired following CBT compared to 
a waiting list control group (4,5). In the study from Gielissen et al. (7), patients from the 
waiting list also received CBT after the waiting period with similar treatment effects. 
CBT for CRF is protocolized and aimed at the aforementioned fatigue perpetuating 
factors (4). CBT starts with educating patients about the cognitive behavioural model of 
CRF. Treatment is tailored: the relevant perpetuating factors are assessed through use 
of specific questionnaires. The patient formulates treatment goals and then starts with 
regulating the sleep-wake pattern. This is followed by reformulating fatigue related 
beliefs and a graded activity program. Low active patients gradually increase their 
level of physical activity; relatively active patients first learn to divide their activities 
more evenly before the start of the graded activity program. If indicated, excessive 
fear of cancer recurrence, insufficient coping with cancer and cancer treatment are 
addressed. It is also discussed how to deal with a perceived lack of support with respect 
to fatigue and how to reduce negative interactions. During therapy, patients realize 
their goals step by step followed by an evaluation of the treatment. The mean number 
of therapy sessions during the 6-month period was 12.5  (S.D. 4.7) in the intervention 
condition and 12.4 (S.D. 4.6) in the waiting list condition in the Gielissen study (4), and 
12.0  (S.D. 5.0) in the Prinsen study (5). A detailed description of the conditions and 
followed procedures concerning both studies can be found in the original published 
papers (4,5).
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Procedures
The municipal registration was consulted in case of unknown address and for the 
purpose of preventing approaching the family of deceased participants. An invitation 
letter and follow-up questionnaires were sent by mail. Patients who did not respond 
within a timeframe of two weeks received the questionnaires again and were contacted 
by phone simultaneously. Non-responders that could not be reached by phone were 
sent a reminder by mail up to 5 times. When patients did not want to fill in question-
naires, they were asked to complete only the primary outcome measure, the subscale 
Fatigue Severity of the Checklist Individual Strength (CIS-fatigue) by phone. The 
local medical ethical committee Arnhem-Nijmegen approved the study (registration 
number: 2015-2048). 
Assessment
With regard to patient characteristics, data on partner status, work status and 
recent life-events were gathered. Patients were asked if they were currently treated 
for fatigue, received treatment by a psychologist or psychiatrist, had seen a specialist 
for a somatic co-morbidity other than cancer, had a recurrence of cancer since their 
treatment with CBT for CRF and/or were treated for cancer in the past six months.
Fatigue severity was assessed with the subscale Fatigue Severity of the Checklist 
Individual Strength (CIS-fatigue), indicating the level of fatigue in the previous two 
weeks, measured with eight items on a seven-point scale (range 8-56). A score of 35 or 
higher indicates severe fatigue. The CIS is found to be a reliable and valid instrument 
with a high internal consistency: Cronbach’s alpha ranges from .92 to .95 in cancer 
survivors (11).
Physical functioning, mental health and bodily pain were assessed with the respective 
subscales of the Short Form-36 (SF-36) (12). Physical functioning at follow-up was 
measured because the negative effect of fatigue on physical functioning is well known 
and CBT had a positive effect on physical functioning in the two RCT’s (4,5). Mental 
health and pain were measured as potential confounders of the long-term effect of 
CBT on fatigue severity. Weighted subscale scores range from 0 to 100, with higher 
scores indicating a better health status. The SF-36 is a valid and reliable instrument for 
different patient populations (13).
 
Perpetuating factors of fatigue directly after CBT
The model of CBT for CRF comprises six perpetuating factors. During CBT, each of the 
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relevant perpetuating factors is targeted with a specific treatment module. Knowledge 
on which patients are vulnerable for a relapse of severe fatigue and whether relapse 
is related to these perpetuating factors would be valuable to optimize our CBT and 
other interventions aimed at fatigue in cancer survivors. The dataset we used did 
not include a consistent useable measure of ‘fear of cancer recurrence’, one of the 
six perpetuating factors,  from both studies. Therefore, this perpetuating factor was 
left out of our analyses. We included the other five perpetuating factors of fatigue, 
measured post-CBT, as potential predictors of fatigue at long-term follow-up:
• Deregulated activities: Self-reported activity level was measured with the 
activity subscale of the CIS. 
• Coping with the experience of cancer (i.e., the extent to which a subject is 
currently occupied with the coping process after cancer and its treatment) was 
measured with the Dutch version of the Impact of Event Scale (IES) (14).
• Dysfunctional cognitions: Self-efficacy with respect to fatigue (i.e., confidence 
in one’s own ability to cope with fatigue) was measured with the Self-Efficacy 
Scale (SES) (15).
• Deregulated sleep-wake cycle: Sleep disturbances were measured with the sleep/
rest subscale of the Sickness Impact Profile-8 (SIP-8) (16). 
• A perceived lack of social support: Discrepancies between amount of received 
and desired amount of social support were measured with the subscale 
‘discrepancies’ (i.e., discrepancies between amount and desired amount of 
social support) of the van Sonderen Social Support Inventory (SSL-D) (17).
Statistical analyses
Data analyses were performed using SPSS (version 22). Threshold for significance 
was p<0.05 (two-tailed). Sample characteristics were analyzed using frequencies, 
percentages and mean scores. 
Each participant had data of three measurement points: baseline, post-CBT 
and long-term follow-up. Analyses were conducted for both fatigue and physical 
functioning as continuous variables and for fatigue as a dichotomous variable (within 
normal range <35, outside normal range 35 or higher). 
 Because the three assessments were clustered within each participant, linear mixed 
model analyses were used to examine the course of fatigue and physical functioning 
over time. Time was included as a categorical variable (using dummy variables) to 
compare scores at long-term follow-up assessment with the scores at the baseline 
and post-CBT assessments. Because of the extensive span of the follow-up period, it 
was important to take into account that besides cancer and its treatment, many other 
C
h
ap
te
r 
8
180
factors can cause and perpetuate fatigue. For both outcomes, additional analyses were 
conducted to assess the influence of the following covariates on the development 
of fatigue over time: somatic co-morbidities (yes/no), cancer recurrence (yes/no), 
significant life events (yes/no), pain (subscale SF-36) and mental health (subscale SF-36). 
A recent review by Abrahams et al. (18) has shown these factors to be of importance 
in CRF.
 The same analyses (with and without covariates) were conducted with fatigue as a 
dichotomous outcome (i.e., within or outside normal ranges) using logistic generalized 
estimating equations (GEE). It was not possible to calculate the time effect between 
baseline and follow-up. Only severely fatigued patients (CISfatigue≥35) were eligible to 
participate in the randomized controlled trials of in this study. Therefore, there were 
only patients with severe fatigue at baseline (score of1 in all patients). This lack of 
variation makes it impossible to estimate proper regression coefficients. This impeded 
calculation of the time effect between baseline and follow-up.
A t-test for independent samples was performed to compare the mean CIS-fatigue 
scores of our participants at follow-up and general population controls.
We performed multiple regression analyses (method enter) to determine whether 
fatigue severity at long-term follow-up (dependent variable) was predicted by fatigue 
severity (block 1) and the fatigue-perpetuating factors measured at post-CBT (poor 
coping with cancer/ treatment, activity regulation, dysregulation of sleep, dysfunctional 
cognitions, a perceived lack of social support and fatigue severity) (block 2).
In a post-hoc analysis we used the mean CIS-fatigue score of the population control 
group (M=24, SD=11) as a reference point to divide our participants in the following two 
groups: a low fatigue group  (CIS-fatigue <24) and a high fatigue group (CIS-fatigue≥24). 
By performing a chi-square test we determined if patients in the low fatigue group 
were less likely to relapse (CIS-fatigue ≥35 at long-term follow-up) than patients in the 
high fatigue group. 
RESULTS
Of the 93 eligible patients, nine had died. We invited 84 patients to participate and 
excluded three participants: two patients were excluded because they reported to have 
received cancer treatment in the six months prior to follow-up and one patient  was in 
the process of medical diagnostics because of possible cancer recurrence. In addition, 
three patients did not participate: one patient did not respond, and for two patients no 
contact details were available. A total of 78 patients participated in the study (78/81; 
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response-rate 96%) (see figure 1 for flowchart of patient inclusion). 
Mean age at long-term follow-up was 55.1 years (SD=10.1), 38 participants were 
female (49%) and the majority of our participants were married or living together 
(76%). Of the total group, 24 participants (31%) had experienced a significant life-event 
in the three months prior to the study and 32 participants (41%) reported the presence 
of a somatic co-morbidity (see also Table 1).
Linear mixed model analyses showed that fatigue levels had increased at long-term 
follow-up compared with the post-CBT assessment (mean change = 10.7 points, 
p<0.001). This time effect remained significant when the covariates were added. Lower 
mental health and higher pain scores predicted higher fatigue levels over time (Table 
3). Fatigue levels at long-term follow-up were still lower compared with the baseline 
assessment (mean change = -12.5 points, p<0.001). Results were largely similar when 
comparing severely and non-severely fatigued patients in logistic GEE analyses.  Time 
effects were comparable, but only pain was a significant covariate. Higher pain levels 
predicted higher levels of fatigue over time (supplementary table 1).
In the previous two RCTS’s, 65 of 78 participants (83%) were recovered from severe 
fatigue (CIS-fatigue<35) directly after CBT. A total of 34 of these 65 participants (52%) 
were still recovered at long-term follow-up. Of the 13 participants (17%) that did not 
recover from severe fatigue directly after CBT, 11 participants were still severely 
fatigued at long-term follow-up whereas 2 participants (15%) were recovered.
Figure 1. Flow chart of patient inclusion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 eligible patients  
Excluded patients 
     2 patients with metastatic tumor after CBT  
     1 possible cancer recurrence 
 
 
Non-participants 
     1 no response after consent 
     1 not locatable 
     1  patient emigrated 
       
Excluded patients 
     9 deceased    
 
 
         
84 patients invited to participate  
78/81 patients completed the 
questionnaires (96%) 
CBT completers  
     70 from the Gielissen study 
     23 from the Prinsen study 
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Physical functioning scores at long-term follow-up were improved compared to 
the baseline assessment (SF36 mean change = 9.1 points, p<0.001). However, the level 
of physical functioning (SF36) was decreased at long-term follow-up compared with 
post-CBT assessment (SF36 mean change = -9.7 points, p<0.001). After controlling for 
covariates, there was no significant reduction in levels of physical functioning between 
post-CBT assessment and follow-up anymore. Pain and somatic comorbidities predicted 
physical functioning over time (Table 3 ). 
Participants' fatigue scores at long-term follow-up were significantly higher than 
fatigue scores in the matched general population control group (resp. CIS-fatigue 
N (%)
Marital status
     Married, living together 59 (76%) 
     Divorced 11(14%)
     Widowed 3 (4%)
     Living alone 5 (6%)
Gender
     Female 38 (49%)
     Male 40 (51%)
Having paid work
     Yes 32 (41%)
     No 46 (59%)
Self-reported somatic co-morbidity
     Yes 32 (41%)
     No 46 (59%)
Significant life events during past three months
     Yes 24 (31%)
     No 54 (69%)
Treatment by psychologist/ psychiatrist during past six months
     Yes 11 (14%)
     No 67 (86%)
Current treatment for fatigue complaints
     Yes 3 (4%)
     No 74 (95%)
     Unknown 1 (1%)
Cancer recurrence (currently no treatment, no metastatic cancer)
     Yes 9 (12%)
     No 69 (88%)
Table 1: Patient characteristics at long-term follow-up assessment (N=78)
L
on
g-
te
rm
 e
ff
ec
ts
 o
f 
fa
ce
-t
o-
fa
ce
 C
B
T
 f
or
 s
ev
er
e 
fa
ti
gu
e 
in
 c
an
ce
r 
su
rv
iv
or
s.
 
183
severity M=34.4 SD=12.4 vs. M=23,9, SD=11.4, p=0.01). 
The blockwise linear regression analysis showed that fatigue at long-term follow-up 
was predicted by the level of fatigue directly after CBT (Supplementary table 2). None of 
the perpetuating factors at post CBT assessment predicted fatigue severity at long-term 
follow-up.  
When comparing the low and high fatigue group at follow-up, patients in the low 
fatigue group at post-CBT assessment were less likely to be severely fatigued  at follow 
up (p<0.05). 
Baseline assessment Post-CBT assessment Long-term follow-up 
Fatigue severity 
Mean (SD) 46.9 (6.6) 23.7 (11.0) 34.4 (12.4)
Fatigue level within normal 
limits (CIS-fatigue<35)
N (%) N=0 (0) N=65 (83.3) N=33 (42.3)
Physical functioning 
Mean (SD) 66.0 (19.5) 84.7 (15.8) 75.4 (22.5)
Table 2. Fatigue and physical functioning at the three measurement points
Level of fatigue Level of physical functioning
ß 95% CI p ß 95% CI p
Crude model
Time baseline_FU 12.47 9.75 to 15.20 <0.001 -9.06 -14.05 to -4.08 <0.001
Time post_FU -10.71 -13.43 to -7.98 <0.001 9.72 4.73 to 14.70 <0.001
Model with covariates
Time baseline_FU 14.66 11.66 to 17.66 <0.001 -15.36 -21.22 to -9.51 <0.001
Time post_FU -4.65 -7.70 to -1.60 0.003 0.42 -5.47 to 6.30 0.889
Mental health -0.24 -0.31 to -0.16 <0.001 0.10 -0.04 to 0.24 0.168
Pain -0.09 -0.15 to -0.03 0.004 0.34 0.23 to 0.45 <0.001
Cancer recurrence 3.73 -2.32 to 9.77 0.225 -0.61 -12.14 to 10.91 0.916
Self-reported comorbidities 2.58 -1.53 to 6.70 0.217 -9.99 -17.94 to -2.03 0.014
Significant life events 2.43 -1.81 to 6.66 0.260 -4.52 -12.68 to 3.65 0.277
Notes. Linear mixed model analyses. Time baseline_FU= time between baseline and follow-up assessment; time post_FU= 
time between post-CBT and follow-up assessment.
Table 3. Levels of fatigue and physical functioning over time
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DISCUSSION
This study was the first to investigate the long term effects of CBT for CRF in cancer 
survivors. Although fatigue levels were improved up to two years after therapy, 
CBT could not avoid prevent that levels of fatigue increased over time. At long-term 
follow-up up to 14 years after therapy, fatigue levels had deteriorated and were higher 
than in general population controls. This deterioration was not explained by cancer 
recurrence, significant life events, somatic co-morbidities, pain, or a reduced mental 
health. Nevertheless, at long-term follow-up, positive effects of CBT on fatigue were 
sustained in a substantial subgroup. Half of patients (51%) who were recovered from 
severe fatigue at post-CBT were still recovered at long-term follow-up. Patients with a 
lower fatigue level at post-CBT were less likely to show relapse.
Just like the levels of fatigue, levels of physical functioning also showed deterioration 
between post-CBT assessment and follow-up. However, this time effect was not 
maintained after correction for covariates, with pain and comorbidities predicting 
physical functioning over time.  We conclude from this that the positive effects of CBT 
for CRF on physical functioning are maintained at long term follow-up. As previous 
studies have shown that higher levels of fatigue are associated with a reduced physical 
functioning (18), it is remarkable that the deterioration of fatigue levels over time did 
not go together with worsening of patients’ level of physical functioning. 
The significant relationship between fatigue severity directly after CBT and 
fatigue levels at long-term follow-up needs to be replicated, but could have clinical 
implications. Reducing fatigue severity as much as possible during therapy may 
improve the long-term effectiveness of CBT. This suggests that it may be beneficial 
to continue treatment with CBT as long as the fatigue level decreases. A maximum 
reduction of the fatigue level is not a treatment goal in itself in the current treatment 
protocol for CBT for CRF. 
The finding that there is relapse in a subgroup of patients at long-term follow-up of 
CBT has been previously found in several studies and in a variety of conditions. Our 
results show similarities with the study of Janse et al. (2017) on the long-term effects 
of CBT for patients with chronic fatigue syndrome (i.e., medically unexplained severe 
fatigue) (8). 
Understanding factors and mechanisms that predict the long-term effect of CBT 
is crucial for the improvement of the existing treatment protocol and for identifying 
patients at risk for a relapse of CRF. After correction for covariates, fatigue still 
deteriorated over time. It is poorly understood  why fatigue levels increased. To 
L
on
g-
te
rm
 e
ff
ec
ts
 o
f 
fa
ce
-t
o-
fa
ce
 C
B
T
 f
or
 s
ev
er
e 
fa
ti
gu
e 
in
 c
an
ce
r 
su
rv
iv
or
s.
 
185
understand the reasons for relapse, longitudinal studies incorporating qualitative 
research methods are needed to assess the course of fatigue, stressors and possible 
fatigue perpetuating factors.
There are several possible explanations for the deterioration after successful 
treatment of CRF: it is possible that patients who developed CRF after being treated for 
cancer had a pre-existent vulnerability for developing fatigue in response to a stressor, 
i.e. a serious somatic illness like cancer. According to the cognitive behavioural model 
of CRF, cancer and its treatment trigger the fatigue but the fatigue perpetuates due 
to cognitive-behavioural factors. Perhaps patients remain vulnerable for developing 
fatigue in response to stressors and the likelihood to encounter serious stressors will 
increase over time, hence the partial relapse at long-term follow-up. This vulnerability 
could also be caused by cancer and its treatment; up to date it is largely unclear how 
biological processes influence the mechanisms underlying CRF and its persistence. It 
could be that CBT for CRF addresses the fatigue but does not change an underlying 
somatic vulnerability which make cancer survivors prone to develop severe fatigue. An 
alternative explanation is that patients relapse into dysfunctional coping in response 
to ‘everyday’ fatigue, and dysfunctional behaviours and cognitions eventually lead 
to severe and persistent fatigue. To understand the reasons for relapse, longitudinal 
studies incorporating qualitative research methods are needed to assess the course 
of fatigue, stressors and possible fatigue perpetuating factors. Our outcome measure 
at long-term follow-up was restricted to fatigue severity. Measurement of scores on 
fatigue-perpetuating factors would have been valuable as well. Insight in these factors 
at long-term follow-up would enable us to test whether deterioration of fatigue scores 
is associated with changes in the perpetuating factors over time.
The strengths of this study are the long follow-up period and the high response rate. 
A limitation of our study is that the primary outcome variable, the level of fatigue, was 
measured only once at long-term follow-up. Patients were only asked about their level 
of fatigue in the previous two weeks. Therefore, it remains unclear whether severe 
fatigue at long-term follow-up was present longer than two weeks. A second limitation 
of our study is that our participants, derived from two RCT's of Gielissen et al.(4) and 
Prinsen et al. (5), all had completed CBT and the post-CBT assessment.  The exclusion of 
patients who did not complete CBT and this assessment may bias our results, and could 
have caused an overestimation of long-term treatment effects. 
In order to prevent relapse, various interventions have been developed: i.e., booster 
sessions of CBT, mindfulness or metacognitive therapy for depression (19). Our previous 
follow-up study has shown that effects of CBT on fatigue severity were maintained 
after a period of two years of follow-up. Therefore, relapse in CBT for CRF occurred 
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only after a period of two years post-CBT. 
It seems more practical and efficient to develop interventions for patients who are 
again referred after relapse of fatigue, instead of applying interventions to prevent 
relapse directly following the end of CBT. It should be determined whether patients 
who have a relapse of severe fatigue following an initially successful CBT, can profit 
from CBT again or whether another evidence based interventions for fatigue (like 
mindfulness or exercise therapy) should be given. 
In summary, we found that significant deterioration of fatigue over time occurred, 
but positive effects of CBT on fatigue severity were sustained in about half of the 
participants at long-term follow-up. Future research should study the underlying 
mechanisms of CRF and aim for optimizing the long-term treatment results of CBT for 
CRF. 
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Severe fatigue
ß 95% CI p
Crude model
Time post_FU -2.93 -3.53 to -2.32 <0.001
Model with covariates
Time post_FU -3.02 -3.80 to -2.23 <0.001
Mental health -0.04 -0.06 to -0.02 0.001
Pain -0.03 -0.05 to -0.01 0.002
Cancer recurrence -0.10 -1.92 to 1.72 0.913
Self-reported co-morbidities -1.06 -2.22 to 0.10 0.073
Significant life events -0.84 -2.00 to 1.72 0.145
Notes. Logistic generalized estimating equations. Only severely fatigued patients were included at baseline, which imped-
ed calculation of the time effect between baseline and follow-up. 
Table S1: Severe fatigue over time
Block 1 Block 2
Predictors ß SE ß p ß SE ß p
Fatigue severity (CIS-fatigue) .351 .123 .005 .103 .174 .557
Poor coping with cancer/ treatment (IES) - - - -.096 .143 .504
Activity regulation (CIS-activity) - - - .573 .410 .211
Dysregulation of sleep (SIP sleep/rest) - - - .029 .030 .333
Dysfunctional cognitions (SES) - - - -.149 .475 .755
Discrepancies in social support (SSL-D) - - - .387 .423 .363
Notes. Abbreviations: CIS-activity=Checklist Individual Strength, subscale Activity, CIS-fatigue=Checklist Individual 
Strength, subscale fatigue severity, IES=Impact of Events Scale; SES=Self-efficacy Scale, SIP=Sickness Impact Profile, SSL-
D=van Sonderen Social Support-Discrepancies.
Table S2:  Multiple regression analysis to predict changes in fatigue severity between post-CBT and long-term 
follow-up
APPENDIX
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This chapter provides a summary and general discussion of the findings of the 
studies in this thesis, including future directions for research and development of 
cognitive behavioral therapy (CBT) for cancer-related fatigue.  
SUMMARY
PART I: ADVANCING KNOWLEDGE OF SEVERE FATIGUE IN BREAST CANCER 
SURVIVORS 
Prevalence and course 
Findings on the prevalence rate of severe fatigue in  breast cancer survivors 
were inconsistent, and the course of the symptom over time was still unclear. The 
meta-analysis in chapter 2 included 27 studies and 12,327 breast cancer survivors, 
and made it possible to explore prevalence rates in further detail. Prevalence rates in 
the included studies varied widely, ranging from 7% to 52%. The pooled prevalence 
of severe fatigue was 27%, but should be interpreted with caution because of high 
heterogeneity. Prevalence rates over time showed a relatively large decrease in the 
first half year after cancer treatment. 
Fatigue-related factors
A large body of research has focused on cancer-related fatigue, but an up-to-date 
systematic review on fatigue-related factors in breast cancer survivors was lacking. 
The meta-analysis in chapter 2 focused on (i) demographic, (ii) disease-related, and 
(iii) treatment-related factors, and the systematic review in chapter 3 provided a 
comprehensive overview and level of evidence for the relationship of fatigue with (iv) 
quality of life and (v) psychological factors in breast cancer survivors:
(i) Demographic factors
Of the included demographic factors, having a partner was a significant protective 
factor: it slightly reduced the risk on having severe fatigue.
(ii) Disease-related factors
Stage of disease was a significant risk factor: breast cancer survivors with stage II 
or III breast cancer were at greater risk to develop severe fatigue than survivors with 
stage 0 or I breast cancer. 
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(iii) Treatment-related factors
The risk for severe fatigue was increased in patients who had received chemotherapy. 
Looking at treatment combinations, the risk for severe fatigue was higher in patients 
treated with surgery, chemotherapy and radiotherapy, with and without hormone 
therapy. The risk was lower in survivors treated with surgery with and without 
radiotherapy. 
(iv) Quality of life
There was strong evidence for a negative relationship between patients’ level of 
fatigue and quality of life. There was moderate to strong evidence for the relationship of 
fatigue with different domains of functioning (i.e., physical, role, cognitive, emotional, 
social, and sexual functioning), pain, work ability, and mental health.
(v) Psychological factors
There was moderate to strong evidence for a relationship of fatigue in breast cancer 
survivors with depressive symptoms, anxiety, distress, sleep disturbances, a lower 
sleep quality, lower levels of physical activity, less hours of exercise activities, coping 
with cancer (i.e., body image and worries about future health), and catastrophizing 
about symptoms.
Fatigue in patients treated for DCIS
In chapter 4, we examined fatigue in patients treated for ductal carcinoma in situ 
(DCIS). A total of 23% of DCIS patients reported severe fatigue. This prevalence rate 
was similar in age-matched breast cancer survivors, but higher than in age-matched 
healthy controls. DCIS patients with severe fatigue reported impaired functioning and 
a lower quality of life than DCIS patients without severe fatigue. Moreover, fatigue 
was correlated with the same psychosocial and behavioral factors as those assumed to 
perpetuate fatigue in breast cancer survivors. 
Detecting severe fatigue in oncology practice
Management of severe fatigue starts with detecting this symptom in routine clinical 
care. In chapter 5, we investigated the screening of fatigue.  The Distress Thermometer 
is implemented in a large number of Dutch hospitals as screening tool for psychological 
distress. Our findings in a sample of newly diagnosed breast and colorectal cancer 
patients indicated that the fatigue item of the Problem List of this instrument could 
be used as quick screening tool for severe fatigue. Given the high number of false 
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positives, a positive screen of severe fatigue should be followed up with an assessment 
with a validated fatigue questionnaire.
PART II: ADVANCING COGNITIVE BEHAVIORAL THERAPY
Internet-based cognitive behavioral therapy
In chapter 6, the development of an internet-based version of CBT (ICBT) was 
described. ICBT is therapist-guided and tailored to the individual patient. Patients start 
with two face-to-face sessions, after which they largely follow their therapy online. 
Results of the randomized controlled trial in chapter 7 showed that ICBT is an 
effective intervention. After ICBT, patients reported lower fatigue levels compared with 
a waiting list control group, with a large effect size and the majority demonstrating 
clinically significant and self-rated improvement. Patients also reported lower levels 
of functional impairment and psychological distress, and a better quality of life after 
ICBT. 
 Comparison of effect sizes of ICBT and face-to-face CBT suggest that both treatment 
formats were equally effective, but less therapist involvement was required for ICBT: 
mean therapist time was 13 hours in face-to-face CBT compared with 7 hours in ICBT. 
However, these comparisons need to be interpreted with caution, as both treatment 
formats were studied in different patient samples. 
Long-term efficacy of CBT
In chapter 8, we reported findings of a long-term follow-up study up to 14 years 
after face-to-face CBT for severe fatigue in cancer survivors. Results of a short-term 
follow-up had shown that treatment effects were preserved after a mean of two years 
after CBT. At long term follow-up, beneficial effects of CBT on fatigue severity were 
maintained in about half of patients: 52% scored within normal ranges at long-term 
follow-up. However, overall, significant deterioration in fatigue levels occurred and 
fatigue levels were higher compared with age-matched general population controls. 
This was still the case after correction for relevant covariates. There was no indication 
of deterioration of physical functioning after correction for relevant covariates like 
pain and somatic comorbidities. 
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GENERAL DISCUSSION
This general discussion will focus on future directions in the research and application 
of CBT for cancer-related fatigue.  The detection of patients who need the intervention, 
optimization of the intervention and its efficiency, nationwide implementation, and 
the long-term efficacy of CBT are  central topics. As research and clinical implications 
are closely linked, these will be given in conjunction with each other.
Detection of patients who need CBT
The fatigue item of the distress thermometer in chapter 4 provides a quick tool to 
detect severely fatigued patients. However, this tool has its limitations: the rate of false 
positives was relatively high and fatigue was only measured on a dichotomous scale. 
Besides, the fact that patients are severely fatigued does not imply that they need a 
fatigue-oriented intervention like CBT. Suggestions to further improve the screening of 
cancer-related fatigue are: 
The use of a computerized adaptive test
Currently, a fatigue item bank (FIB) is developed as part of the National Institutes of 
Health (NIH) Patient-Reported Outcomes Measurement Information System (PROMIS) 
Roadmap initiative (1,2). This FIB can bring the screening of fatigue to a next level. Items 
in this bank are calibrated by item response theory models and represent differing 
levels of a symptom along a standardized continuum. This standardization makes it 
possible to compare items from different fatigue instruments with each other (2). The 
FIB already enabled the development of a reliable, computerized adaptive test (CAT), 
in which items are sequentially selected from the item bank using a computerized 
algorithm, based on a patient’s previous answers (3). This FIB-based CAT needs to be 
tested in Dutch cancer patients and, if validated, its implementation in Dutch oncology 
practice is warranted to measure fatigue as precisely and efficient as possible.  
 
Distinguishing unmet care needs
It is hard to recruit patients for intervention studies. In the RCT in chapter 7, the 
uptake of ICBT was lower than the prevalence of severe fatigue suggests. This might 
partly be explained because not all severely fatigued patients want help. For instance, 
some patients may feel like fatigue is a normal consequence of cancer and cancer 
treatment, and are not aware of treatment possibilities. Others could have found ways 
to cope with fatigue and do not feel limited by it. Future research should not only focus 
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on the prevalence of severe fatigue, but should also explore if and why it is an unmet 
care need.  
 
Optimizing CBT
Three RCT’s have demonstrated that CBT is effective in reducing fatigue in cancer 
survivors. However, for which patients CBT works and how changes in fatigue severity 
are initiated by CBT is still unknown. Both should be clarified in future research to 
further improve the efficacy of CBT and to personalize interventions. 
Mediators of CBT: how does it work?  
Mediators are intervening variables that account for the relationship between 
CBT and the change in fatigue (4). Previous research on face-to-face CBT for cancer 
survivors with various diagnoses showed that an increase in objective physical activity 
did not mediate the reduction in fatigue (5). Other mediators have not been explored 
yet. In CBT, each treatment module addresses a distinct fatigue-perpetuating factor 
(e.g., a deregulated sleep-wake cycle or dysfunctional cognitions). A first step would be 
to determine to what extent changes in these fatigue-perpetuating factors account for 
the effect of CBT on fatigue severity. This would reveal which factors need more or less 
attention during CBT to target cancer-related fatigue more effectively and efficiently.
  Recently, Wolvers et al. examined mechanisms of change of a mobile Health 
(mHealth) physical activity intervention for fatigue in cancer survivors. Again, analyses 
showed that an increase in objective physical activity did not explain the effect of 
the mHealth intervention on fatigue in cancer-related fatigue. Instead, changes in 
cognitions (i.e., increased self-efficacy and perceived physical activity) were correlated 
with a reduction of levels of fatigue (6). This is in line with findings on mediators of CBT 
for patients with chronic fatigue syndrome (7-9) and chronic fatigue in patients which 
chronic diseases (10,11).
Moderators of CBT: what works for whom? 
Moderators influence the direction or magnitude of the relationship between CBT 
and the change in fatigue (4). Specific moderators of the effect of CBT on cancer-related 
fatigue have not been explored yet. Although most patients benefit from CBT, recovery 
is not achieved in about a quarter of patients (12,13). Insight in moderators could reveal 
characteristics that explain why some patients do and others do not benefit from CBT. 
  Recently, Mustian e.a. explored moderators of fatigue-oriented interventions in 
general in meta-regression analyses (14). Fatigue-oriented interventions seemed more 
beneficial for patients with early stages of disease and patients who had completed 
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cancer treatment, whereas differences in age, sex, and type of cancer did not influence 
intervention effects (14). 
  Building on this, different types of interventions for cancer-related fatigue 
are probably suitable for different subgroups of patients. For instance, one could 
hypothesize that exercise interventions are suitable for survivors who have exercised 
frequently in the past, whereas psychological interventions could be more beneficial 
for patients with more outspoken dysfunctional cognitions. Exploration of moderators 
should be continued in further detail to reveal what type of fatigue-oriented 
interventions work for which subgroups of patients. In this way, patients can be offered 
the type of intervention from which they are most likely to benefit.
Clustering of symptoms
In case of symptom clusters, treatment should focus on the symptom that is most 
debilitating and important for a patient. As for CBT, therapy is only started if severe 
fatigue is the most prominent symptom. However, this does not mean that cancer-
related fatigue is an isolated symptom. In the exploration of moderators and mediators, 
potential clustering of fatigue with other relevant symptoms needs to be taken into 
account. The systematic review in chapter 3 showed a high level of evidence for the 
relation of fatigue with pain and depressive symptoms. This is in accordance with 
other studies that designated the pain-depression-fatigue cluster as one of the most 
prevalent symptom clusters in adults with and without a history of cancer (15,16). These 
symptoms often go hand-in-hand as certain features overlap (e.g., lack of energy and 
anhedonia), tangling up their assessment and treatment. Given the interrelatedness of 
the symptoms, effects of CBT on fatigue severity may ‘cross-over’ and also reduce the 
burden of depressive symptoms, pain, or both (16). It has not been examined yet if this 
is also the case in CBT for severe fatigue in cancer survivors. These findings indicate 
that CBT may  influence fatigue, depressive symptoms and pain simultaneously. To 
optimize personalized CBT, future research needs to determine the role and place of 
these symptoms in the intervention for individual patients. 
Unraveling the process of CBT
Another way to gain understanding in the black box behind the therapeutic effect, 
is the use of ecological momentary assessments (EMA), consisting of a large number 
of momentary measures of fatigue and potential perpetuating factors in a patient’s 
natural environment (17). The drawbacks of this method are an increased focus on 
fatigue and fatigue-perpetuating cognitions, which may decrease the therapeutic 
effect, and the difficulty of determining appropriate short questions to measure 
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outcomes. However, the use of EMA during therapy does enable tracking of a patient’s 
individual response and measurement of momentary changes in fatigue and potential 
perpetuating factors. As a result, more reliable conclusions on causality can be drawn 
and individualized treatment models can be improved. This may enable us to target 
cancer-related fatigue more specifically and effectively.
Optimizing treatment efficiency
To improve the limited treatment capacity of CBT, an internet-based version was 
developed with the intention to reduce the time spend for each patient. Chapter 7 
showed that ICBT seemed more time efficient than face-to-face CBT (reduction in 
therapist time of 43%), while treatment effects were comparable (13). However, the 
treatment formats still need to be compared with each other in one study population. 
Possibilities to further improve time efficiency of ICBT also need to be explored, 
including:
Use of mobile applications
For an easy and direct registration of sleep and wake times, the graded activity 
program, and diaries for dysfunctional cognitions, mobile applications could be a 
useful addition during ICBT. This also provides the possibility to give patients direct, 
interactive automated feedback on these intervention elements, which could further 
decrease therapist involvement (18). Evidence already exists for the efficacy of mobile 
applications in increasing physical activity (19). This evidence includes a physical 
activity mHealth intervention, developed by Wolvers et al, which was shown to be 
effective in reducing severe fatigue in cancer survivors (6). 
Reduction of treatment duration
The duration of ICBT of six months is long compared with other web-based 
interventions for fatigue in cancer survivors that took only 9 to 12 weeks to complete 
(20,21). However, the longer duration may partly account for the more beneficial effect 
of CBT on fatigue severity. A meta-analysis has identified the duration of psychosocial 
interventions as the most important moderator of treatment effects on quality of life of 
cancer patients. Interventions of more than 12 weeks were found to be more effective 
than shorter interventions (22). It needs to be explored if the duration of ICBT can be 
shortened without losing efficacy. EMA could be used to determine the optimal dose of 
therapy by measuring  patients’ fatigue level frequently during CBT to gain insight in 
their individual responses to therapy. 
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Integration of video consults
At some crucial points in therapy, e-mailing might not be effective enough and video 
consults should be used. Examples are moments when the patient is stuck or considers 
to discontinue ICBT, and modules that generally require more therapist guidance (e.g., 
modules addressing dysfunctional cognitions and fear of cancer recurrence). In these 
kind of situations, more direct communication through video consults may reduce the 
number of e-mails and therapist time, and could accelerate the treatment process. 
Nationwide implementation 
The development of evidence-based CBT does not automatically make it available 
for all patients who need it. Implementation is crucial to enable the uptake of CBT 
into routine clinical practice, but this is often a bottleneck for care innovations. 
Approximately two-thirds of organizations’ efforts to implement changes fail (23). 
Consequently, many interventions found to be effective in research settings remain 
unused and do not end up with the patients who need it (23,24).
  In 2016, the Netherlands Comprehensive Cancer Organization has selected 
face-to-face CBT for fatigue in cancer survivors to enhance its implementation, as 
part of the project “Implementation of evidence-based psychosocial interventions for 
people with cancer.” ICBT is not within the scope of this project, and would require 
a different implementation process. For instance, other skills need to be learned to 
therapists and a web-portal needs to be adopted in the care system of new centers. A 
separate implementation project for ICBT is required to make it available for all breast 
cancer survivors who need it. In advance, further insight in the external validity and 
cost-effectiveness of ICBT must be gained.  
External validity
The efficacy of face-to-face CBT has been demonstrated in two previous RCTs on 
cancer survivors with various tumor types (12, 25). The RCT in chapter 7 included a 
relatively young sample of female breast cancer survivors. Further work is required 
to prove the effectiveness of ICBT for survivors of other tumor types, with a focus on 
subgroups that were not represented in the RCTs: males, older patients, and patients 
who had received other intensive cancer treatments like stem cell transplantation. An 
RCT in which ICBT is compared with regular care (evidence-based face-to-face CBT) is 
the gold standard to prove the efficacy of ICBT for survivors of tumor types other than 
breast cancer (26). However, conducting another RCT might not be attainable due to 
time and resource constraints. 
 Alternatively, the next step after our RCT in a well-controlled setting could be a 
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pragmatic trial without any restrictions regarding patients’ tumor type. A pragmatic 
trial could answer the question if our results are applicable and generalizable to routine 
clinical practice (27). This would control for the external validity of our RCT results in 
a broader sense, as efficacy studies are often better resourced. For instance, therapists 
in a study setting often have a lower clinical load, are more experienced, and receive 
more training and supervision. As a result, evidence-based interventions are not 
always (equally) effective in routine clinical practice (27). In case of a pragmatic trial, 
the control condition should be face-to-face CBT instead of a waiting list condition. This 
provides the opportunity to compare the efficacy and efficiency of the two intervention 
formats in one study population.
 Another option to determine if ICBT is effective for patients with other tumor types 
is a single-case experimental study (28). In this design, a participant would receive 
ICBT after a no-treatment baseline phase. Fatigue would be measured frequently and 
repeatedly during this baseline phase and assessments continue into the ICBT treatment 
phase. Experimental control can be established by randomizing a participant to a start 
point of the ICBT. It has been recommended to perform a series of replicated single-case 
experiments to demonstrate treatment effectiveness more convincingly, for example 
with a multiple baseline design across participants (28,29). Single-case experimental 
studies are particularly appropriate for survivors of rare types of cancer, with separate 
series of replicated experiments per tumor type. 
Cost-effectiveness
An economic evaluation of CBT is also an important issue for future research. 
Nowadays, reducing the costs of mental health care is increasingly important. As 
stated in the multiannual plan (2013-2020) of the Dutch Association of Mental Health 
and Addiction Care (GGZ Nederland), there have been significant cuts in the budget 
for mental health, and the remaining funds must be spent as efficiently as possible 
(30). Results in chapter 7 indicated that treatment effects of ICBT were comparable to 
those of regular face-to-face CBT. At the same time, the intervention seemed more time 
efficient (13). These findings make it likely  that ICBT is more cost-effective, because it 
is more time-efficient than face-to-face CBT. However, ICBT also comes with additional 
expenses like costs for web hosting. In line with our recommendation in the previous 
paragraph, a direct comparison of  face-to-face CBT and ICBT in one study population 
is required to evaluate its cost-effectiveness.   
Implementation process
To implement ICBT, a national network of treatment centers that will provide the 
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intervention needs to be created. In advance, a problem analysis is required to identify 
potential facilitating and hindering factors of the implementation. Examples of barriers 
that hamper implementation can occur at various levels: from the involved individual 
professionals and patients (e.g., lack of knowledge, skills or motivation to change) to 
a broader social, organizational, economic and political context (e.g., organization 
of care processes and policies) and the innovation itself (e.g., feasibility and attracti-
veness) (31).
 Strategies to overcome potential barriers for implementation need to be developed. 
An example is a strategy aimed at a lack of knowledge on the existence of ICBT by 
potential referrers (e.g., general practitioners and oncologists) and breast cancer 
survivors who need the intervention. Promotion actions to inform these target 
populations about the ICBT treatment option is of importance to overcome this 
barrier. Once started, implementation should be an iterative process that is evaluated 
continuously (31). A nationwide network of treatment centers that provide ICBT and 
an implementation manual that enables health care professionals to implement ICBT 
independently in the future should be end products of the implementation process. 
Long-term efficacy 
The long-term efficacy of ICBT is open to question for future research. For face-to-face 
CBT, it has been shown to be effective up to two years after therapy. From that point, 
fatigue levels tend to deteriorate over time. To get a more complete picture of the 
efficacy of CBT on the long run, and reasons for relapse, it is necessary to measure 
patients more frequently during the follow-up period. 
General vulnerability for fatigue
Up to 14 years after face-to-face CBT, there had probably been new triggers of fatigue, 
like distressing life events or somatic comorbidities other than cancer. Patients with 
a relapse of severe fatigue after successful treatment with CBT could have a general 
vulnerability for developing fatigue. This vulnerability may partly be explained 
by underlying personality traits or somatic vulnerability caused by cancer and its 
treatment in the past. 
 Knowledge on personality traits of severely fatigued breast cancer survivors 
is scarce and further research is warranted. Two descriptive studies found that 
neuroticism predicted patients’ level of fatigue after breast cancer treatment after 
controlling for depression (32,33). Though successfully treated in CBT, this personality 
trait may increase a patient’s risk for relapse of severe fatigue in response to new 
stressors in life. In addition, a recent review of Saligan et al. revealed several biological 
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factors that are related with fatigue in cancer patients, including dysregulations in the 
immune system, metabolic and neuroendocrine functions, and the hypothalamic-pi-
tuitary-adrenal axis (34). These biological factors may cause an increased vulnerability 
for developing fatigue.
Dealing with relapse after CBT
In CBT, patients have learned skills to cope with severe fatigue, which they can 
reapply after therapy. The use of follow-up booster sessions to help patients with 
preserving these skills has long been advocated as maintenance strategy of CBT (35). 
However, findings of the follow-up study in chapter 8 showed that fatigue levels only 
start to deteriorate from two years after face-to-face CBT. Starting to provide standard 
booster sessions after such a long period after therapy is difficult and seems inefficient 
due to practical constraints.
 Initiatives to prevent a relapse would be more feasible. At this point, research on 
successful strategies in preventing or treating recurrence of severe fatigue in cancer 
survivors is lacking. Paying more attention to a personalized relapse prevention 
plan after successful completion of CBT could be of importance. In the current CBT 
protocol, this plan is discussed in the evaluative session after CBT. However, an extra 
session can be spent on formulating preventive actions and early signs of a relapse of 
severe fatigue. This should result in an actual standardized plan for patients to take 
home after the final face-to-face session and to rely on after completion of therapy. A 
personalized relapse prevention plan should be added as extra assignment in ICBT as 
well. Moreover, the option for re-referral in case of recurrence of severe fatigue should 
be encouraged with referrers and patients.  
CLOSING REMARKS
The large body of studies that have already focused on severe fatigue in breast 
cancer survivors show that this symptom is taken seriously. Hopefully, insights and 
future directions resulting from this thesis will further improve the effects and 
availability of CBT for severe fatigue in (breast) cancer survivors. Because after all, it is 
most important that the burden of this debilitating symptom will be reduced.   
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Wereldwijd is borstkanker het meest voorkomende tumortype bij vrouwen. Steeds 
meer patiënten worden succesvol behandeld voor borstkanker en overleven deze 
ziekte. Een deel van hen heeft echter last van blijvende gevolgen van de ziekte en de 
behandeling hiervan. Eén van deze gevolgen kan ernstige vermoeidheid zijn. Dit komt 
veel voor tijdens en na afloop van de behandeling en is belemmerend voor patiënten. 
  De doelen van dit proefschrift zijn: (1) het vergroten van de kennis over ernstige 
vermoeidheid na borstkanker (deel I) en (2) het verbeteren van de behandeling van 
vermoeidheid na borstkanker, met een focus op cognitieve gedragstherapie (deel II). 
In deze samenvatting worden de belangrijkste resultaten van de onderzoeken uit dit 
proefschrift besproken. 
DEEL I: VERGROTEN VAN KENNIS OVER VERMOEIDHEID NA BORSTKANKER 
Het was nog onduidelijk hoeveel procent van de patiënten last heeft van vermoeidheid 
na borstkanker, wat het beloop is van deze vermoeidheid en welke factoren eraan 
gerelateerd zijn.
 Om hier inzicht in te krijgen, deden we een systematisch literatuuronderzoek, waarin 
we alle studies over vermoeidheid na borstkanker bij elkaar zochten (systematische 
review). We hadden de beschikking over de gegevens van 27 verschillende studies met 
in totaal 12,327 patiënten. Deze gegevens hebben we geanalyseerd in een zogenaamde 
meta-analyse.   
 In hoofdstuk 2 rapporteren we de resultaten van meta-analyses naar de prevalentie 
en risicofactoren van vermoeidheid na borstkanker. In hoofdstuk 3 geven we een 
overzicht van de factoren die gerelateerd zijn aan vermoeidheid na borstkanker, op 
basis van 57 studies. We beschrijven de samenhang van vermoeidheid met aspecten 
van kwaliteit van leven en psychologische factoren. Tevens bepalen we hoeveel bewijs 
er is voor de samenhang met vermoeidheid. 
Prevalentie en beloop
De prevalentie van ernstige vermoeidheid varieert sterk tussen studies: het 
percentage vermoeide patiënten loopt uiteen van 7 tot 52%. Als we alle percentages 
samennemen in een meta-analyse, komen we tot een gepoolde prevalentie van 27%. 
Dit betekent dat ongeveer één op de vier patiënten ernstig vermoeid is na behandeling 
van borstkanker. Deze schatting moet voorzichtig geïnterpreteerd worden vanwege 
grote verschillen tussen de studies. 
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  De prevalentie van vermoeidheid neemt af in de eerste zes maanden na de 
behandeling van borstkanker. Nadien wisselt het beloop sterk, zonder duidelijke 
afname. 
Relatie van vermoeidheid met andere factoren
(1) Demografische factoren
Het hebben van een partner geeft een kleine vermindering van het risico op ernstige 
vermoeidheid na borstkanker. 
(2) Ziekte-gerelateerde factoren
Patiënten met een hoger ziektestadium (stadium II of III) hebben een hoger risico 
op ernstige vermoeidheid dan patiënten met een lager ziektestadium (stadium 0 of 
I). Ziektestadia geven aan hoeverre de ziekte zich in het lichaam heeft uitgebreid. Dit 
wordt bepaald door de grootte van de tumor, het aantal uitzaaiingen in de lymfeklieren 
en het aantal uitzaaiingen op afstand. 
(3) Behandelingsgerelateerde factoren
Het risico op ernstige vermoeidheid is hoger bij patiënten die behandeld zijn met 
chemotherapie. We keken ook naar verschillende combinaties van behandelingen 
voor kanker. Het risico op ernstige vermoeidheid is hoger bij patiënten behandeld 
met een combinatie van een operatie, chemotherapie en radiotherapie, met of zonder 
hormoontherapie. Het risico is lager bij patiënten die alleen zijn behandeld met een 
operatie, met of zonder radiotherapie.
(4) Kwaliteit van leven
We vonden sterk bewijs voor een negatieve relatie tussen de ernst van de 
vermoeidheid en de kwaliteit van leven van patiënten: hoe vermoeider patiënten 
zijn, des te lager is hun kwaliteit van leven. Ook vonden we matig tot sterk bewijs 
voor de samenhang van meer vermoeidheid met meer pijn, een lager werkvermogen, 
een slechtere mentale gesteldheid, en een verminderd functioneren (lichamelijk, 
rol, cognitief, emotioneel, sociaal, en seksueel functioneren). Hieruit kunnen we 
concluderen dat vermoeidheid samenhangt met een scala aan beperkingen in het 
dagelijks leven van patiënten. 
(5) Psychologische factoren
We vonden sterk bewijs voor een relatie van vermoeidheid na borstkanker met 
meer depressieve symptomen, meer angst, meer slaapstoornissen, een hogere neiging 
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tot catastroferen (doemdenken) over symptomen. Tot slot vonden we matig bewijs 
voor de relatie van meer vermoeidheid met meer distress (de algemene psychische last 
die mensen ervaren), een lager lichamelijk activiteitenniveau, een lagere slaapkwa-
liteit en meer moeite met verwerking van de ziekte (lichaamsbeeld en zorgen over 
toekomstige gezondheid). Het is van belang om in behandelingen voor vermoeidheid 
na borstkanker aandacht te besteden aan deze factoren.
Vermoeidheid na behandeling van DCIS
Hoofdstuk 4 is specifiek gericht op patiënten met een ductaal carcinoom in situ 
(DCIS). Dit is een voorstadium van borstkanker, dat behandeld wordt met een operatie 
en/of radiotherapie. Patiënten met DCIS hebben geen kanker, maar krijgen wel dezelfde 
behandelingen als patiënten met kanker. Dit kan DCIS een verwarrende diagnose 
maken voor patiënten. 
 We brachten vermoeidheid in kaart bij 89 vrouwen die zijn behandeld voor DCIS. 
In totaal is 23% van hen ernstig moe. Deze prevalentie is vergelijkbaar met vrouwelijke 
leeftijdsgenoten die zijn behandeld voor borstkanker (25%). Ernstige vermoeidheid 
komt aanzienlijk minder vaak voor bij gezonde vrouwelijke leeftijdsgenoten (6%). 
Vermoeidheid hangt samen met meer slaapproblemen, vermijding van activiteiten, 
‘alles-of-niets’ gedrag, gebrek aan sociale steun, niet-helpende gedachten over 
vermoeidheid, moeite met verwerking van de diagnose DCIS, en angst om in de toekomst 
kanker te krijgen. Van deze factoren is bekend dat ze vermoeidheid na kanker in stand 
kunnen houden. Deze factoren worden daarom aangepakt in cognitieve gedrags-
therapie voor vermoeidheid na kanker. Dit is een bewezen effectieve psychologische 
behandeling voor vermoeidheid. 
Aangezien vermoeidheid veel voorkomt na behandeling van DCIS, is het waardevol 
om hier ook een specifieke behandeling voor te ontwikkelen. Factoren die gerelateerd 
zijn aan vermoeidheid na kanker en vermoeidheid na DCIS komen overeen.  De 
behandeling voor vermoeidheid na DCIS kan daarom gebaseerd worden op bestaande 
cognitieve gedragstherapie voor vermoeidheid na kanker. Hierbij moet wel rekening 
worden gehouden met DCIS-specifieke factoren, zoals verwerking van de soms 
verwarrende diagnose. 
Opmerken van ernstige vermoeidheid in de dagelijkse praktijk
Een juiste aanpak van ernstige vermoeidheid na kanker begint met het signaleren 
van dit symptoom in de klinische praktijk. De Lastmeter wordt in veel Nederlandse 
ziekenhuizen gebruikt als screeningsinstrument voor de last die mensen ervaren op 
lichamelijk, emotioneel, sociaal en praktisch gebied tijdens en na behandeling van 
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kanker. De Lastmeter bevat een ‘Probleemlijst’, waarin patiënten aankruisen of ze last 
hebben van bepaalde problemen, waaronder vermoeidheid. We onderzochten of we 
deze vermoeidheidsvraag kunnen gebruiken om ernstige vermoeidheid te signaleren 
in een groep patiënten met borst- en darmkanker. 
Door de vermoeidheidsvraag te gebruiken, spoorden we vrijwel alle patiënten met 
ernstige vermoeidheid op. De Lastmeter lijkt daarmee een zinvol screeningsinstrument 
om vermoeidheid in de dagelijkse praktijk op te sporen. 
Wel was er bij gebruik van de vermoeidheidsvraag sprake van een overschatting, 
doordat een deel van de patiënten onterecht als ernstig moe werd gezien. Na een 
positieve screening moet daarom een uitgebreidere vermoeidheidsvragenlijst worden 
afgenomen om de ernst van de vermoeidheid te bepalen.
 
DEEL II: VERBETERING VAN COGNITIEVE GEDRAGSTHERAPIE
Er zijn verschillende behandelingen ontwikkeld voor vermoeidheid na kanker. 
Er is bewijs voor de werkzaamheid van cognitieve gedragstherapie, waaronder de 
behandeling die is ontwikkeld door het Nederlands Kenniscentrum voor Chronische 
Vermoeidheid (NKCV). 
Bij cognitieve gedragstherapie gaat men ervan uit dat de vermoeidheid is ontstaan 
in de periode van de diagnose en behandeling van kanker. Na afloop van behandeling 
vormen  de ziekte en behandeling geen verklaringen meer voor het aanhouden van 
de vermoeidheid. Andere factoren komen dan in het spel en houden vermoeidheids-
klachten in stand. Voorbeelden hiervan zijn ontregelingen in het slaap-waakritme en 
een sterk wisselend activiteitenniveau. Via cognitieve gedragstherapie leren patiënten 
hoe ze deze instandhoudende factoren zelf kunnen aanpakken, door doen en denken 
in reactie op de vermoeidheid te veranderen.
 Eerder onderzoek had reeds laten zien dat cognitieve gedragstherapie met 
gesprekken tussen patiënt en therapeut leidt tot een vermindering van vermoeidheid 
na kanker. Maar de behandelcapaciteit is beperkt; er is vaak een wachttijd voor 
patiënten voordat zij kunnen starten met behandeling. De gesprekstherapie bestaat 
uit gemiddeld 12 tot 14 sessies in een periode van 6 maanden. Er zijn maar een paar 
behandelcentra in Nederland waar de therapie als behandeloptie beschikbaar is.   
De internettherapie Op weg naar herstel
Wij ontwikkelden een internetvariant van de cognitieve gedragstherapie om 
behandelcapaciteit te vergroten en de behandeling minder belastend te maken voor 
patiënten. In hoofdstuk 6 beschrijven we de ontwikkeling van deze internettherapie 
‘Op weg naar herstel’. De internettherapie betreft een online versie van de bewezen 
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effectieve gesprekstherapie en is ontwikkeld voor vermoeidheid na borstkanker. De 
internettherapie wordt begeleid door een ervaren en getrainde therapeut via e-mail, 
telefonische consulten en video-consulten. Patiënten starten met twee gesprekken, 
waarna ze de therapie via het internet volgen. In de therapie leren patiënten hoe ze 
de factoren kunnen aanpakken die de vermoeidheid in stand houden. De therapie 
bestaat uit acht behandelonderdelen en wordt op maat gemaakt voor de patiënt. Dit 
betekent dat patiënten alleen de onderdelen volgen die voor hen relevant zijn. Welke 
onderdelen van toepassing zijn, wordt bepaald met vragenlijsten en een actometer 
(bewegingsmeter). 
Studie naar het effect
De resultaten van de studie in hoofdstuk 7 laten zien dat de internettherapie Op weg 
naar herstel effectief is. In totaal deden er 132 vrouwen met ernstige vermoeidheid na 
borstkanker mee aan de gerandomiseerde en gecontroleerde studie. Patiënten werden 
via loting willekeurig ingedeeld in (1) een groep die de internettherapie volgde of 
(2) een groep die op de wachtlijst werd geplaatst voor de reguliere gesprekstherapie 
(controlegroep). Wij volgden alle deelnemers gedurende een periode van zes maanden. 
Vermoeidheid en bijkomende klachten werden op twee momenten gemeten: bij start 
van het onderzoek en na zes maanden.
Na zes maanden rapporteren patiënten die internettherapie hebben gevolgd 
minder vermoeidheid vergeleken met de controlegroep. In totaal herstelt 73% van de 
patiënten en is niet langer ernstig moe, vergeleken met 27% van de patiënten uit de 
controlegroep. Ook rapporteren patiënten na internettherapie minder beperkingen in 
hun dagelijks leven, minder psychologische last, en een betere kwaliteit van leven dan 
de controlegroep.  
De effecten van internet- en gesprekstherapie op vermoeidheid na kanker zijn 
vergelijkbaar. Maar internettherapie kost therapeuten minder tijd (gemiddeld 7 uur) 
dan gesprekstherapie (gemiddeld 13 uur). De behandelvormen zijn echter niet in 
één studie onderzocht, maar in twee verschillende groepen patiënten. De verschillen 
tussen de twee therapievormen moeten daarom voorzichtig worden geïnterpreteerd.
Lange termijn effect van cognitieve gedragstherapie
Het is belangrijk om te weten of effecten van de reguliere cognitieve gedragstherapie 
voor vermoeidheid met gesprekken ook op de langere termijn behouden blijven. 
Resultaten van een eerdere follow-up studie lieten al zien dat de positieve effecten op 
vermoeidheid en beperkingen tot ongeveer twee jaar na behandeling blijven bestaan. 
Het was echter onbekend hoe het patiënten daarna vergaat.  
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In de studie in hoofdstuk 8 onderzoeken we vermoeidheid tot 14 jaar na reguliere 
cognitieve gedragstherapie. We bekijken of patiënten die na cognitieve gedrags-
therapie hersteld waren van ernstige vermoeidheid, nog steeds hersteld zijn op de 
lange termijn. In totaal scoort 52% van hen binnen normaalwaarden op vermoeidheid 
tot 14 jaar na de therapie. 
Ook hebben we gemiddelde vermoeidheidsscores in de totale groep patiënten 
geanalyseerd (wel en niet hersteld van ernstige vermoeidheid na cognitieve gedrags-
therapie). Hierbij zagen we dat gemiddelde vermoeidheidsscores verslechteren op de 
lange termijn. De vermoeidheidsscores zijn hoger dan de scores van leeftijdsgenoten 
uit de algemene bevolking. Dit verandert niet na correctie voor mogelijke verstorende 
variabelen (zoals de aanwezigheid van lichamelijke ziekten en pijnklachten). 
Daarnaast hebben we het gemiddelde scores op het lichamelijk functioneren 
bekeken in de totale groep patiënten. We zagen geen verslechtering in scores op het 
lichamelijk functioneren; ook niet na correctie voor mogelijke verstorende variabelen. 
Dit laat zien dat effecten op het lichamelijk functioneren van cognitieve gedrags-
therapie behouden blijven op de lange termijn.  
Toekomstig onderzoek en verdere ontwikkeling van cognitieve gedrags-
therapie 
In hoofdstuk 9 bespreken we aandachtspunten voor vervolgonderzoek naar 
cognitieve gedragstherapie voor vermoeidheid na kanker en de toepassing hiervan 
in de klinische praktijk. We geven aanbevelingen voor het opsporen van patiënten 
die baat kunnen hebben bij de behandeling. Ook gaan we in op verdere optimalisatie 
van de internettherapie, waarbij we mogelijkheden benoemen om de effectiviteit en 
efficiëntie van de therapie verder te verbeteren. Tevens geven we suggesties voor 
landelijke verspreiding van de internettherapie. Tot slot bespreken we mogelijkheden 
om meer inzicht te krijgen in het lange-termijn effect van de behandeling en positieve 
behandeleffecten te behouden. 
Slotwoord
Veel studies hebben zich al gericht op ernstige vermoeidheid na borstkanker. Dit laat 
zien dat dit onderwerp serieus wordt genomen. Uiteindelijk gaat het er om dat de last 
en belemmeringen die patiënten ondervinden door vermoeidheid na kanker worden 
verminderd. Hopelijk zullen de bevindingen van dit proefschrift de effectiviteit en 
beschikbaarheid van behandelingen voor ernstige vermoeidheid na (borst)kanker 
verbeteren.
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Training activities
Courses & Workshops Year(s) ECTS
NCEBP (RIHS) introductie cursus 2013 2.0
Basiscursus Regelgeving en Organisatie voor Klinisch 
onderzoekers (BROK)
2013 2.0
Endnote workshop Radboudumc 2013 0.1
Advanced conversation 2013 2.0
NCEBP (RIHS) PhD retreat 2013 1.0
Academic Writing 2014 3.0
The art of presenting science 2014 1.5
Management voor promovendi 2015 2.0
Wetenschapsjournalistiek 2015 3.0
Onderzoeksdag Medische Psychologie 2016 1.0
Education in a nutshell 2016 1.0
ICBM conference workshop e-health 2017 0.5
Seminars & lectures N/A N/A
Symposia & congresses
IPOS congress, Rotterdam (oral) 2013 0.5
ICBM congress, Groningen (visitor) 2014 0.5
VNO-ChroVer, Nijmegen (oral) 2014 0.5
PHD PORTFOLIO
Name PhD candidate: Harriët Abrahams PhD period: 01/04/2013 - 01/08/2017
Department: Department of Medical 
Psychology
Promotors: Prof. Dr. Maroeska Rovers, 
Prof. Dr. Hans Knoop
Graduate School: Radboud Institute for 
Health Sciences
Co-promotors: Dr. Marieke Gielissen, 
Dr. Stans Verhagen
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Year(s) ECTS
Nationaal mammacongres, Ermelo (oral) 2015 0.5
IPOS congress, Dublin, United Kingdom (3 orals) 2016 1.5
Theme meeting ‘Women’s health’ (laptop demonstration) 2016 0.5
A-CaRe symposium, Amsterdam (visitor) 2016 0.5
Annual health meeting, Amsterdam (poster) 2016 0.5
VGCT congress, Veldhoven (laptop demonstration) 2017 1.5
ICBM congress, Melbourne, Australia (3 orals) 2017 1.0
ARPH congress, Leiden (oral) 2017 0.5
IPOS congress, Berlin (1 oral; 1 poster) 2017 1.5
Other
VNO-ChroVer, secretary 2013, 2014 0.5
Journal Club Psychosocial Oncology 2013-2017 5.0
Reviewer: 2 scientific papers for peer-reviewed journals 2017 0.2
Teaching activities
Lecturing
Tutor Cancer Research, Bachelor Biomedische 
Wetenschappen, Radboudumc 
2013 2.0
Supervision of internships / other
Thesis supervisor, Bachelor Medical Sciences,  
Radboudumc
2013, 2014, 3.0
Thesis supervisor, Master Medical Sciences,  
Radboudumc
2015 1.5
TOTAL 40.8
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DANKWOORD
Alone we can do so little; together we can do so much.
Het proefschrift is af! Maar dit heb ik niet alleen gedaan. Dit werk was niet mogelijk 
zonder de bijdragen van vele anderen. Een aantal van hen wil ik in het bijzonder 
bedanken.
Allereerst gaat mijn dank uit naar alle deelnemers uit de studies in dit proefschrift. 
Jullie deelname maakt het mogelijk om de kennis  over vermoeidheid na borstkanker 
vooruit te brengen. Bedankt voor jullie inzet, tijd en openhartigheid. 
Daarnaast bedank ik Pink Ribbon voor het financieel mogelijk maken van dit 
onderzoek. 
 
Uiteraard wil ik ook mijn promotoren en copromotoren bedanken. 
Hans Knoop, je gaf mij het vertrouwen om dit mooie project te gaan doen, en was 
van begin tot eind nauw betrokken. Hierbij wist je op al mijn vragen een antwoord, 
en dacht je enthousiast mee over onderzoeksideeën en -resultaten. Ik heb veel van je 
geleerd en ben je hier dankbaar voor. Evenals voor de kans die je me na afloop van 
mijn promotietraject hebt gegeven. In mijn combi-functie van postdoc onderzoeker 
en therapeut kan ik mijn ambities kwijt, en ik vind het leuk dat we onze goede 
samenwerking hierin voortzetten. 
Maroeska Rovers, met een aantal korte maar krachtige gesprekken hielp je me 
op weg naar de publicatie van mijn meta-analyse. Dank hiervoor, en  voor jouw 
waardevolle tips en feedback tijdens de afronding van mijn proefschrift. 
Marieke Gielissen, het was een voorrecht om te worden begeleid door een ervaren 
postdoc onderzoeker als jij, met expertise in het onderwerp vermoeidheid na kanker. 
Je hielp me om mijn weg in de wetenschap te vinden. Hierbij kon ik alles aan je vragen 
en met je bespreken. Dank voor jouw fijne begeleiding en al wat ik van je geleerd heb!
Stans Verhagen, jij hield steeds een oogje in het zeil: het project liep goed, maar ging 
het ook nog steeds goed met de promovendus? Ik ben blij dat ik gebruik kon maken van 
jouw kennis, wijze raad en bemoedigende woorden. Dank hiervoor! 
 
Ik bedank de leden van de manuscriptcommissie prof. dr. de Wilt, dr. Broeders en 
prof. dr. Riper voor het lezen en beoordelen van mijn proefschrift. 
 
Mijn dank gaat ook uit naar alle betrokken professionals vanuit de deelnemende 
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centra (Radboudumc, VieCuri Medisch Centrum, Elkerliek Ziekenhuis, Ziekenhuis 
Gelderse Vallei, Canisius-Wilhelmina Ziekenhuis, Maasziekenhuis Pantein, Slingeland 
Ziekenhuis, Ziekenhuis Bernhoven, Care for Cancer). Jullie hebben er een grote rol in 
gespeeld dat de inclusie van de CHANGE-studie succesvol is volbracht. Dank voor de 
prettige samenwerking en jullie inzet voor de werving van deelnemers! 
Co-auteurs, dank voor de fijne samenwerking en jullie feedback op mijn 
manuscripten. 
Marlies Peters, in het VBK-overleg dacht je iedere week uitgebreid mee over mijn 
agendapunten. Jouw toegankelijkheid en openheid waren hierbij erg prettig. Dank 
voor je waardevolle input op mijn inclusieperikelen, vragen en ideeën.  
Monique de Lugt en Wilma Kleijer,  dankzij jullie inspanningen voor implementatie 
van screening met de Lastmeter, is de Lastmeter-database ontstaan. Hieruit zijn twee 
artikelen uit dit proefschrift tot stand gekomen. Dank voor het faciliteren van deze 
artikelen en onze prettige samenwerking hierin! 
Lidewij van Gessel, het was leuk om mee te werken aan jouw artikel. Dank voor 
jouw toewijding; de memorabele respons rate van 96% zal niet snel overtroffen 
worden. 
Stagiaires Lies Smits, Anna Zeckzer en Kevin de Krosse: jullie hulp was onmisbaar 
bij het scheppen van orde in de grote Lastmeter-database. Dank voor jullie inzet en de 
bijdragen aan de artikelen die hieruit voortkwamen.  
 
Mijn oud-collega’s van het NKCV team in Nijmegen wil ik bedanken voor de 
betrokkenheid bij mijn onderzoek, en de gezellige praatjes in de wandelgangen en 
tijdens de lunchwandelingen! Ik heb met plezier deel uitgemaakt van dit hechte team. 
Lianne en Judith, jullie ontfermden je over alle deelnemers en metingen van de 
CHANGE-studie. Dit hebben jullie super gedaan. Ik ben dankbaar dat ik dit met een 
gerust hart aan jullie kon toevertrouwen. 
Susanne, Thea, Ellen, Dennis, Linde en José, dank voor het behandelen van de 
patiënten uit de CHANGE-studie. Jullie verhalen uit de praktijk brachten mijn dataset 
tot leven. Dit maakte steeds weer duidelijk waar ik het onderzoek voor deed, wat erg 
motiverend werkte. 
Anthonie, Margreet, Megan, Stephan, Amilie, Lotte, Stephanie, Jan, Marieke en 
Iris: dank voor de leerzame en motiverende brainstorms over onze onderzoeksideeën, 
en voor alle gezelligheid!  
Judith Prins, ik voelde me altijd welkom op de afdeling Medische Psychologie.  Ik 
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heb het hier naar mijn zin gehad op de onderzoekskamer in het laatste jaar van mijn 
promotie, en vond het leuk om deel uit te maken van de onderzoeksgroep Psychosociale 
Oncologie. Dank aan jou en Marieke, Sanne, José, Melanie, Félix, Belinda, Lynn, 
Simône, Floor en Annemiek voor de inspirerende journal clubs en overleggen, en de 
leuke interacties daar omheen! 
Ik wil ook mijn oud-collega’s van afdeling Medische Psychologie bedanken voor 
alle gezellige gezamenlijke lunches. Deze zorgden voor welkome afleiding op de vele 
schrijfdagen in de laatste fase van mijn promotietraject. 
Dank aan mijn huidige collega’s van het NKCV team in Amsterdam voor de 
betrokkenheid en interesse bij de laatste loodjes van mijn promotie. Ik ben blij om in 
dit fijne team te werken en van jullie te leren! 
Laurien Buffart, dank voor je warme ontvangst van mij in je onderzoeksteam! Het 
is leuk om met een bevlogen onderzoeker als jij samen te werken, en een unieke kans 
om gebruik te kunnen maken van de schat aan data in de Polaris-database. 
Annelies Wisse, je wist de lay-out van ons online behandelportaal perfect passend 
te maken bij onze doelgroep. Heel fijn dat je bereid was om ook de lay-out van dit 
proefschrift te ontwerpen. Dit maakt het voor mij compleet. Dank voor onze leuke 
samenwerking in dit proces!
Dank aan mijn lieve vriendinnen voor de betrokkenheid, en alle leuke dates van de 
afgelopen jaren. Deze geven me steeds weer veel energie! 
Hanneke, vanaf dag 1 in het Radboudumc was je mijn maatje. Eerst als collega, en 
al snel ook als vriendin. Mijlpalen liet je niet voorbij gaan zonder een attent kaartje, 
borrel, sushi-lunch of etentje. Ook op moeilijkere momenten was je er voor me. Dank 
voor jouw support en alle gezellige momenten, waarvan er nog veel zullen volgen! Het 
was even slikken toen je van het bureau naast me naar Boston verhuisde. Ik volg je 
ontwikkelingen daar met veel plezier en ben trots op jou!
Ellis, toen ik startte met promoveren, woonden we nog bij elkaar om de hoek. 
Later werd de afstand groter, maar je staat nog altijd even dichtbij. Je interesse bleef 
onverminderd en steeds als ik je zie, is het als vanouds. 
Vicky, onze band is sterk. Ook na jouw verhuizing naar Stockholm is dit zo gebleven. 
Je leeft altijd met me mee, en weet steeds weer de juiste woorden te vinden, waar ik 
veel aan heb.  
Eva, toen ik halverwege mijn promotietraject was, startte jij. Het is leuk om onze 
promotie-ervaringen te delen en wat was het tof om samen op congres in Leiden te 
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zijn! Ik volg met trots hoe jij je projecten vormgeeft en successen behaald.   
Eetclub-maatjes Eliza, Kim, Hilde en Elbrich, jullie beginnen spontaan te juichen, 
wanneer ik middenin een restaurant hoor dat ik een publicatie heb behaald. Dit 
moment staat symbool voor jullie enthousiaste support van de afgelopen jaren!  
Paranimfen Juliane en Martine, tijdens mijn promotietraject waren jullie nauw 
betrokken. Ik ben dan ook blij dat jullie tijdens mijn verdediging aan mijn zijde staan! 
Juliane, wij startten tegelijkertijd met onze ambitieuze RCT’s, en hadden hierin veel 
steun aan elkaar. Maar niet zonder vele gezellige lunchwandelingen en koffiedates, 
waarin we onze weekendactiviteiten en vakanties uitgebreid bespraken. Deze dates 
zetten we nu voort in een vriendschap die mij dierbaar is. 
Martine, vriendschap op het eerste gezicht bestaat: in de brugklas hadden wij 
meteen een klik. Wat was het leuk dat we allebei in het Radboud werkten, en elkaar 
vaak tussendoor konden zien. Dit mis ik nu ik hier niet meer werk. Inmiddels ben je al 
zo lang mijn beste vriendin, dat je voor mij voelt als familie. 
Lieve schoonfamilie, gekscherend vragen jullie vaak of ik het nog volhoud met 
jullie. Dat doe ik zeker, en met plezier! Dank voor jullie interesse in mijn onderzoek in 
de afgelopen jaren. Ik waardeer het dat jullie dit met enthousiasme hebben gevolgd. 
Pap en mam, jullie zijn de liefste ouders die ik me kan wensen. Jullie zijn mijn basis 
en staan altijd voor me klaar! Ik ben dankbaar voor het rotsvaste vertrouwen en de 
lieve steun, die jullie mij al mijn leven lang geven. Hier vaar ik op en ik kom steeds 
weer met veel plezier gezellig langs in Brabant. 
Lieve Yvon, ook al ben je al 24 jaar, en zijn de rollen qua wijze raad steeds vaker 
omgedraaid: je blijft altijd mijn kleine zusje, en ik ben blij met jou!  
Lieve Nick, jij staat altijd achter me, zo ook tijdens mijn promotietraject. Je deelde 
mijn enthousiasme, brainstormde met me mee, en sprak me moed in wanneer ik dit 
nodig had. Dit heeft mij dag in dag uit gesteund. Je betekent veel voor mij. Heel veel 
dank voor jouw vertrouwen, liefde en support!
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CURRICULUM  VITAE
Harriët Abrahams werd op 19 januari 1989 geboren 
in Tilburg en groeide op in Hilvarenbeek. In 2007 
behaalde zij haar gymnasiumdiploma aan het Mill-Hill 
college te Goirle. Daarna begon ze aan de bachelor 
Psychologie & Gezondheid aan de Universiteit van 
Tilburg. Na het afronden van haar bacheloropleiding 
in 2010 koos ze voor de tweejarige masteropleiding 
Medische Psychologie. In het tweede jaar heeft ze haar 
klinische stage voltooid op de afdeling Psychiatrie van het St. Elisabeth ziekenhuis te 
Tilburg. Haar onderzoeksstage voerde zij uit op de afdeling Medische Psychologie en 
Klinische Neuropsychologie van de Universiteit van Tilburg. Deze stage richtte zich 
op het cognitief functioneren van vrouwen met borstkanker. Naast haar opleiding 
was ze werkzaam als onderzoeksassistent bij een e-health project, gericht op een 
online interventie voor angst en depressie bij patiënten met een implanteerbare 
cardioverter defibrillator. In 2012 is Harriët cum laude afgestudeerd, waarop ze in 
2013 werd aangesteld als promovenda bij het Nederlands Kenniscentrum Chronische 
Vermoeidheid (NKCV) bij het Radboudumc. Centraal in dit promotieonderzoek stond 
de ontwikkeling van ‘Op weg naar herstel’, een online cognitieve gedragstherapie voor 
vrouwen met ernstige vermoeidheid na borstkanker. De resultaten van dit onderzoek 
zijn te lezen in dit proefschrift. 
Inmiddels is het NKCV over gegaan naar Amsterdam en momenteel werkt Harriët 
als therapeut bij dit centrum. Ze behandelt patiënten met vermoeidheid na kanker, 
het chronisch vermoeidheidssyndroom en vermoeidheid bij chronische ziekten. 
Ze combineert deze baan in de klinische praktijk met een functie als postdoctoraal 
onderzoeker. Zij werkt aan een alliantieproject van afdeling Medische Psychologie van 
het Academisch Medisch Centrum (AMC) en de afdeling Epidemiologie en Biostatistiek 
van het VU Medisch Centrum te Amsterdam. Met behulp van reeds verzamelde data 
vanuit een internationaal consortium (Polaris-studie) onderzoekt ze de werkingsme-
chanismen van psychosociale interventies voor kankergerelateerde vermoeidheid.
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